



SOL Global Investments Corp.

MANAGEMENT'S DISCUSSION AND ANALYSIS

**For the three-month period ended February 28, 2023
and the three-month period ended February 28, 2022**

(Expressed in Canadian Dollars)

Dated as of May 1, 2023

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

INTRODUCTION

SOL Global Investments Corp. (the "Company" or "SOL Global") was incorporated under the laws of the Province of Ontario, Canada on January 28, 2005. The common shares of the Company (the "Common Shares") are listed on the Canadian Securities Exchange (the "CSE") under the symbol "SOL", the OTCCK in the United States of America under the symbol "SOLCF", and on the Frankfurt Exchange under the symbol "9SB". The Canadian dollar is the Company's functional and reporting currency. Unless otherwise noted, all dollar amounts within this report are expressed in Canadian dollars. This management discussion and analysis ("MD&A") is dated May 1, 2023, and should be read in conjunction with the unaudited interim condensed financial statements of the Company for the three-month period ended February 28, 2023 and the three-month period ended February 28, 2022 (the "Financial Statements"). Additional information about the Company is available on the Company's SEDAR profile at www.sedar.com or the Company's website at <https://solglobal.com/>.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This MD&A contains forward-looking information and statements ("forward-looking statements") within the meaning of applicable securities laws, which may include, but are not limited to, statements with respect to the future financial or operating performance of the Company. Forward-looking statements contained herein that are not clearly historical in nature may constitute forward-looking information. Forward-looking statements reflect the current expectations of management regarding the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the actual results, performance or events to be materially different from any future results, performance or events that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of this MD&A. Although the Company has attempted to identify important factors that could cause actual results, performance or events to differ materially from those described in the forward-looking statements, there could be other factors unknown to management or which management believes are immaterial that could cause actual results, performance or events to differ from those anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or events may vary materially from those expressed or implied by the forward-looking statements contained in this MD&A. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Forward-looking statements contained herein are made as of the date of this MD&A and the Company assumes no responsibility to update forward looking statements, whether as a result of new information or otherwise, other than as may be required by applicable securities laws.

BUSINESS OVERVIEW

SOL Global is a diversified international investment and private equity holding company engaged in the small and mid-cap sectors. The Company's investments range from minority positions to large strategic holdings with active advisory mandates with an objective of providing shareholders with a long term returns through capital appreciation, dividends and interest from its investments. The investment sectors are primarily Cannabis but also include Retail, Agriculture, QSR & Hospitality, Media Technology & Gaming, Clean Energy and New Age Wellness.

The Company's investment objectives are to provide shareholders with long-term capital appreciation, dividends and interest by investing in an actively managed portfolio of securities of public and private companies. These companies may be operating in or derive a significant portion of their revenue from the cannabis and/or hemp industry. Notwithstanding the foregoing, the Company is not exclusively focused on investments in the cannabis industry. The Company continues to seek value investments and have invested significant capital in opportunities in other industries, with a view towards the Company's investment objectives. The Company plans to reinvest any profits on its investments to further the growth and development of the Company's investment portfolio.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

UNITED STATES REGULATORY RISK AROUND THE CANNABIS INDUSTRY

In the United States of America, the possession and/or use of cannabis or cannabis related products remains in violation of federal law as cannabis continues to be categorized as a Schedule I controlled substance under the U.S. Controlled Substances Act (the "CSA"). However, medical and adult-use cannabis has been legalized and is regulated in certain states. Thirty-six states, four of five permanently inhabited U.S. territories and the District of Columbia recognize, in some way medical use of cannabis. In addition, fifteen states plus the District of Columbia recognize, in some way adult recreational use of cannabis. As such, companies who are involved in the cannabis industry in the United States are subject to conflicting and inconsistent state and federal legislation, regulation, and enforcement. Presently, violations of federal laws and regulations in the United States of America may result in fines, penalties, administrative sanctions, convictions or settlements arising from either civil or criminal proceedings commenced by the United States federal government or private citizens. Finally, given the inconsistency in the laws at the federal and state level in the United States of America, the approach to the enforcement of cannabis laws may change at any time. **For the reasons set forth above, the Company's existing interests and operations in the United States cannabis markets may become the subject of heightened scrutiny by regulators, stock exchanges, clearing agencies and other authorities due to the fact that the possession and/or use of cannabis or cannabis related products remains illegal under U.S. federal law, and that enforcement of relevant laws is uncertain and, therefore, a significant risk. Readers are also encouraged to review the following sections of this MD&A: "Regulatory Developments – Regulatory Developments in the United States", "Issuers with U.S. Cannabis-Related Assets" and "Risk Factors".** As at February 28, 2023, the fair value of the Company's investments in cannabis and related investments in the United States of America totaled \$20.1 million (November 30, 2022: \$20.5 million). The fair value of non-U.S. cannabis, cannabis related investments and non-cannabis investments totaled \$112.9 million (November 30, 2022: \$124.5 million). In all U.S. jurisdictions in which the Company or its subsidiaries, as applicable, carries out cannabis-related activities, it (or the applicable subsidiaries) has obtained legal advice regarding compliance with applicable state regulatory frameworks, exposure and implication arising from U.S. federal laws in the states where it conducts operations. As of the date hereof, neither the Company nor, to its knowledge, any of its subsidiaries in which the Company has "direct", "indirect" or "material ancillary involvement" in the U.S. cannabis industry (as described under Staff Notice 51-352 – Issuers with U.S. Marijuana Related Activities ("Staff Notice 51-352")) have received any notices of violation, denial or non-compliance from U.S. authorities, and the Company believes that the activities of its subsidiaries who are engaged in direct involvement of the cultivation or distribution of cannabis in the United States are being done in compliance with applicable state law, however strict compliance with state laws may not act as a shield to federal criminal liability. See "Risk Factors" and "Regulatory Developments" in this MD&A.

Notwithstanding the illegality of cannabis under U.S. federal law, the Company has historically had access to both public and private capital in Canada in order to continue to support its continuing operations, including public and/or private equity offerings of its Common Shares, warrants, convertible debentures and notes. The Company's executive team and the board of directors of the Company (the "Board") also have extensive relationships with sources of private capital (such as funds and high net worth individuals), that could potentially be available. Commercial banks, private equity firms and venture capital firms have approached the cannabis industry cautiously to date. However, there are increasing numbers of high-net-worth individuals and family offices that have made meaningful investments in companies and projects similar to the Company's projects. Although there has been an increase in the amount of private financing available over the last several years, there is neither a broad nor deep pool of institutional capital that is available to issuers that are involved in the cannabis industry. There can be no assurance that additional financing will be available to the Company when needed or on terms which are acceptable. See "Risk Factors" in this MD&A.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

FINANCINGS

Non-revolving loan term facility

On September 3, 2021, the Company entered into a secured loan from an arm's length private lender (the "Lender") in the principal amount of \$50,000,000 (the "Loan"). The Loan has a term of 12 months, bears interest at the rate of 9% per annum and is secured by a general security agreement. The Loan was entered into for the sole purpose of facilitating its subsidiary's acquisition of all of 1235 Fund LP's rights under the Debenture. To secure the Loan, the Company pledged shares in SOL Verano Blocker 1 LLC, Blue Sky Holdings USA Inc. and other wholly-owned subsidiaries and limited partnerships of the Company. Pursuant to the Loan, the Lender is charging the Company a standby fee of 1.2% per annum until the drawdown date, 2% facility fee and 9% interest per annum calculated on an actual/360 basis. Due to company defaulting on the payments the rate of interest increased by five percent (5%) per annum to fourteen percent (14%). Interest will continue to accrue at default rate (14%) until all outstanding obligations, including unpaid interest are fully paid.

The Loan shall mature and be due and payable in full one year from the date of the advance of the Loan (the "Maturity Date"). The company amended the payment terms several which resulted in facility expense. As of February 28, 2023, the Company recorded \$4.4 million in facility fees and \$2.0 million in interest expense (November 30, 2022 - \$3.9 million in facility fees, Accrued Interest - \$2.4 million). On September 3, 2021, the Company drew down the entire Loan in the amount of \$50 million to fund the settlement payment in connection with the settlement of litigation with 1235 Fund LP relating to the Debenture. The Company paid a facility fee of \$1 million to the Lender and \$0.1 million in legal fees. Pursuant to the Loan, commencing sixty days from the advance date and continuing until the earlier of the demand and the Maturity Date, 10% of the outstanding balance of the amount of the Loan shall be paid on the 7th day of each month along with interest. As of February 28, 2023, the Company has made principal payments totaling \$45.5 million and \$0.8M in interest payment towards the Loan (November 30, 2022 - Principal - \$44.5 million and). The Company accrued \$4,417,335 (November 30, 2022 - \$3,894,636) in financing expenses related to facility fees which were incurred due to amending original payment terms several times.

Term Loan

On June 3, 2022, the Company entered into a loan agreement with a private lender for a secured loan in the principal amount of \$10 million (the "June 2022 Loan"). The June 2022 Loan has a term of 12 months and bears interest at the rate of 9% per annum. The June 2022 Loan is guaranteed by Verano Blocker 1 LLC, a wholly owned subsidiary of SOL Global, and Blue-Sky Holdings USA Inc. ("Blue Sky"), an indirect subsidiary of SOL Global; and is secured with a general security agreement of Blue Sky, which consists primarily of an indirect interest in real estate located in Miami, Florida. The use of proceeds of the June 2022 Loan (net of fees and expenses of the lender) was to reduce the principal amount of an existing secured loan in the principal amount of \$50,000,000 received from the Company from a separate arm's length private lender on September 3, 2021. As of February 28, 2023, the Company has accrued interest of \$246,822.

IFRS 10, DESIGNATION AS AN INVESTMENT COMPANY

The following criteria within IFRS 10, Financial Statements ("IFRS 10"), were assessed by the Company to determine whether it qualifies as an investment entity: (a) the Company obtains funds from one or more investors for the purpose of providing those investors with investment management services; (b) the Company commits to its investors that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and (c) the Company measures and evaluates the performance of substantially all its investments on a fair value basis. As at August 1, 2018 and up to the date of the Financial statements, the Company determined that it met the definition of an investment entity. As a result of this classification, effective August 1, 2018, the Company deconsolidated its subsidiaries and recognized the interests held as financial instruments classified at fair value through profit /loss.

NORMAL COURSE ISSUER BID

On March 2, 2021, the Company announced its intention to commence a normal course issuer bid ("NCIB"), which was completed on September 3, 2021, and under which the Company purchased 2,737,805 Common Shares representing approximately 5% of its issued and outstanding Common Shares. All Common Shares purchased under the NCIB were purchased on the open market through the facilities of the CSE at the prevailing CSE market price for the Common Shares

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

at the time of purchase. Common Shares acquired by the Company under the NCIB were purchased for cancellation. During the year-ended November 30, 2021, a total of 2,737,805 Common Shares were re-purchased through the NCIB.

SUBSTANTIAL ISSUER BID

On September 23, 2021, the Company announced the launch and terms of its substantial issuer bid, pursuant to which the Company offered to purchase for cancellation up to \$30,000,000 of its outstanding Common Shares by way of a "Dutch auction" at a price of not less than \$4.05 and not more than \$4.25 per Common Share in increments of \$0.05 per Common Share. The Company closed the substantial issuer bid on December 8, 2021, with the cancellation of 7,407,404 of the Company's Common Shares for an aggregate purchase price of \$30 million.

Income Statement Analysis Comparison for the Three-Month period ended February 28, 2023 and Three-month period ended February 28, 2022

	Three-month period ended February 28, 2023	Three-month period ended February 28, 2022	Variance
	\$	\$	\$
Revenue			
Net change in fair value of investments	(12,810,470)	(81,591,643)	68,781,173
Interest and other income	680,712	525,367	155,345
Foreign exchange gain (loss)	(15,027)	(43,712)	28,685
Total revenue	(12,144,785)	(81,109,988)	68,965,203
Expenses			
Salaries and consulting fees	679,109	1,377,134	(698,025)
Share based compensation	-	9,113	(9,113)
General and administrative	639,231	847,111	(207,880)
Interest expense	593,769	871,201	(277,432)
Financing expense	526,782	1,355,077	(828,295)
Professional fees and transaction costs	126,356	1,118,207	(991,852)
Total expenses	2,565,247	5,577,844	(3,012,597)
Income (loss) from continuing operations before taxes	(14,710,212)	(86,687,832)	71,977,800

Comparison of Income Statement for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022

Net loss from continuing operations before income taxes totalled (\$14.7) million for the three-month period ended February 28, 2023, compared to (\$86.7) million for the three-month period ended February 28, 2022. This represents an increase of \$72.0 million. Total revenue totalled (\$12.1) million for the three-month period ended February 28, 2023, compared to revenue of (\$81.1) million for the three-month period ended February 28, 2022. This represents an increase of \$69.0 million between periods. Total expenses were \$2.6 million for the three-month period ended February 28, 2023, compared to \$5.6 million for the three-month period ended February 28, 2022, which represents an decrease of \$3.0 million.

Significant reasons for the changes in income and loss from operations:

- The net change in fair value of investments of \$69.0 million is primarily due to: As of February 28, 2023, the company recorded \$nil in unrealized loss compared to February 28, 2022 when the company recorded unrealized loss of \$26.2M.
- The company recorded unrealized gain of \$2.5M in its public investments compared to loss of \$33.8M in February 28, 2022.
- The remaining in losses suffered by Cannabis companies due to compressed valuations decline due to lack of institutional investment due to regulatory, legal and banking issues, as a result, the Company impaired the majority of its cannabis investments. In addition, interest and other income decreased by \$0.2 million between periods.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

- Interest Expense decreased by \$0.3 million, compared to February 28, 2022. This decrease can be attributed to the company making continuous principal repayment on non-revolving line of credit loan.
- Financing expense decreased by \$0.8 million compared to February 28, 2022. On September 3, 2021, the Company drew down the \$50 million line of credit to pay 1235 Fund LP as part of the legal settlement. The Company accrued \$1.4 million CDN in facility fees to the private lender compared to \$0.5M for period ending February 28, 2023.
- Salaries and consulting fees decreased by \$0.7 million compared to the prior period due to employee departures in FY 2022 combined with decreased M&A activities which resulted in decreased use of consultants.
- Professional fees and transaction costs decreased by \$1.0 million between periods. This is primarily due to decrease in M&A activities.
- General & administrative expenses decreased by \$0.2 million between periods. In the prior period, the Company entered into a new lease agreement for a new office and commercial airplane. The Company recorded Nil in depreciation expense compared to \$0.3 million in prior period.

INVESTMENTS

Investments are measured and carried at fair value at each reporting period. Fair value measurements are based on a three-level fair value hierarchy, based on inputs used in determining the fair value of financial assets and liabilities. The hierarchy of inputs is summarized as follows:

- Level 1 - inputs used to value financial assets and liabilities are unadjusted quoted prices in active markets for identical assets or liabilities.
- Level 2 - inputs used to value financial assets and liabilities that are other than quoted prices included in Level 1 that are observable either directly or indirectly for the asset or liability. Level 2 investments are valued based on the prices of recent transactions among arm's length market participants and through incorporating observable market data and using standard market convention practices.
- Level 3 - inputs used to value financial assets and liabilities are not based on observable market data.

Investments consisted of the following at February 28, 2023:

Financial assets measured at fair value	Cost \$	Level 1 \$	Level 2 \$	Level 3 \$	Total Fair Value \$
Common shares	194,451,74	21,431,095	27,351,013	61,972,110	110,754,218
Commercial Asset	13,803,091	-	20,963,781	-	20,963,781
Warrants	4,350,485	235,013	488,572	518,461	1,242,046
Investments Subtotal	212,605,316	21,666,108	48,803,366	62,490,571	132,960,045
Promissory notes receivable	10,286,655	-	-	1,979,607	1,979,607
Convertible debentures	1,576,709	-	-	160,035	160,035
Total	224,468,679	21,666,108	48,803,366	64,630,213	135,099,687

Investments consisted of the following at November 30, 2022:

Financial assets measured at fair value	Cost \$	Level 1 \$	Level 2 \$	Level 3 \$	Total Fair Value \$
Common shares	231,257,039	20,938,806	29,745,985	70,783,430	121,468,221
Commercial Asset	14,645,038	-	21,818,721	-	21,818,721
Warrants	4,350,485	235,013	509,022	992,726	1,736,761
Investments Subtotal	250,252,562	21,713,819	52,073,728	71,776,156	145,023,703
Promissory notes receivable	9,577,888	-	-	2,519,842	2,519,842
Convertible debentures	6,376,502	-	-	2,260,370	2,260,370
Total	266,206,952	21,713,819	52,073,728	76,556,368	149,803,915

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Change in level 3 investments

The following table presents the changes in assets classified in Level 3 of the fair value hierarchy for the three-month period ended February 28, 2023, and the year-ended November 30, 2022.

	Private Equities \$	Convertible debentures \$	Promissory notes \$	Warrants \$	Total Fair Value \$
Balance December 1, 2021	105,215,792	20,349,413	7,103,411	4,029,907	136,698,523
Purchases	4,218,788	-	2,361,520	-	6,580,308
Unrealized gains (losses)	(101,484,626)	(10,517,061)	(6,092,652)	(3,037,181)	(121,131,520)
Disposal ⁽²⁾	(15,485,784)	(7,571,982)	(1,374,150)	-	(24,431,916)
Transfer to Level 2 ⁽¹⁾	(21,672,756)	-	-	-	(21,627,756)
Transfer from Level 2 to Level 3 ⁽³⁾	99,992,016	-	-	-	99,902,016
Interest on income promissory note	-	-	521,713	-	521,713
Balance, November 30, 2022	70,783,430	2,260,370	2,519,842	992,726	76,556,368
Purchases	8,002,838	-	-	-	8,002,838
Unrealized gains (losses)	(9,282,881)	-	(733,046)	(474,265)	(10,490,192)
Disposal	(7,531,276)	(2,100,335)	(35,000)	-	(9,666,611)
Interest on income promissory note	-	-	227,812	-	227,812
Balance, February 28, 2023	61,972,111	160,035	1,979,608	518,461	64,630,215

1. Core Scientific, Inc via SPAC Merger on January 29, 2022, started trading on NASDAQ. Fair value of Core Scientific was presented in Level 3 for the period ending November 30, 2021 and is shown as part of level 1 for free-trading shares for the period ending November 30, 2022.
2. USD\$2M in Jones Soda convertible debt converted to 4,025,035 Jones Soda free trading shares in Q3 2022 and USD\$1.3M of Engine Media Holdings, Inc. ("Engine Media") convertible debt transferred to private company in exchange for 3,322,500 common shares of Heavenly.
3. Private company was previously included as part of Level 2, and for the period ending November 30, 2022, they were reclass to Level 3.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Significant unobservable inputs

The key assumptions the Company used in the valuation of level 3 investments include, but are not limited to, the value of recently completed financings by the investee, entity-specific information, and publicly available information of comparable entities.

	Fair value as at Feb 28, 2023 \$	Fair value as at Nov 30, 2022 \$	Range of Input	Valuation technique	Unobservable inputs
Private company common shares	61,972,111	70,783,430	Lack of Marketability Discount rates: 20% - Discount rates: 26- 28% Other Investment Specific Discounts: 5%-100%	Recent transaction and financings, Discounted cash flow methodology, trends in comparable companies and/or transactions	Period-end transaction prices, discount rates, growth and margin estimates, investment specific adjustments
Convertible debentures	160,035	2,260,370	Volatility 67.2%- 130.2%, Other Investment Specific Discount: 22- 75%	Black-Scholes option pricing and Discounted cash flow methodology	Expected volatility, Discount rate, investment specific adjustments
Promissory notes	1,979,608	2,519,842	Discount rate 6% - 100%	Discounted cash flow methodology	Discount rate
Warrants	518,461	992,726	Volatility: 58.54% - 214% Illiquidity discount for Private Warrants: 20%	Black-Scholes option pricing	Expected volatility, investment specific adjustments
Total	64,630,215	76,556,368			

For the Level 3 investments, the inputs used are judgmental using managements best estimates. A small increase or decrease in the key assumptions would result in a corresponding significant change to the total fair value of Level 3 investments. The overall effect of changing the values of the unobservable inputs by a set percentage, the significance of the impact and the range of reasonably possible alternative assumptions may differ significantly between investments, given their different terms and circumstances. The results cannot be extrapolated due to non-linear effects that changes in valuation assumptions may have on the fair value of these investments. Furthermore, the analysis does not indicate a probability of such changes occurring and it does not necessarily represent the Company's view of expected future changes in the fair value of these investments. The Company used a combination of valuation techniques as determined by the nature of each investment and security type. All valuation techniques rely on assumptions that may differ, to a reasonable degree, between informed professionals. This may include, but is not limited to, comparable multiples, discount rates, growth rates, increases or decreases in margins, the likelihood of certain events to take place in the future, the intensity of competition in a market, future volatility of market prices, credit worthiness of borrowers, and adjustments for investee specific factors.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

	February 28, 2023	November 30, 2022
	\$	\$
Investments		
Common shares, in public and private companies	110,754,218	121,468,221
Commercial Assets	20,963,781	21,818,721
Common share purchase warrants, in public companies	1,242,046	1,736,761
Total Investments	132,960,045	145,023,703
Convertible debentures, in public companies	160,035	2,260,370
Promissory notes, in private companies	1,979,607	2,519,842

As at February 28, 2023, the fair value of the Company's investments in cannabis and related investments in the United States of America totaled \$20,090,025 (November 30, 2022: \$20,477,067). The fair value of non-United States of America cannabis, cannabis related investments and non-cannabis investments totaled \$112,870,020 (November 30, 2022: \$124,546,636).

Investments

The Company's investments totalling \$132,960,045 (November 30, 2022: \$145,023,703) include common shares in public and private companies, Commercial Assets, and common share purchase warrants of public companies. The Company values its common shares of public and private companies at price quotations in active markets. The Company values its common shares in private companies based on various factors including, but not limited to, present market conditions, values of comparable companies, internal or external valuations, the per share price of recent financings or transactions undertaken by the private company, and the like. Internal valuations of private companies generally rely on a combination of approaches including market multiples of comparable companies, valuations and multiples of comparable transactions and intrinsic estimates of value such as discounted or capitalized cash flow methodologies.

Comparable market multiples rely on assumptions about the comparability of publicly traded companies. Multiples are adjusted for factors that are specific to private companies or the investment. For example, an illiquidity discount of 20% was applied to value companies that are not publicly traded based on the trading multiples of publicly traded comparable companies. Additional adjustments for size, market share, superior or inferior margins, among other considerations were applied where appropriate. The application and size of each adjustment is subject to professional judgement. A 10% change in a revenue or earnings multiple may significantly change the estimated value of an investment.

Often, private companies raise capital in multiple rounds. Occasionally, the Company invests in a round that was subsequently followed by another capital raise at a different valuation and a different price per share where unrelated third-party investors subscribed. The Company generally considers these arm's-length equity financing to be strong evidence of the fair market value of the investment at, or near, the time of the raise.

Intrinsic methods for valuing private companies are highly subject to professional judgement and are recorded as the midpoint of a range following a sensitivity analysis. Factors specific to each investment, such as forward-looking projections of sales and costs often rely on material non-public information provided by investees to investors. Small changes in discount rates, meant to reflect the risk of future cash flows, can have material effects on valuations. Many of the Company's investments are of a "high risk, high reward" nature due to the relatively early-stage of investee company operations and industry and market volatility and accordingly discount rates ranging from 26% - 50% are used in income-approach valuations.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

	February 28, 2023	November 30, 2022
Expected volatility	58.54%-214%	54.25%-116.87%
Risk-free interest rate	4.24%	3.89%
Expected life (in years)	0.09-0.96	0.34-1.21
Expected dividend yield	0.0%	0.0%
Underlying share price	\$0.04-\$3.58	\$0.04-\$10.20

Convertible Debentures

The fair value of convertible debentures in public and private companies totalled \$160,035 (November 30, 2022: \$2,260,370). Convertible debentures represent an amount advanced bearing interest between 5% and 10% per annum and maturing before September 1, 2027. If exercised, the convertible debentures will convert into common shares in the underlying businesses or entity. Certain convertible debentures convert into units, which consist of common shares and a common share purchase warrant.

As of February 28, 2023, accrued interest totalled \$Nil (November 30, 2022: \$Nil). The fair value of the debt features of the convertible debentures were estimated using the present value of future cash flows, discounted at a market discount rate of 14.8% (November 30, 2021: 21.1%) based on an estimate of the synthetic credit rating. The ratings were estimated based on a range of factors used to assess the creditworthiness of a borrower. In addition, a 75% cash flow impairment was conservatively considered for a certain relatively immaterial convertible debenture due to cash flow challenges in the underlying business. For certain convertible debentures investments made only weeks or months before year-end, the cost of the convertible debenture is assumed to represent its fair value, and the value of the debt portion is implied by reference to the cost less the value of the conversion feature estimated through the Black-Scholes option pricing model. The fair value of the conversion features were estimated using a Black-Scholes option pricing model with the following assumptions:

	February 28, 2023	November 30, 2022
Expected volatility	67.2%-130.2%	24%-129.0%
Risk-free interest rate	3.0%-3.7%	3.25%-3.89%
Expected life (in years)	1.2-4.8	0.21
Expected dividend yield		0.0%
Underlying share price	\$0.41-\$126.53	\$0.005-\$2.36

Promissory Notes

As of February 28, 2023, a total of \$1,979,607 with a cost of \$9,577,888 (November 30, 2022: \$2,519,842 with a cost of \$9,577,888) was held in promissory notes that were due from private companies. Interest accrued for the promissory notes as of February 28, 2023, was \$227,812 (November 30, 2022 - \$521,173).

Commercial Asset

On July 23, 2021, one of the Company's subsidiaries entered into a joint venture agreement on a real estate development project, in which SOL currently owns 45% of the joint venture. The Company has advanced \$13,803,091 CDN (\$11,395,441 USD) to the joint venture. As of February 28, 2023, Commercial Asset was valued at \$20,963,781 (November 30, 2022 - \$20,963,781)

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Investment Holdings

House of Lithium Ltd. ("House of Lithium")

On November 9, 2021, the Company announced it had completed the disposition of its electric vehicle and clean-technology investment portfolio (the "Portfolio") to House of Lithium, an electric mobility and climate tech platform. 38,758,776 Class B common shares were issued to the Company (and its direct subsidiary) in exchange for the Assets which were valued at \$77,517,553. The Portfolio includes the following assets:

Damon Motors Inc. ("Damon"), based in Vancouver, British Columbia

Damon Motors is a global technology leader disrupting urban mobility. With offices in San Rafael, California and headquarters and manufacturing in Vancouver, Canada, Damon is on a mission to cause a paradigm shift for safer, smarter motorcycling. The company is delivering on its promise with award-winning innovation and unprecedented technologies.

Damon's award-winning electric superbikes, including HyperSport and HyperFighter, offer unparalleled safety, comfort, 5G connectivity and performance with groundbreaking technology and zero tailpipe emissions. Proprietary features include its CoPilot™ 360° advanced warning system, complete with a 7" LCD display that streams a rearview from the rear-facing camera; Shift™, which transforms the riding position between sport and commuter modes while in motion; and HyperDrive™, the world's first monocoque constructed, 100 percent electric, multi-variant powertrain platform, which enables Damon to rapidly introduce new models that share 85 percent of the parts of its sibling models.

On October 6th, 2022, Damon announced that it had exceeded a \$90M order backlog with the potential of exceeding \$250M through international partnerships. Damon has leased a 108,000 square foot plant in Surrey, British Columbia to prepare to scale manufacturing for the production of Damon's flagship HyperSport electric motorcycle, with initial deliveries expected in early 2023. Subsequent to the year ended November 30, 2022, Damon announced that it had formed a partnership with Indika Energy, Indonesia's leading diversified energy company. Indika has also made an undisclosed investment in Damon and will serve as the distributor for Damon's line of motorcycles in the Indonesian market.

Damon's state-of-the art innovations have received numerous awards including the CES 2020 and 2022 Innovation Award, the Edison Best New Product Award, the Big Sustainability Award, Fast Company's World Changing Idea, the GOOD DESIGN® Award, a Digital Trends Top Tech, a Red Herring Top 100, a North America finalist award for CleanTech, Popular Science's Best of What's New Award, and a Robb Report "Best of the Best" award for motorcycle innovation. Damon's investors include Round13 Capital, Techstars, Fontinalis Partners, Extreme Venture Partners, Benevolent Capital Partners, and Pallasite Ventures. Visit <https://damon.com/>.

Tevva Motors Ltd. ("Tevva"), based in London, UK

Tevva is a leading developer of hydrogen and electrification systems for commercial vehicles. Its technology across the electric powertrain drives superior performance, is applicable to a broad range of vehicles and duty cycles and provides a solution which prevents emissions in urban areas, whilst enabling a fully practical vehicle for operators. Tevva has a modular approach to its technology design, enabling cost-effective integration into OEM vehicle platforms resulting in numerous competitive benefits for end users, including a significant reduction in total cost of ownership compared to diesel vehicles.

On June 30, 2022, Tevva announced the launch of its landmark 7.5-tonne hydrogen fuel cell-supported heavy goods vehicle (HGV) to be manufactured, designed and mass-produced in the UK. The hydrogen-electric truck will have a range of up to 310 miles, and its hydrogen tanks can be refilled in 10 minutes. HGVs contribute approximately 18% of the UK's greenhouse gas emissions in the transport sector, according to government figures. By adding a hydrogen fuel cell system to its battery-electric HGV design, Tevva delivers zero-emission solutions to fleet operators across various industries and sectors and can be a key contributor to the decarbonization of transportation in Europe and North America.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

In September 2022, Tevva's first series of BEV 7.5 tonne trucks began rolling off the assembly line at its Tilburry, Essex factory. Customers are now receiving orders and Tevva trucks are operational on the road. Subsequent to the period ended November 30, 2022, Tevva received Community Whole Vehicle Type Approval (ECWVTA) for its 7.5 tonne (t) battery-electric truck, a key regulatory milestone towards mass production and sale across the UK and Europe. The first mass-produced electric trucks have started to be delivered from their UK base to customers including Expect Distribution, Travis Perkins, and Royal Mail. The company expects to sell up to 1,000 electric trucks in 2023.

On February 28, 2023, Tevva announced that it had entered into a strategic partnership with Ecobat, the global leader in battery recycling, for the repair, repurposing and recycling of its lithium-ion batteries. The partnership kicks off with a 12-month pilot phase for first-life battery management, with the opportunity to expand into additional energy storage and recycling solutions.

Tevva is well positioned to become a global leader and manufacturer of medium to large-size zero-emission electric trucks by establishing localized production and selling trucks across the world, progressing to continental Europe and North America soon. With a strong management team and impressive track record of key milestone achievements, Tevva aims to create at least three production facilities with total capacity above 9,000 units per year by 2025. Tevva has raised over \$140M from investors, including \$57M in 2022. Visit <https://tevva.com/>.

Revolution Brands International, LLC ("Revolution Brands"), based in Miami, Florida

Revolution Brands International, LLC is a leading global designer, manufacturer, marketer and distributor of recreational electric vehicles, lifestyle products and mobile connectivity accessories. Headquartered in Miami, the organization operates as the parent company for a diverse portfolio of well-recognized brands across its core segments that include Kimoa, SimplyEV, Simply by Clik, House of Lithium and Minimoto – providing consumers with a wide range of high-quality and future-forward products through customer service-focused ecommerce and an expanding network of retail locations. Revolution Brands also recently acquired a majority stake in lifestyle brand Kimoa International LLC ("Kimoa"). Simply EV will be the preferred retailer for Kimoa across the U.S.

Onet Global Inc. ("Navier"), based in San Francisco, California

Navier is building long-range, high-speed electric hydrofoiling boats that provide a smooth zero emission ride. It aims to enable clean, efficient, and affordable waterborne transportation for congested coastal cities around the world by reducing small marine vessel operational cost by 90%. Navier was founded by Sampriti Bhattacharyya who holds a PhD in mechanical engineering from MIT and has worked on flight control systems at NASA. Navier has partnered with renowned Maine-based shipyard Lyman-Morse to build the Navier 30, its 30-foot, all-electric, hydrofoil-equipped boat.

As America's first electric hydrofoiling craft, and the longest range electric marine craft in the world, N30 is truly a game-changer. It is designed by a team of exceptional engineers and roboticists from MIT, CMU and Berkeley along with America's Cup lead Naval Architect Paul Bieker.

The N30 platform is built to fundamentally change the unit economics of moving things and people on the water, thereby enabling a whole new opportunity for clean, scalable waterborne transportation which was never possible before. The zero-emission Navier 30 will be capable of a range exceeding 75nm at 20 knots, and was launched at Art Basal in Miami at the end of 2022. It has established a partnership with San Francisco Water Taxi to begin trials for commercial transportation using Navier's hydrofoil electric boats. Visit <https://www.navierboat.com/>.

Arevo Inc. ("Arevo"), based in Milpitas, California and Ho Chi Minh City, Vietnam

Arevo is a leading 3D printing company that works with product makers to develop and manufacture new products with ultra-strong lightweight continuous carbon fiber. Arevo enables more complex structural parts over traditional composites and additive manufacturing solutions to iterate products faster and explore mass customization. Customers include companies from consumer, industrial, automotive, heavy industries, construction and aerospace sectors. Arevo recently

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

launched a partnership with Kimoa, the Revolution Brands-owned retail brand of racing legend Fernando Alonso, for a line of custom 3D-printed carbon fiber composite e-bicycles. The new custom bicycle brand will enable customers to order frames printed according to their unique measurements and aesthetic preferences. A kiosk-based, in-store Kimoa Lab Experience will let customers experience the customization process in SimplyEV stores across the U.S. Visit <https://arevo.com/>.

Switch Holdco Limited ("Switch Motorcycles"), based in Queenstown, New Zealand

Switch Motorcycles is a new wave production electric motorcycle company founded in 2017 which, in early 2020, launched its pre-production prototype - the globally acclaimed eSCRAMBLER™. The product was designed entirely in 3D by ex-Yamaha Japan Advanced Labs and former Flat Tracking champion Michel Riis Eriksen. The eSCRAMBLER™ was the winner of the Bike EXIF 2020 Bike of the Year award. Switch Motorcycles is taking pre-orders, for Q1 2023 delivery, for the eSCRAMBLER™, the world's first production electric scrambler, which powered by a 50 kW (~70 hp) air-cooled IPM electric motor sending power to the rear wheel via a gates carbon belt. The 13kWh LG 21700 li-ion battery pack provides over 150 kms of range (93 miles). Visit <https://switchmotorcycles.com/>.

Kiwi Campus Inc. ("Kiwibot"), based in Los Angeles, California and Medellin, Colombia

Kiwibot is a leading last-mile robotics delivery platform, developed at the University of California, Berkeley. Founded in 2017 by Felipe Chávez Cortés and Gerard Casale, Kiwibot provides an end-to-end robotic infrastructure to restaurant chains and food delivery aggregators in cities including San Jose, Palo Alto, Miami, and Detroit, using its largely autonomous "Kiwibots", which boast proven operational technology with autonomous obstacle avoidance sensors and sidewalk and corner location detectors.

The food delivery market has experienced rapid growth with sales in the US increasing over 5x since 2018. Kiwibot solves the issue of increasingly expensive traditional delivery services by offering lean and cost-effective operations through better unit economics driven by reduced labor costs. Through partnerships with the San Jose Department of Transportation, Shopify, Olo, Ordermark, and others, Kiwibot is directly integrating with over 120 restaurants in San Jose. Through its partnership with SODEXO, Kiwibot has deployed over 500 robots across 26 college campuses in the United States. In December 2022, Kiwibot announced a partnership with Grubhub, a global food delivery service to deploy robots on more college campuses. Visit <https://www.kiwibot.com/>.

Trevor Motorcycles BV ("Trevor"), based in Antwerp, Belgium

Trevor was founded in 2020 by Philippe Stella and Jeroen-Vincent Nagels and has built a fully electric motorcycle with a "less-is-more" design, incorporating the very latest electric vehicle features and technologies in its lightweight and performance dirt bikes. Designed in California, Trevor's first model, the DTRe Stella, styled by ex-Alta designer John McInnis, is clean and modern, with a battery pack that is integrated into the trellis frame and manufactured by Workhorse Speed Shop. Trevor is preparing to ship the first batches of its DTRe Stella electric motorcycle later this year. Visit <https://www.trevormotorcycles.com/>.

In conjunction with the portfolio disposition and launch of House of Lithium, on November 9, 2021, the Company purchased from House of Lithium 2,000,000 common shares at a price of \$2.00 per share for \$4,000,000. As additional consideration House of Lithium issued to the Company 5,000,000 warrants to purchase an additional common share at a price of \$2.00 for 24 months following the date of issuance, and 2,777,777 warrants to purchase an additional common share at a price of \$3.60 for 24 months following the date of issuance.

In March 2022, House of Lithium completed a private placement equity financing with numerous third-party investors, issuing 1,872,205 shares at \$3.60 per share for gross proceeds of \$6,739,938.

As at February 28, 2023, the Company owned approximately 65.09% of the common shares of House of Lithium on a partially diluted basis.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

The fair market value of the Company's position in House of Lithium as at February 28, 2023, was \$43,361,484 (November 30, 2022 - \$49,723,665). The Company estimated the value of House of Lithium's equity using a Net Asset Value approach by summing the fair market value of its investment assets (determined through cost, market, and income based methods as appropriate) and adjusting for its net cash and debt positions as of the valuation date. A Black-Scholes option pricing model was used to value the warrants. During the year ended November 30, 2022, the Company recorded an unrealized loss of \$13,572,338 (November 30, 2022, unrealized loss: \$35,659,692) on its investment in House of Lithium.

House of Lithium continues to advance towards a public listing. Future drivers of change in the Company's investment include House of Lithium's ability to successfully achieve a public listing, and the continued mass adoption of electric and mobility and green technology alternatives.

Casters Holdings Inc.

In September 2019, the Company purchased convertible notes with a principal value of US\$400,000 in Casters Holdings Inc. ("Casters") which operates through its subsidiary Fylo Inc ("Fylo"). The Company subsequently converted the notes into 1,345,889 shares. In 2021, the Company invested an additional US\$200,000 in Fylo's Series A2 funding round and approximately US\$4 million in its Series B funding round and US\$4 million in its subsequent approximately US\$40 million Series C funding round.

The fair value of the Company's investment at November 30, 2022 was \$11,650,275 (year ended November 30, 2022: \$11,650,275). During the quarter ended February 28, 2023, the Company recorded an unrealized loss of \$Nil (November 30, 2022: unrealized loss of \$6,100,142). Fylo is a digital marketing and data business with a suite of compliance cloud software and services built to overcome the complexities of highly regulated industries. It delivers data, media, retail, and regulatory solutions that enable organizations to streamline compliance, increase efficiencies, and scale with speed. Its omnichannel advertising platform allows customers to run high impact campaigns across desktop, mobile, CTV, and more using enterprise-grade data. It also markets its products to law firms, marketing agencies and other customers that interact or operate in regulated industries.

In 2021, Fylo purchased DataOwl, a software company that develops customer relationship management ("CRM") and business operating solutions for cannabis dispensaries. Following the integration of the platforms, Fylo intends to market what it describes as the industry's "first end-to-end marketing solution", combining consumer data, digital advertising, regulatory compliance, CRM, and loyalty programs tied to a business' POS system.

Fylo has continued to expand its capabilities to drive growth through strategic partnerships and acquisitions. In December 2021, Fylo announced a partnership with Tremor Video, a leading programmatic video and connected TV platform. In February 2022, Fylo announced the launch of Jurisdiction Dashboard, a powerful new feature in the Fylo Regulatory Database. The dashboard, which updates in real-time, provides a complete, strategic view of jurisdiction-level cannabis activity and history, helping users quickly compare jurisdictions, spot trends, and identify and move on data-driven growth opportunities faster. In June 2022, Fylo acquired NineSixteen, an interactive retail display network that delivers high-impact digital experiences in physical retail locations. Fylo's business has shifted towards marketing solutions for mainstream brands and other applications for its tools and datasets.

Material drivers of fair value include growth in Fylo's customer base, datasets, and increased demand for regulatory compliance software as well as its continued expansion into new segments by diversifying its product offerings. Future fair value increases may be driven by penetration of Fylo's tools into other verticals with complex regulatory needs. The Company's investment was measured at fair value based on the price of the most recent financing where arm's length third parties participated and adjusted for company specific risks associated with ongoing operations.

Captor Capital Corp. (CSE:CPTR)

Captor Capital Corp. ("Captor") is a vertically integrated cannabis investment company listed on the Canadian Securities Exchange, OTC USA and the Frankfurt Stock Exchange. Captor cultivates, manufactures and distributes recreational and medical marijuana-based products to consumers through its leading brands and dispensary retail stores. Captor Capital has a 51% controlling stake in a California joint venture portfolio which has two CHAI Cannabis Co. branded dispensaries, four One Plant branded dispensaries and 3 additional California cannabis retail licenses for stores under construction.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

As at February 28, 2023, the fair market value of this position was \$2,077,459 (year ended November 30, 2022: \$3,757,963). In April 2021, the Company invested \$3.9 million in units of Captor for \$0.95 per unit. Each unit comprised of one share and one half of a share purchase warrant. A full warrant had a term of 2 years and a strike price of \$1.20. As at February 28, 2023, the Company held 9,343,963 shares and 2,052,632 warrants. SOL Global's position in Captor was measured at fair value based on the market price of Captor's shares. Warrants were valued using the Black-Scholes option pricing model. During the period ended February 28, 2023, the Company recorded an unrealized loss of \$15,578 (year ended November 30, 2022: unrealized loss of \$8,649,119). The material drivers of change in the fair market value include expansion of the retail footprint, potential acquisitions, and the recent downturn in cannabis sector capital markets.

On June 21, 2022, Captor announced the commencement of a strategic review process to identify, examine, and pursue strategic alternatives to Captor's current business. In July 2022, Captor announced the signing of a letter of intent for a reverse takeover transaction with Rimstock Holdings Limited ("Rimstock"). Rimstock, a UK-based company, designs and manufactures high quality, lightweight, forged alloy wheels for some of the world's most prestigious automotive OEMs. Rimstock manufactures wheels at its facility in West Bromwich in the West Midlands and operates foreign sales and marketing subsidiaries in Germany and the USA.

In 2018, Rimstock successfully transitioned from the production of cast rims to forged aluminum, which are relied upon heavily by the electric and premium/performance vehicle markets as Rimstock technology has been specifically engineered to provide high performance standards while factoring in weight and torque. Following a management change in 2021, Rimstock secured mid-to-long term contracts with premium and super premium brands who use Rimstock as their wheel platform of choice.

Captor is directly engaged in the cultivation and/or distribution of cannabis in accordance with U.S. state licences, however the Company does not control Captor. Accordingly, the Company's investment in Captor may be considered to be "ancillary industry involvement" as described under Staff Notice 51-352. See "Regulatory Developments – Regulatory Developments in the United States", "Issuers with U.S. Cannabis-Related Assets" and "Risk Factors". To the best of the Company's knowledge, Captor is in compliance with all applicable federal and state guidelines.

Simply Better Brands Corp

Simply Better Brands Corp. ("SBBC") leads an international omni-channel platform with diversified assets in the emerging plant-based and holistic wellness consumer product categories. Its mission is focused on leading innovation for the informed Millennial and Generation Z populations in the rapidly growing plant-based, natural, and clean ingredient space. SBBC continues to focus on expansion into high-growth consumer product categories including CBD products, plant-based food and beverage, and the global pet care and skin care industries. SBBC's product portfolio includes PureKana, a leader in the CBD oils and tinctures space. It has shown persistent growth and margin defensibility since its founding in 2017.

As at February 28, 2023, the Company held 5,544,120 shares with a fair market value of \$2,429,071 (November 30, 2022 – 1,616,525 shares with a fair market value of \$351,608). During the year ended November 30, 2022, the Company recorded an unrealized gain of \$1,084,820 (year ended November 30, 2022: unrealized loss of \$1,962,717).

In 2022, SBBC delivered top line revenue growth of over 400% and achieved gross margin expansion while simultaneously reducing debt.

SBBC announced an increase to its previously announced 2022 outlook:

- *Expected consolidated net sales increased to \$65 million from \$50-\$55 million*
- *Expected gross margin as a percentage of net sales of 63%-65%*

Despite SBBC's strong growth and expansion of its product portfolio through strategic acquisitions and partnerships, the fair value of the Company's investment in SBBC has declined due to challenging market conditions for small-cap consumer discretionary equities. On June 7, 2022, SBBC terminated the previously announced letter of intent to merge with craft soda company Jones Soda (CSE:JSDA) (OTCQB:JSDA) due to unfavourable market conditions. Key drivers of growth are continued robust customer acquisition for its PureKana product line, and the distribution and expansion of TRUBAR.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Common C Holdings LP (Common Citizen)

On August 24, 2021, the Company made an investment of US\$20,000,000 in Common C Holdings LP ("Common Citizen"). Common Citizen focuses on cannabis production, cultivation, processing, retail and wholesale distribution for both the medical and adult market in Michigan and across the United States. Launched in Detroit in 2018, the Common Citizen brand takes a deliberate, people-first approach to its business strategy — from production to retail. In July 2021, Michigan's cannabis revenues were greater than US\$170 million. As at February 28 2023, the fair value of the Company's investment in Common Citizen was \$13,629,449 (November 30, 2022 - \$13,629,449). During the quarter ended November 30, 2022, the Company recorded an unrealized loss of \$Nil (November 30, 2022 -\$11,973,239) on its investment in Common Citizen.

Through streamlining management functions, optimizing product mix, economies of scale and scope and other efficiency initiatives, Common Citizen has achieved success in consolidating, vertically integrating and operating in the Michigan market. Consequently, in 2022 Common Citizen achieved significantly improved revenue, gross margin, EBITDA, and adjusted EBITDA vs 2021 on an absolute and per unit basis. However, equity valuations of comparable publicly traded cannabis companies have declined with rising interest rates impacting broader equity markets and frontier industries in particular. The Company valued its investment in Common Citizen using the comparable public company multiples method with a liquidity discount applied to reflect the reduced liquidity of private investments compared to public peers.

The total Michigan cannabis market is estimated to be greater than \$1.5 billion and is expected to grow to \$4 billion in the next 3-5 years. Common Citizen takes a deliberate, people-first approach to its business strategy and, in concert with its licensed partners, is well-positioned to capture a significant portion of the growing Michigan cannabis market. Future drivers of value in the Company's investment will be driven by the successful acquisition and integration of retail cannabis outlets, vertical integration, and margin expansion related to efficiency initiatives.

Jones Soda Co. (CSE:JSDA)

Jones Soda Co. ("Jones Soda") together with its subsidiaries, develops, produces, markets, and distributes beverages in the United States, Canada, and internationally. Jones Soda offers iconic premium soft drinks, fountain products, co-brand, and private label products. It also sells various products online including soda with customized labels, candies, and wearables. Jones Soda sells and distributes its products through a network of independent distributors, and national and regional retail accounts, as well as through grocery stores, convenience stores, gas stations, and restaurants. It operates 210 Meijer stores in six Midwest states. The Company acquired shares and convertible debt in Jones Soda through private financings as well as through purchases in the open market.

As at February 28, 2023, the Company held 14,796,380 common shares of Jones Soda and 8,855,035 common share purchase warrants. The warrants have a US\$0.625 strike price and are exercisable until February 14, 2024. The fair market value of the Company's position in Jones Soda as at February 28, 2023 was \$5,523,938 (November 30, 2022- \$5,896,251). The fair market value was determined based on the trading price of Jones Soda on November 30, 2022, and the use of the Black-Scholes option pricing model to value the warrants. As at February 28, 2023, the Company owned approximately 22% of Jones Soda on a partially diluted basis. During the quarter ended February 28, 2023, the Company recorded an unrealized loss of \$372,313 (year ended November 30, 2022: unrealized gain of \$13,243,918) on its investment in Jones Soda.

Full year 2022 financial summary:

- Revenue increased 29% to \$19.1 million in 2022 compared to \$14.8 million in 2021, primarily driven by growth in core bottled business through retail and alternative channels
- Gross profit as a percentage of revenue was 26.9% in 2022 compared to 29.7% in 2021, driven by increased material costs
- Net loss was \$6.4 million or \$(0.07) per share, compared to a net loss of \$1.8 million, or \$(0.03) per share, driven by expenses related to entry into the cannabis beverage market

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Future changes in fair value may be driven by market conditions, Jones Soda's ability to mitigate inflationary and supply chain pressures, market penetration and development of Jones Soda's core products, and the commercial success of Jones Soda's new cannabis beverage line, Mary Jones. On June 7, 2022, SBBC terminated the previously announced letter of intent to merge with craft soda company Jones Soda due to unfavourable market conditions.

In June 2021, Jones Soda announced plans to launch a cannabis-infused beverage line, which was later launched as 'Mary Jones Cannabis Soda' in early 2022. As such, Jones Soda is now directly engaged in the cultivation and/or distribution of cannabis in accordance with U.S. state licences, however the Company does not control Jones Soda. Accordingly, the Company's investment in Jones Soda may be considered to be "ancillary industry involvement" as described under Staff Notice 51-352. See "Regulatory Developments – Regulatory Developments in the United States", "Issuers with U.S. Cannabis-Related Assets" and "Risk Factors". To the best of the Company's knowledge, Jones Soda is in compliance with all applicable federal and state guidelines.

Livwrk SOL Wynwood LLC

In July 2021, Livwrk SOL Wynwood LLC ("Livwrk SOL") acquired a 2.4-acre assemblage (the "Property") in the Wynwood area of Miami, Florida for investment purposes. The property includes a retail storefront and an office building with associated land. Headquartered in Miami, SOL Global recognized the potential for the city to continue to develop into a hub for technology development, innovation, and entrepreneurship, and the impact that it would have on real estate in the city, and thus saw an investment in Miami real estate as a logical way to diversify its investment portfolio, and add strategic real asset exposure while opening opportunities for value creation through synergies with other investments in the Miami area. As of November 30, 2022, the Company maintained a 45% equity interest in Livwrk SOL.

The fair market value of SOL Global's investment in Livwrk SOL as of February 28, 2023, was \$20,963,781. During the quarter ended February 28, 2023, the Company recorded an unrealized gain of \$Nil (year ended November 30, 2022: unrealized gain of \$1,697,231) on its investment in the asset.

The Company determined the fair market value of its investment in Miami real estate, based on its pro-rata share of the net equity in the Miami real estate holding company, Livwrk SOL. The net equity was determined by estimating the value of the real estate asset and subtracting the net debt. The value of the real estate asset was estimated using the market approach, through observation of and comparison to recent sales of pre-development stage real estate in the Wynwood area of Miami.

In early 2022 Livwrk SOL submitted plans to the Miami Urban Development Review Board for a mixed-used development. The review board approved of the submitted proposal. The proposed development comprises two buildings on separate parcels of land rising 8 to 12 stories each. One parcel would consist of 420 multifamily residential units and 59,461 square feet of office space above 29,057 square feet of ground floor commercial space. The other parcel would be developed as an apartment/hotel with 122 units, atop 8,996 square feet of ground floor commercial space. In total, both buildings would collectively yield 922,466 square feet including 611,855 square feet of residential and amenity space, 100,220 square feet of office and commercial space, and a 210,361-square-foot parking structure for 564 vehicles and 50 racks for nearly 800 bicycles.

Both structures feature distinguished designs containing a variety of materials, textures and colors that compliments the surrounding context of the developing neighborhood while reminiscing the roots of earlier buildings in Wynwood.

The change in the fair value of the Company's investment in Livwrk SOL has been driven by the continued strength of strategically located, large Miami development property values and emergence of Wynwood as a destination neighborhood, offset by a decrease in the Company's stake in Livwrk SOL with other investors funding pre-development costs. Future changes in fair value may be driven by Livwrk SOL's ability to advance development, the continued growth of Miami and Wynwood specifically, and the strength of the broader real estate market and capital markets for real estate development.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Marsico AXS CS LLC

In September 2021, the Company, through a wholly owned subsidiary, invested US\$11.5 million in Marsico CS, an investment vehicle of Colorado-based Marsico Capital Management. Marsico CS was set up as an investment vehicle for the purpose of raising capital and investing in Core Scientific, and subsequently completed its investment in Core Scientific.

Core Scientific is a large-scale net carbon-neutral blockchain infrastructure provider and miner of digital assets in North America. Core Scientific has operated blockchain infrastructure in North America since 2017, using its facilities and intellectual property portfolio of more than 70 patents or applications for digital asset hosted mining and self-mining. Core Scientific operates data centers in Georgia, Kentucky, North Carolina, and North Dakota. Core Scientific's proprietary Minder® fleet management software combines hosting expertise with data analytics to deliver maximum uptime, alerting, monitoring and management of all ASICs and GPUs in Core Scientific's network.

As of September 30, 2021, over 50% of the power used in Core Scientific's operation was generated from non-carbon emitting sources by local power providers pursuant to long-term power contracts. Core Scientific determines whether power is generated from non-emitting energy sources from dispatch reports or grid generation mix reports provided by Core Scientific power providers. Based on these reports Core Scientific purchased Green-e certified renewable energy credits ("RECs") to offset 100% of the carbon produced as a result of its contracted power. Core Scientific expects to maintain its 100% net carbon neutrality by increasing its overall use of renewable power and by purchasing RECs when necessary. An intended de-Special Purpose Acquisition Company ("SPAC") transaction between Core Scientific and Power and Digital Infrastructure Acquisition Corp. ("XPDI"), a listed SPAC, was announced in July 2021. The de-SPAC transaction between Core Scientific and XPDI closed in January 2022. The resulting company, named Core Scientific Inc., began trading on the NASDAQ exchange on January 20, 2022.

The fair market value of the Company's position in Core Scientific as at November 30, 2022 was determined by valuing the debt and equity components of the underlying Core Scientific convertible debenture held by Marsico CS.

The fair market value of the Company's position in Core Scientific as of February 28, 2023, was \$8,746,009 (November 30, 2022 - \$8,746,009). During the quarter ended February 28, 2023, the Company recorded an unrealized loss of \$Nil (year ended November 30, 2022: unrealized loss - \$12,926,747) on its investment in Core Scientific. The change in value was driven by the high volatility in the market price for Core Scientific shares following its de-SPAC and its ability to raise reasonably priced debt financing as interest rates have risen in the broader market. Future changes in fair value will be driven by the cryptocurrency market and popularity of Bitcoin, and Core Scientific's ability to mine for digital assets profitably and efficiently and to attract customers for hosting services, while managing its costs and mitigating inflationary pressures on energy costs.

In June 2022, Core Scientific released a monthly update in which it announced that it disposed of USD\$167M worth of Bitcoin in June, and continued to add data center capacity, grow our self-mining assets and deploy additional collocated ASIC servers for customers. Subsequent to the year ended November 30, 2022, Core Scientific Labs filed for bankruptcy protection due to the extended downturn in the price of Bitcoin. It later received an offer for a US\$75M DIP facility from B. Riley and with Bitcoin prices recovering, has strengthened its balance sheet. The Secured Convertible Notes that the Company holds interest in, was noted by B. Riley as not likely to be defaulted on. The Company continues to monitor the proceedings closely but is optimistic that the full value of its investment can be realized.

Andretti Acquisition Corp. (NYSE:WNNR)

Andretti Acquisition Corp. (NYSE: WNNR) ("Andretti") is a SPAC formed for the purpose of effecting a business combination with one or more businesses or entities. While Andretti may pursue a business combination in any industry, Andretti is primarily focused primarily on the broadly-defined automotive industry. This industry includes, but is not limited to, advanced mobility and related next-generation technologies, premium and performance vehicles, and replacement automotive parts. Two key members of the management team are racing legends Mario and Michael Andretti, and Andretti seeks to focus on opportunities that can benefit from the iconic Andretti brand name.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Management's experience in the auto-racing and automotive space, paired with the Company's varied investments in electric mobility presented a unique opportunity to participate in the SPAC side of the EV market with a top-tier team. The Company co-sponsored the SPAC's initial public offering (IPO) and received 1,490,923 Class B founders shares that convert to Class A common shares upon closing of a qualifying acquisition. The Company also purchased 3,450,000 warrants that give the right to purchase Class A common shares of Andretti at a US\$11.50 strike price.

The fair value of the Company's investment in Andretti as of February 28, 2023 was \$12,376,986 (November 30, 2022 - \$14,063,047). The Company recorded an unrealized loss of \$1,686,061 on its investment in Andretti during the quarter ended February 28, 2023 (year ended November 30, 2022: unrealized gain - \$9,708,158). The fair value of the Company's investment in Andretti as of February 28, 2023, was determined based on the sum of the closing trading price of the Company's Andretti shares and warrants, which are both publicly traded. The fair value of the shares was discounted to account for illiquidity of the Class B founders shares held by the Company not converting into the tradeable Class A common shares until a qualifying transaction is completed.

The increase in fair value of the Company's investment in Andretti was driven by the successful IPO of the Andretti SPAC and future increases in the fair value will be driven by market conditions for SPACs and Andretti successfully executing a qualifying acquisition.

Build A Rocket Boy Ltd.

Build a Rocket Boy Ltd. ("BARB") is an independent video game company based in Edinburgh, Scotland, founded by Leslie Benzies in 2016 focused on the future of cutting-edge AAA games. Benzies is the highest grossing video game designer, director, and producer of the last two decades, whose games have accumulated \$15bn in aggregate global revenue. Grand Theft Auto (GTA) and Red Dead Redemption are the two most notable franchises he's credited with overseeing.

BARB is currently in production of its inaugural video game, EVERYWHERE, an open world social massively multi-player online game (MMO) set to launch in mid to late 2023. BARB believes the future of entertainment lies at the intersection of video games, user generated content (UGC) and virtual worlds, where a captive venue allows the consumer to shop (e-commerce), watch, listen and socialize within the forum. BARB is pursuing a community-first approach that will be the key driver underlying the success of its accompanying metaverse and igniting the embedded crypto cloud-based economy. Both the AAA game and the metaverse are powered by proprietary tools, technology stack and architecture.

Since inception, BARB has attracted a crop of award-winning seasoned game developers, who now total ~450 across four studios in Edinburgh, Budapest, Los Angeles, and Guangzhou.

On August 23, 2022, BARB was featured at Opening Night Live, the launch party for Gamescom, Europe's largest and preminent gaming conference. The studio showcased this official teaser trailer for Everywhere, its immersive "freemium" play-to-earn gaming, multimedia and metaverse platform, while offering a more subtle hint toward its standalone AAA game, Mindseye, embedded at the end of the clip.

The fair value of the Company's investment in BARB as of February 28, 2023 was \$2,317,714 (November 30, 2022 - \$2,317,714). The Company recorded an unrealized loss of \$Nil during the quarter ended February 28, 2023 (year ended November 30, 2022: unrealized loss - \$247,790). The Company determined the fair value of its investment in BARB using a market-based approach.

Future drivers of fair value changes include the release and degree of commercial success of BARB's inaugural game, "Everywhere".

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Tokenise International Inc.

Tokenise International Inc. ("Tokenise") aims to develop a fully regulated tokenized-security exchange allowing individuals to participate in fractional ownership or royalties by invested in security tokens.

Tokenise was founded on the understanding that the tokenization of securities and other assets has the potential to transform the accessibility and efficiency of capital markets. The Tokenise Group comprises of a regulated Stock Exchange, a Brokerage and Central Securities Depository to democratize the process of enabling consumers to acquire fractional units in various asset types, to reduce friction and barriers to participation and to empower individuals and institutions around the world to take control of their financial future through a regulated environment.

The Company's investment in Tokenise in May 2021, was driven by the Company's belief in the emergence of tokenization and fractionalization/securitization of new asset-classes as an emerging theme with the increasing popularity of retail investment, combined with the Company's confidence in Tokenise's highly experienced team including founder Michael Kessler, to navigate a complicated regulatory involvement for tokenization.

The fair value of the Company's investment in Tokenise as of February 28, 2023, was \$2,807,496 (November 30, 2022 - \$2,807,496). The Company recorded an unrealized gain of \$Nil during the quarter ended February 28, 2023. (Unrealized gain - \$125,898 during the year ended November 30, 2022). The Company determined the fair value of its investment in Tokenise based on the observed price per share of a recent arm's length secondary sale of Tokenise shares.

Future drivers of fair value changes include Tokenise's success in launching a regulated tokenized exchange and ability to generate modelled economic results from operating the exchange through attracting users (both individuals/entities seeking to tokenise assets or equity and individuals/entities seeking to buy and/or trade tokenized securities). This will be driven by both the quality and attractive of Tokenise's platform and the broader capital markets and emergence of tokenization.

SELECTED QUARTERLY FINANCIAL INFORMATION (expressed in thousands except per share amounts)

	28-Feb-23	30-Nov-22	31-Aug-22	31-May-22	28-Feb-22	30-Nov-21	31-Aug-21	31-May-21	28-Feb-21	30-Nov-20	31-Aug-20	31-May-20
	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Total revenue	(12,145)	(46,477)	(11,156)	(96,193)	(81,110)	(37,412)	12,513	334,885	249,003	46,833	61,098	25,530
Net (loss) income	(10,809)	(53,435)	(12,497)	(86,668)	(86,688)	(76,607)	(62,367)	64,653	208,128	34,095	43,695	1,314
(Loss) income per share, basic	(0.20)	(1.00)	(0.25)	(1.90)	(1.94)	(1.47)	(1.17)	1.21	3.80	0.87	0.81	0.02
Loss (income) per share, fully diluted	(0.20)	(1.00)	(0.25)	(1.90)	(1.94)	(1.32)	(1.10)	1.14	3.58	0.83	0.78	0.02
Total assets	143,226	153,125	244,618	263,641	358,564	480,491	594,937	599,409	549,380	298,234	252,337	199,372
Working capital surplus	31,265	41,891	160,744	173,039	247,103	361,311	410,669	477,577	419,579	211,368	216,488	178,712

During the twelve most recent quarters the following items have had a significant impact on the Company's results:

- Made significant investments in numerous companies including House of Lithium, Verano Holdings, Common C Holdings, Core Scientific, Florida Real Estate, MedMen, Cansortium, CannCure, Heavenly, Engine, DNA Genetics and numerous others.
- Completed a substantial issuer bid, pursuant to which the company cancelled 7,407,404 common shares for an aggregated purchase price of \$30 million.
- Completed a \$50M private placement financing by way of the issue and sale of a senior secured non-convertible debenture. The Debenture would bear an interest rate of 6.0% per annum and mature on June 30, 2022. For further information, please refer to the heading "Legal claims related to the Debenture commenced by the lender against the Company and commenced by the Company against the lender" above and subsequently settled with the lender for \$120M.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

- Entered into a \$50M single advance non-revolving loan term facility with the a private company for the sole purpose of acquiring all of 1235 Fund LP's rights under the Debenture. On September 3, 2022, the company drew down the \$50M line of credit to pay 1235 Fund LP as part of the legal settlement.
- CannCure entered into a business combination agreement with Bluma pursuant to which CannCure completed a reverse takeover of Bluma on June 11, 2021 and Bluma commenced trading on the CSE on June 15, 2021.
- Verano completed its merger with AltMed and its affiliated companies and concurrently completed a reverse takeover of Majesta and became publicly-listed on the CSE under the ticker CNSX:VRNO. Verano commenced trading on February 17, 2022.

LIQUIDITY AND CAPITAL RESOURCES

As of February 28, 2023, the Company had cash and cash equivalents of \$0.1 million (November 30, 2022: \$0.1 million) and positive working capital of \$31.3 million (excluding right of asset, leasehold improvements and lease liability) (November 30, 2022: \$47.3 million). The Company's financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business and does not reflect adjustments to assets and liabilities that would be necessary if it were unable to continue as a going concern. For the three-month period ended February 28, 2023, the Company recorded a net loss of \$10,809,255 (Year-end November 30, 2022: Loss of \$297,020,051), had positive cash flows from operations and, as it is an investment company, has no regular sources of income other than its investment activities. The Company had a history of operating losses and negative cash flows from operations, with the exception of net income generated for the year ended March 31, 2019, November 30, 2020 and November 30, 2021. The Company is reliant on net income from continuing operations and capital markets for future funding to meet its ongoing obligations. The application of the going concern concept is dependent on the Company's ability to receive continued financial support from its stakeholders and, ultimately, on the Company's ability to generate profitable operations in the future. These circumstances indicate the existence of material uncertainty may cast significant doubt as to the Company's ability to continues as a going concern.

SHARE CAPITAL STRUCTURE

The Company's authorized capital consists of an unlimited number of Common Shares without par value. As at the date of this MD&A, there were a total of 54,441,981 Common Shares issued and outstanding. As at May 1, 2023, the Company's issued and outstanding shares, stock options and deferred share units were as follows:

	Amount
Common Shares	54,411,981
Stock options	124,000
Deferred share units	638,000
Total fully diluted	55,203,981

OFF-BALANCE SHEET ARRANGEMENTS

The Company has no off-balance sheet arrangements.

COMMITMENTS AND CONTINGENCIES

Litigation

The Company will record a provision for losses when claims become probable, and the amounts can be reasonably estimated. The Company is subject to various claims, lawsuits and other complaints arising in its ordinary course of business. The Company is aware of no more outstanding actions relating to its disposal of LATAM Holdings Inc. No amounts have been accrued in these Financial Statements.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

On August 8, 2022, Reby and Restanca LLC (Reby's largest shareholder and the party appointed to represent the remaining selling shareholders) brought a claim against House of Lithium in the Delaware Court of Chancery alleging a breach of a stock purchase agreement between Reby and House of Lithium (the "Reby Agreement"). House of Lithium's position is that no such breach under the agreement occurred, and House of Lithium will vigorously defend the claim. The final Debrief took place March 30, 2023, with a decision coming within 90 days. The Company is not a party to the action and SOL Global has not been named in any action relating to the Reby Agreement. No amounts have been accrued in these Financial Statements. As at February 28, 2023, the company owned approximately 65.09% of the common shares of House of Lithium on a partially diluted basis.

Right of Use Asset and Lease Liability

On May 30, 2020, the Company commenced a new office lease for office space in Miami, Florida, which expires on May 30, 2025, and recorded a lease liability and a corresponding right of use asset in the amounting to \$1,276,775. The lease liability was measured at the present value of the remaining lease payments, discounted using the Company's incremental borrowing rate which was determined to be 9% per annum for similar assets. The right of use asset was initially recorded at the present value of the lease obligation and the Company recorded depreciation of \$31,919 for the three-month period ended February 28, 2023 (November 30, 2022: \$127,678).

On August 1, 2021, the Company commenced a new office lease for office space in Toronto, Ontario which expires on September 30, 2024, and recorded a lease liability of \$1,367,377 and a corresponding right of use asset adjusted for prepaid rent in the amount of \$1,559,485. The lease liability was measured at the present value of the remaining lease payments, discounted using the Company's incremental borrowing rate which was determined to be 4.99% per annum for similar assets. The right of use asset was initially recorded at the present value of the lease obligation with adjustment for prepaid rent and the Company recorded depreciation of \$113,834 for the three-month period ended February 28, 2023 (November 30, 2022: \$434,093).

On March 1, 2021, the Company entered into a dry lease agreement with a third party whereby the Company will use the third party's commercial airplane for M&A and business activities. During the period ended February 28, 2023, as of November 30, 2022, the Company was no longer using the airplane and accordingly wrote of the right of use asset amounting to \$372,681. As of November 30, 2022, the Company impaired the liability and recorded gain on termination of the lease for \$263,491.

Set out below are the carrying amounts of right of use assets and lease liabilities recognized and the movements during the year:

	Right-of-use asset \$	Lease Liabilities \$
As at December 1, 2021	3,686,089	3,802,419
Termination	(372,682)	(636,172)
Depreciation	(1,390,459)	-
Accretion	-	122,749
Payments	-	(672,827)
As at November 30, 2021	3,686,089	3,802,419
Depreciation	(145,754)	-
Accretion	-	27,132
As at February 28, 2023	1,777,195	2,643,301

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

The following is a schedule of minimum lease payments over the lives of the right-of-use lease:

2023	623,831
2024	634,342
2025	195,515
2026	201,381
2027	207,422
2028	213,645
2029	220,054
2030	111,653
Total	2,407,843

LEASEHOLD IMPROVEMENTS

As of February 28, 2023, the Company has incurred costs relating to leasehold improvements of \$622,877 for the Miami office. (November 30, 2022: \$632,661).

Airplane Improvements

On March 1, 2021, the Company entered into an agreement with third party whereby the Company will use third party's commercial airplane for M&A and business activities. As of November 30, 2022, the company had terminated the agreement with the third party spent and incurred a realized loss of \$2,733,362.

PROMISSORY NOTE PAYABLE

As of February 28, 2023, a total of \$1,329,027 with a cost of \$1,150,000 (November 30, 2022: \$1,312,107 with a cost of \$1,150,000) was held in promissory notes. Interest accrued as of February 28, 2023, was \$279,027 (November 30, 2022 - \$262,107).

RELATED PARTY TRANSACTIONS

Parties are considered related if one party has the ability, either directly or indirectly, to control the other party or exercise significant influence over the other party in making operating and financial decisions. Parties are also related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is a related party transaction when there is a transfer of resources or obligations between related parties. The Company has identified its directors and senior officers as key management who are considered to be related parties.

During the three-month period ended February 28, 2023, the Company incurred payroll related costs of \$263,551 (February 28, 2022: \$422,651) with directors and senior officers as key management. As of February 28, 2023, \$2,402,289 (February 28, 2022: \$Nil) was included in account payable and accrued liabilities related to amounts due to directors and senior officers as key management that had not been paid.

During the three-month period ended February 28, 2023, the Company incurred the following payroll related costs:

	Three-month period ended February 28, 2023	Three-month period ended February 28, 2022
	\$	\$
Salaries and consulting fees (1)	263,551	422,651
Total	263,551	422,651

On February 27, 2023, the company elected Paul Kania, CFO to act as interim CEO. Former CEO, Kevin Taylor to transition from the company to a strategic advisory role working directly with SOL's portfolio companies, specifically in his role of Chairman and CEO of House of Lithium Ltd., SOL Global's largest single holding., SOL Global has elected Ms. Deena Siblock and Mr. Mehdi Azodi to the Board of Directors, effective immediately. Olivier Centner will step down as

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

an independent director of the Company's board of directors and continue to be involved as a special advisor to the Company with an active focus on the Company's investee companies.

(b) Transactions with related parties

Transactions with House of Lithium

On November 9, 2021, the Company announced it had completed the disposition of its electric vehicle and clean technology investment portfolio ("the assets", or collectively "the portfolio") to House of Lithium, an electric mobility platform and climate tech focused spinoff company, preparing for an upcoming public listing. 38,758,776 Class B and 2,000,000 Class B common shares valued at \$2 per share were issued. 5,000,000 warrants exercisable at \$2 for two years, and 2,777,777 warrants exercisable for \$3.60 for two years were issued.

	Cost	FMV
Total assets transferred to HOL	66,058,969	40,969,719
Purchase of equity units	4,000,000	1,950,801
Purchase of warrants	-	440,964
Total	70,058,969	43,361,484

As at February 28, 2023, the Company owned approximately 65.09% of the common shares of House of Lithium on a partially diluted basis. The fair market value of the Company's position in House of Lithium as at November 30, 2022, was \$43,361,813 (February 28, 2022 - \$81,517,552). As of February 28, 2023, the company accrued management fee of \$150,000 CDN (February 28, 2022 - \$Nil) and the company owed \$1,437,442 (February 28, 2022 - \$546,968)

SOL Global Investments Corp

Management’s discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

ISSUERS WITH U.S. CANNABIS-RELATED ASSETS

On February 8, 2018, the Canadian Securities Administrators published Staff Notice 51-352, as amended, setting out the Canadian Securities Administrators’ disclosure expectations for specific risks facing issuer with direct, indirect or ancillary involvement in activities including the cultivation, possession or distribution of marijuana in the United States (“US Marijuana-Related Activities”). Staff Notice 51-352 establishes minimum disclosure requirements for all issuers with US Marijuana-Related Activities, including those with direct and indirect involvement in the cultivation and distribution of cannabis, as well as issuers that provide goods and services to third parties involved in the United States cannabis industry.

All reporting issuers with U.S. Marijuana-Related Activities are expected to clearly and prominently disclose certain prescribed information in prospectus filings and other applicable disclosure documents, including this MD&A, in order to fairly present all material facts, risks and uncertainties about issuers with U.S. cannabis-related activities. In accordance with Staff Notice 51-352, below is a table of concordance that is intended to assist readers in identifying those parts of this MD&A that address the disclosure expectations outlined in Staff Notice 51-352

Industry Involvement	Specific Disclosure Necessary to Fairly Present all Material Facts, Risks and Uncertainties	Disclosure or Cross-Reference
All Issuers with U.S. Marijuana-Related Activities	Describe the nature of the issuer’s involvement in the U.S. marijuana industry and include the disclosures for at least one of the direct, indirect and ancillary industry involvement types noted in this table.	See the discussion of the Company’s investments under the heading “ <i>Investment Holdings</i> ”.
	Prominently state that marijuana is illegal under U.S. federal law and that enforcement of relevant laws is a significant risk.	See the discussion under the heading “ <i>United States Regulatory Risk Around the Cannabis Industry</i> ”. See the discussion under the heading “ <i>Regulatory Developments</i> ”. See the description of risks under the heading “ <i>Risk Factors</i> ”.
	Discuss any statements and other available guidance made by federal authorities or prosecutors regarding the risk of enforcement action in any jurisdiction where the issuer conducts U.S. marijuana-related activities.	See the discussion under the heading “ <i>United States Regulatory Risk Around the Cannabis Industry</i> ”. See the discussion under the heading “ <i>Regulatory Developments</i> ”.
	Outline related risks including, among others, the risk that third-party service providers could suspend or withdraw services and the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S.	See the description of risks under the heading “ <i>Risk Factors</i> ”.
	Given the illegality of marijuana under U.S. federal law, discuss the issuer’s ability to access both public and private capital and indicate what financing options are / are not available in order to support continuing operations.	See the discussion under the heading “ <i>United States Regulatory Risk Around the Cannabis Industry</i> ”. See the description of risks under the heading “ <i>Risk Factors</i> ”.
	Quantify the issuer’s balance sheet and operating statement exposure to U.S. marijuana-related activities.	See the discussion under the heading “ <i>United States Regulatory Risk Around the Cannabis Industry</i> ”.
	Disclose if legal advice has not been obtained, either in the form of a legal opinion or otherwise, regarding (a) compliance with applicable state regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law.	See the discussion under the heading “ <i>United States Regulatory Risk Around the Cannabis Industry</i> ”. See the discussion under the heading “ <i>Regulatory Developments</i> ”.

SOL Global Investments Corp

Management’s discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Industry Involvement	Specific Disclosure Necessary to Fairly Present all Material Facts, Risks and Uncertainties	Disclosure or Cross-Reference
U.S. Marijuana Issuers with indirect involvement in cultivation or distribution. ⁽¹⁾	Outline the regulations for U.S. states in which the issuer’s investee(s) operate.	See the discussion under the heading “Regulatory Developments”.
	Provide reasonable assurance, through either positive or negative statements (which may include statements that the issuer is not aware of non-compliance), that the investee’s business is in compliance with applicable licensing requirements and the regulatory framework enacted by the applicable U.S. state. Promptly disclose any non-compliance, citations or notices of violation, of which the issuer is aware, that may have an impact on the investee’s license, business activities or operations.	See the discussion under the heading “United States Regulatory Risk Around the Cannabis Industry.”. See “Investment Holdings” See the discussion under the heading “Regulatory Developments”. See the description of risks under the heading “Risk Factors”.

Notes:

- (1) Indirect industry involvement arises where an issuer has a non-controlling investment in an entity who is directly involved in the U.S. marijuana industry.

REGULATORY DEVELOPMENTS

The commercial medical cannabis industry is a relatively new industry, and the Company anticipates that such regulations will be subject to change. The Company’s operations are subject to a variety of laws, regulations, guidelines and policies relating to the manufacture, import, export, management, packaging/labeling, advertising, sale, transportation, distribution, storage and disposal of the product candidates and also laws and regulations relating to drugs, controlled substances, health and safety, the conduct of operations, and the protection of the environment. While to the knowledge of management, the Company is currently in compliance with all such laws, any changes to such laws, regulations, guidelines, and policies due to matters beyond the control of the Company may adversely affect its operations and performance.

In accordance with Staff Notice 51-352, the Company will evaluate, monitor and reassess the disclosure contained herein, and any related risks, on an ongoing basis and the same will be supplemented, amended and communicated to investors in public filings, including in the event of government policy changes or the introduction of new or amended guidance, laws or regulations regarding marijuana regulation.

Regulatory Developments in the United States

In the United States, cannabis is regulated at the state and federal level. To the Company’s knowledge, there are to date a total of 44 U.S. states, the District of Columbia, and the territories of Puerto Rico, the U.S. Virgin Islands, Guam, and the Northern Mariana Islands have legalized some form of cannabis for medical use, while 19 states and the District of Columbia have legalized the adult-use of cannabis for recreational purposes. As more and more states legalized medical and/or adult-use cannabis, the federal government attempted to provide clarity on the incongruity between federal prohibition under the Controlled Substances Act of 1970 (the “CSA”) and these state-legal regulatory frameworks. Notwithstanding the permissive regulatory environment of medical cannabis at the state level, cannabis (other than hemp) continues to be illegal under U.S. federal law, with cannabis categorized as a Schedule I controlled substance under the CSA. The United States has a complex regulatory landscape when it comes to medical cannabis. The CSA regulates the possession, importation, manufacture, distribution and dispensing of controlled substances under United States federal law. Controlled substances are classified into schedules based on their potential for abuse by a patient or other user. Cannabis, other than hemp, is classified as a Schedule I substance under the CSA. Classification of substances under the CSA is determined jointly by the U.S. Drug Enforcement Agency and the U.S. Food and Drug Administration. The United States Department of Justice defines Schedule I drugs, substances, or chemicals as “drugs with no currently accepted medical use and a high potential for abuse.” The FDA has approved Epidiolex, which contains a purified form of the drug

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

CBD, a non-psychoactive cannabinoid in the cannabis plant, for the treatment of seizures associated with two epilepsy conditions. The FDA has not approved cannabis or cannabis compounds as a safe and effective drug for any other condition.

On August 29, 2013, then Deputy Attorney General, James Cole, authored a memorandum (the "Cole Memorandum") directing that individuals and businesses that rigorously comply with state regulatory provisions in states that have strictly-regulated legalized medical or recreational cannabis programs should not be a prosecutorial priority for violations of federal law. The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the Department of Justice has never provided specific guidelines for what regulatory and enforcement systems it deems sufficient under the Cole Memorandum standard. In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the Department of Justice should be focused on addressing only the most significant threats related to cannabis. States where medical cannabis had been legalized were not characterized as a high priority.

The U.S. Department of the Treasury's Financial Crimes Enforcement Network ("FinCEN") issued a memorandum on February 14, 2014 (the "FinCEN Memorandum") outlining the pathways for financial institutions to bank state-sanctioned cannabis businesses in compliance with federal enforcement priorities. The FinCEN Memorandum echoed the enforcement priorities of the Cole Memorandum and states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal money laundering laws. Under these guidelines, financial institutions must submit a Suspicious Activity Report ("SAR") in connection with all cannabis-related banking activities by any client of such financial institution, in accordance with federal money laundering laws. These cannabis-related SARs are divided into three categories – cannabis limited, cannabis priority, and cannabis terminated – based on the financial institution's belief that the business in question follows state law, is operating outside of compliance with state law, or where the banking relationship has been terminated, respectively. On the same day the FinCEN Memorandum was published, the DOJ issued a memorandum (the "2014 Cole Memorandum") directing prosecutors to apply the enforcement priorities of the Cole Memorandum in determining whether to charge individuals or institutions with crimes related to financial transactions involving the proceeds of cannabis-related conduct.

On January 4, 2018, former Attorney General Jeff Sessions issued a memorandum (the "Sessions Memorandum") that rescinded the Cole Memorandum effective upon its issuance. The Sessions Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of United States Attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution that are already in place. Those principles are included in chapter 9.27.000 of the United States Attorneys' Manual and require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community. As a result of the Sessions Memorandum, federal prosecutors are free to use their discretion to decide whether to prosecute cannabis activities despite the existence of state-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and resultantly it is uncertain how active federal prosecutors will be in relation to such activities. Furthermore, the Sessions Memorandum did not discuss the treatment of medical cannabis by federal prosecutors. However, former Attorney General Sessions' revocation of the Cole Memorandum and the 2014 Cole Memorandum has not affected the status of the FinCEN Memorandum, nor has the Department of the Treasury given any indication that it intends to rescind the FinCEN Memorandum itself. Though it was originally intended for the 2014 Cole Memorandum and the FinCEN Memorandum to work in tandem, the FinCEN Memorandum is a standalone document which explicitly lists the eight enforcement priorities originally cited in the Cole Memorandum. As such, the FinCEN Memorandum remains intact, indicating that the Department of the Treasury and FinCEN intend to continue abiding by its guidance. However, in the United States, it is difficult for cannabis-based businesses to open and maintain a bank account with any bank or other financial institution.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

On November 7, 2018, U.S. Attorney General Jeff Sessions resigned. On February 14, 2019, William Barr was confirmed as U.S. Attorney General. Mr. Barr resigned as Attorney General on December 23, 2021. On March 11, 2022, former Chief Judge of the United States Court of Appeals for the District of Columbia Circuit, Merrick Garland, was sworn in as

Attorney General of the United States. While Attorney General Garland indicated in his confirmation hearing that he did not feel that enforcement of the federal cannabis prohibition against state-licensed business would not be a priority target of the Department of Justice resources, no formal enforcement policy has been issued to date. There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. If the Department of Justice policy under Attorney General Garland were to aggressively pursue financiers or owners of cannabis-related businesses, and United States Attorneys followed such Department of Justice policies through pursuing prosecutions, then the Company could face (i) seizure of its cash and other assets used to support or derived from its cannabis operations, (ii) the arrest of its employees, directors, officers, managers and investors, and charges of ancillary criminal violations of the Controlled Substances Act for aiding and abetting and conspiring to violate the Controlled Substances Act by virtue of providing financial support to cannabis companies that service or provide goods to state-licensed or permitted cultivators, processors, distributors, and/or retailers of cannabis, and/or (iii) the barring of its employees, directors, officers, managers and investors who are not United States citizens from entry into the United States for life. Unless and until the United States Congress amends the Controlled Substances Act with respect to cannabis and the President approves such amendment (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current U.S. federal law criminalizing cannabis.

One legislative safeguard for the medical cannabis industry, appended to the federal budget bill, remains in place following the rescission of the Cole Memorandum. For fiscal years 2015, 2016, 2017, 2018, 2019, 2021 and 2022 Consolidated Appropriations Acts (currently referred to as the "Rohrabacher/Blumenauer Amendment", and sometimes referred to as the "Rohrabacher/Farr" or "Joyce/Leahy" Amendment) to prevent the federal government from using congressionally appropriated funds to enforce federal cannabis laws against regulated medical cannabis actors operating in compliance with state and local law. In 2022, President Biden became the first President to propose a budget with the Rohrabacher/Blumenauer Amendment included. On February 18, 2022, the amendment was renewed through the signing of a stopgap spending bill, effective March 11, 2022.

Nevertheless, for the time being, cannabis remains a Schedule I controlled substance at the federal level. The Federal government of the U.S. has always reserved the right to enforce federal law regarding the sale and disbursement of medical or adult-use cannabis, even if state law sanctions such sale and disbursement. While the Cole Memorandum and the Rohrabacher/Blumenauer Amendment gave medical cannabis operators and investors in states with legal regimes greater certainty regarding federal enforcement as to establish cannabis businesses in those states, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law. If the U.S. federal government begins to enforce U.S. federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, the Company's business, results of operations, financial condition and prospectus could be materially adversely affected.

There is a growing consensus among cannabis businesses and numerous members of Congress that prosecutorial discretion is not law and temporary legislative riders, such as the Rohrabacher/Blumenauer Amendment, are an inappropriate way to protect lawful medical cannabis businesses. Numerous bills have been introduced in Congress in recent years to decriminalize aspects of state-legal cannabis trades. The Company has observed that each year more congressmen and congresswomen sign on and cosponsor cannabis legalization bills. In light of all this, it is anticipated that the federal government will eventually repeal the federal prohibition on cannabis and thereby leave the states to decide for themselves whether to permit regulated cannabis cultivation, production and sale, just as states are free today to decide policies governing the distribution of alcohol or tobacco.

The most comprehensive proposal for reform of federal legislation on cannabis was introduced on July 14, 2022, by Senate Majority Leader Chuck Schumer (D-NY) along with Cory Booker (D-NJ), and Ron Wyden (D-OR) when they released draft legislation titled the Cannabis Administration and Opportunity Act (the "CAOA"). The CAOA removes cannabis from Schedule I of the CSA which would permit its decriminalization and allow the expungement of federal non-violent cannabis crimes. The CAOA would impose a federal tax on cannabis of 10% in its first year of enactment, eventually increasing to

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

25% in 5% increments. The taxes raised would be used to petition fund programs to benefit communities disproportionately impacted by the "War on Drugs".

The CAO A enshrines the current State cannabis licensing regimes but introduces additional federal permitting of cannabis wholesalers. Regulatory responsibility for cannabis control would be transferred from the U.S. Drug Enforcement Agency ("DEA") to the Alcohol and Tobacco Tax and Trade Bureau ("TTB"), the Bureau of Alcohol Tobacco Firearms and Explosives ("ATF").

The publication of the CAO A by Democratic congressional leaders represents a significant milestone in the move toward federal legalization of cannabis. While the CAO A indicates that legalization may come with significant federal tax burden, federal legalization will also bring long-awaited benefits to the industry of the removal of the Section 280e tax burden, clarity as to the status of state-licensed cannabis businesses, broad access to the banking and card payment system, increased availability, and reduced cost, of capital.

At the time of the CAO A announcement, Senator Schumer indicated such a bill currently does not have sufficient support in the Congress to pass. Although he originally targeted Spring 2022 for passage of legislation based on the CAO A draft, he is now targeting formal introduction of a revised draft of the CAO A in the Senate for April 2022, and the contents of such revised draft have not yet been disclosed. Therefore, it is unclear whether provisions in the CAO A that are favorable to the cannabis industry, such as preserving the current state regulatory system, will remain in any final legislation. In addition, the CAO A lacks clarity regarding the transition of cannabis control from the DEA to TTB and the FDA, which presents the risk that existing operators may face a period of regulatory uncertainty if legislation similar to the CAO A is enacted. Such uncertainty may impede growth of, and investment in, incumbent cannabis businesses, while exposing them to increased competition from the illicit market.

On December 4, 2021, the House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement Act of 2021 (the "MORE Act"). The MORE Act would provide for the removal of cannabis from the list of controlled substances in the CSA and other federal legislation. It would end the applicability of Section 280E to cannabis businesses but would impose a 5% federal excise tax. The MORE Act was not passed by the Senate prior to the end of the 116th Congress. On May 28, 2022, the MORE Act was reintroduced in the House of Representatives. There is no guarantee the MORE Act will become law in its current form. Overall, there were more than 1500 cannabis-related bills moving through state legislatures and Congress for the 2021 sessions.

There can be no assurance that the CAO A, the MORE Act or similar comprehensive legislation that would de-schedule cannabis and de-criminalize will be passed in the near future or at all. If such legislation is passed, there is no guarantee that it will include provisions that preserve the current state-based cannabis programs under which the Company's subsidiaries operate or that such legislation will otherwise be favorable to the Company and its business.

Reform of Federal Legislation on Industrial Hemp

Additionally, the Agriculture Improvement Act of 2018 (the "2018 Farm Bill") was signed into law by President Trump on December 20, 2018. With the passage of the 2018 Farm Bill, hemp and CBD products with less than .3% THC have been removed from Schedule I of the CSA. This will allow market participants such as the Company to cultivate, process and dispense hemp and certain CBD products (with less than .3% THC) throughout the United States without violating the CSA, and will also serve to open up banking and financial services for hemp and CBD operators. The 2018 Farm Bill explicitly preserved the United States Food and Drug Administration's authority to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act and Section 351 of the Public Health Service Act. The agency held public commentary workshops and rulemaking proceedings relative to the issuance of regulations to govern the nascent CBD marketplace and products on May 31, 2019. The FDA held a public hearing to determine the safety, manufacturing, product quality, marketing, labeling, and sale of CBD products, and opened the forum to public comments on the matter. In November of 2021, the FDA also held a research conference on cannabinoids and gender to discuss data on how cannabis compounds affect woman and men differently. In a statement released on January 8, 2022, FDA Commissioner Stephen Hahn and Principal Deputy Commissioner Dr. Amy Abernethy noted that "over a short period of time, our society has seen a rapid increase in the interest and availability of cannabidiol (CBD)

SOL Global Investments Corp

Management’s discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

products and other products derived from cannabis. However, we still have a limited understanding of the safety profile of CBD and many other cannabis-derived compounds.” In the same statement, Commissioner Hahn committed to developing and refining plans for research projects at the FDA to address the gaps in current CBD data research capabilities. As the FDA continues its rulemaking proceedings, the Company will be an active participant.

To date, three different hemp seed-derived ingredients have received Generally Recognized As Safe (“GRAS”) notices from the FDA: hulled hemp seed, hemp seed protein powder, and hemp seed oil. The hemp seed-derived ingredients that are the subject of these GRAS notices contain only trace amounts of THC and CBD, which the seeds may pick up during harvesting and processing when they are in contact with other parts of the plant. Aside from these three hemp seed ingredients, no other cannabis or cannabis-derived ingredients, including ingredients sourced from hemp, have been the subject of a food additive petition, an evaluated GRAS notification, or have otherwise been approved for use in food by the FDA. The FDA’s current stated position is that it is a prohibited act under the Federal Food, Drug, and Cosmetic Act to introduce into interstate commerce a food to which CBD or THC has been added, or to market a product containing these ingredients as a dietary supplement.

On June 7, 2018, the Strengthening the Tenth Amendment Through Entrusting States Act (the “STATES Act”) was introduced in the Senate by Republican Senator Cory Gardner of Colorado and Democratic Senator Elizabeth Warren of Massachusetts. A companion bill was introduced in the House by Democratic representative Jared Polis of Colorado. The bill provides in relevant part that the provisions of the CSA, as applied to cannabis, “shall not apply to any person acting in compliance with state law relating to the manufacture, production, possession, distribution, dispensation, administration, or delivery of marijuana.” Even though cannabis will remain within Schedule I of the CSA under the STATES Act, the bill makes the CSA unenforceable to the extent it conflicts with state law. In essence, the bill extends the limitations afforded by the protection within the federal budget—which prevents the DOJ and the DEA from using funds to enforce federal law against state-legal medical cannabis commercial activity—to both medical and adult-use cannabis activity in all states where it has been legalized. The STATES Act was reintroduced on April 4, 2019, in both the House and the Senate. Since the STATES Act is currently draft legislation, there is no guarantee that the STATES Act will become law in its current form.

On March 18, 2022, the SAFE Banking Act was reintroduced in the House of Representatives. On March 23, 2022, the bill was reintroduced in the Senate as well. The House previously passed the SAFE Banking Act in September 2019, but the measure stalled in the Senate. As written, the SAFE Banking Act would allow financial institutions to provide their services to state-legal cannabis clients and ancillary businesses serving state-legal cannabis businesses without fear of federal sanctions. There is no guarantee the SAFE Banking Act will become law in its current form, if at all.

The States In Which We Invest, Their Legal Framework and How It Affects Our Business

Regulatory Developments in the State of Pennsylvania

The Pennsylvania medical marijuana program was signed into law on April 17, 2016 under Act 16 and provided access to state residents with one or more of 17 qualifying conditions. The state, which consists of over 12 million U.S. citizens and qualifies as the fifth largest population in the U.S., operates as a high-barrier market with very limited market participation. The state originally awarded only twelve (12) licenses to cultivate/process and twenty-seven (27) licenses to operate retail dispensaries (which entitled holders up to three (3) medical dispensary locations). On June 30, 2021, Pennsylvania Governor Tom Wolf signed into law PA House Bill (“HB”) 1024, amending Act 16. HB 1024 implemented several changes to Act 16 including but not limited to the ability for grower/processors to obtain and transport bulk post-harvest plant material between grower/ processors to process medical marijuana. The amendatory legislation also expanded the list of qualifying conditions, permits limited remediation of cannabis flower, requires the Department of Agriculture to update its list of approved pesticides and expands the number of clinical registrants and affords clinical registrants with the same rights as grower/processors.

There are two principal license categories in Pennsylvania: (1) cultivation/processing and (2) dispensary. All cultivation/processing establishments and dispensaries must register with Pennsylvania Department of Health under the provisions of Act 16 (35 P.S. §§ 10231.101—10231.2110) and Chapters 1141, 1151 and 1161 of the Pennsylvania regulations. Registration certificates are valid for a period of one year and are subject to annual renewals after required fees are paid and the business remains in good standing. The Pennsylvania Department of Health must renew a permit

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

unless it determines the applicant is unlikely to maintain effective control against diversion of medical cannabis and the applicant is unlikely to comply with all laws as prescribed under the Pennsylvania medical marijuana program.

Under applicable laws, the licenses permit the license holder to cultivate, manufacture, process, package, sell and purchase medical marijuana pursuant to the terms of the licenses, which are issued by the Pennsylvania Department of Health under the provisions of Act 16 and Pennsylvania regulations. The medical cultivation/processing licenses permit the licensee to acquire, possess, cultivate, manufacture/process into medical marijuana products and/or medical marijuana-infused products, deliver, transfer, have tested, transport, supply or sell marijuana and related supplies to medical marijuana dispensaries. The retail dispensary licenses permit the license holder to purchase marijuana and marijuana products from cultivation/processing facilities, as well as allow the sale of marijuana and marijuana products.

Pennsylvania Storage / Reporting / Inventory Requirements

A dispensary shall have separate and locked limited access areas for storage of medical marijuana products that are expired, damaged, deteriorated, mislabeled, contaminated, recalled, or whose containers or packaging have been opened or breached until the medical marijuana products are returned to a grower/processor, destroyed or otherwise disposed of as required under § 1151.40 (relating to management and disposal of medical marijuana waste). A dispensary shall maintain all storage areas in a clean and orderly condition and free from infestation by insects, rodents, birds and pests.

A grower/processor shall ensure that a facility has separate and locked limited access areas for storage of seeds, immature medical marijuana plants, medical marijuana plants, medical marijuana and medical marijuana products that are expired, damaged, deteriorated, mislabeled, contaminated, recalled or whose containers or packaging have been opened or breached until the seeds, immature medical marijuana plants, medical marijuana plants, medical marijuana and medical marijuana products are destroyed or otherwise disposed of as required under § 1151.40 (relating to management and disposal of medical marijuana waste). A grower/processor facility shall maintain all storage areas in a clean and orderly condition and free from infestation by insects, rodents, birds and pests.

A grower/processor and dispensary shall use the electronic tracking system prescribed by the Department of Health containing the requirements in section 701 of Act 16 (35 P.S. § 10231.701). Pennsylvania has elected to use MJ Freeway's electronic tracking system.

A dispensary shall maintain the following inventory data in its electronic tracking system; (1) medical marijuana products received from a grower/processor; (2) medical marijuana products dispensed to a patient or caregiver; (3) damaged, defective, expired or contaminated medical marijuana products awaiting return to a grower/processor or awaiting disposal. A dispensary shall establish inventory controls and procedures to conduct monthly inventory reviews and annual comprehensive inventories of medical marijuana products at its facility. A written or electronic record shall be created and maintained of each inventory which includes the date of the inventory, a summary of the inventory findings, and the employee identification numbers and titles or positions of the individuals who conducted the inventory

A grower/processor shall maintain the following inventory data in its electronic tracking system which must include an accounting of and an identifying tracking number for; (1) the number, weight and type of seeds; (2) the number of immature medical marijuana plants; (3) the number of medical marijuana plants; (4) the number of medical marijuana products ready for sale; (5) the number of damaged, defective, expired or contaminated seeds, immature medical marijuana plants, medical marijuana plants, medical marijuana and medical marijuana products awaiting disposal. A grower/processor shall establish inventory controls and procedures to conduct inventory reviews and comprehensive inventories at its facility. The following requirements apply; (1) inventory reviews of medical marijuana plants in the process of growing, and medical marijuana and medical marijuana products that are being stored for future sale shall be conducted monthly; (2) comprehensive inventories of seeds, immature medical marijuana plants, medical marijuana plants, medical marijuana and medical marijuana products shall be conducted at least annually. A written or electronic record shall be created and maintained of each inventory conducted under this requirement that includes the date of the inventory, a summary of the inventory findings, and the employee identification numbers and titles or positions of the individuals who conducted the inventory.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Pennsylvania Security Requirements

A grower/processor shall have security and surveillance systems, utilizing commercial-grade equipment, to prevent unauthorized entry and to prevent and detect an adverse loss. The security and surveillance systems must include, subject to additional requirements of the Department of Health, (1) a professionally monitored security alarm system that includes: (i) coverage of all facility entrances and exits, (ii) two silent security alarms, (iii) an audible security alarm, (iv) a device capable of sending a prerecorded voice message requesting dispatch to a law enforcement, public safety or emergency services agency, (v) a failure notification system that provides an alert to a designated security person within 5 minutes after the failure, (vi) smoke and fire alarms, (vii) auxiliary power sufficient to maintain operation of specified growing and processing areas for at least 48 hours following a power outage, (viii) the ability to ensure all access doors are not solely controlled by an electronic access panel to prevent locks from becoming released during a power outage, and (ix) motion detectors; (2) a professionally monitored security and surveillance system that is operational 24 hours per day, 7 days per week and records all activity in images capable of clearly revealing facial detail; (3) the ability to display the date and time clearly and accurately; (4) the ability to record and store all images captured by each surveillance camera for a minimum of 2 years in a format that may be easily accessed for investigative purposes; (5) a security alarm system separate from the facility's primary security system covering the limited access area or other room where the recordings under paragraph (4) are stored.

The Department of Health also requires certain inspection and document retention policies as well the installation of commercial-grade, nonresidential steel doors and door locks on each room where seeds, immature medical marijuana plants, medical marijuana plants, medical marijuana and medical marijuana products are stored, and on each external door of the facility.

A dispensary shall have security and surveillance systems, utilizing commercial-grade equipment, to prevent unauthorized entry and to prevent and detect an adverse loss. The security and surveillance system must include, subject to additional requirements of the Department of Health, (1) a professionally monitored security alarm system that includes: (i) coverage of all facility entrances and exits, (ii) two silent security alarms, (iii) an audible security alarm, (iv) a device capable of sending a prerecorded voice message requesting dispatch to a law enforcement, public safety or emergency services agency, (v) a failure notification system that provides an alert to a designated security person within 5 minutes after the failure, (vi) smoke and fire alarms, (vii) auxiliary power sufficient to maintain security and surveillance systems for at least 48 hours following a power outage, (viii) the ability to ensure all access doors are not solely controlled by an electronic access panel to prevent locks from becoming released during a power outage, and (ix) motion detectors;; (2) a professionally-monitored security and surveillance system that is operational 24 hours per day, 7 days per week and records all activity in images capable of clearly revealing facial detail; (3) the ability to clearly and accurately display the date and time; (4) the ability to record and store all images captured by each surveillance camera for a minimum of 2 years in a format that may be easily accessed for investigative purposes; (5) a security alarm system separate from the facility's primary security system covering the limited access area or other room where the recordings under paragraph (4) are stored. The separate security alarm system must meet the same requirements as the facility's primary security alarm system. The Department of Health also requires certain inspection and document retention policies as well as access restrictions for certain personnel to the security system and security records.

Pennsylvania Transportation Requirements

A grower/processor may transport and deliver seeds, immature medical marijuana plants, medical marijuana plants, medical marijuana and medical marijuana products to a medical marijuana organization or an approved laboratory in Pennsylvania in accordance with certain guidelines promulgated by the Department of Health, including but not limited to, requiring (1) the use of a global positioning system to ensure safe, efficient delivery of the seeds, immature medical marijuana plans, medical marijuana plants, medical marijuana and medical marijuana products to a medical marijuana organization or approved laboratory between 7 a.m. and 9 p.m.; and (2) a transport vehicle must be staffed with at least two individuals, at least one of whom must remain with the vehicle at all times that the vehicle contains seeds, immature medical marijuana plans, medical marijuana plants, medical marijuana and medical marijuana products to ensure the security of the products.

A dispensary may transport and deliver medical marijuana products to a medical marijuana organization in Pennsylvania in accordance with certain guidelines promulgated by the Department of Health, including but not limited to, requiring (1) the use of a global positioning system to ensure safe, efficient delivery of the medical marijuana products to a medical

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

marijuana organization between 7 a.m. and 9 p.m.; and (2) transport vehicle must be staffed with at least two individuals, at least one of whom must remain with the vehicle at all times that the vehicle contains medical marijuana products to ensure the security of the products.

Pennsylvania Inspections

The Department of Health may conduct announced or unannounced inspections or investigations to determine the medical marijuana organization's compliance with its permit, Act 16, or the regulations. An investigation or inspection may include but is not limited to; (1) inspection of a medical marijuana organization's site, facility, vehicles, books, records, papers, documents, data, and other physical or electronic information; (2) questioning of employees, principals, operators, financial backers, authorized agents of, and any other person or entity providing services to the medical marijuana organization; and (3) inspection of a grower/processor facility's equipment, instruments, tools and machinery that are used to grow, process and package medical marijuana, including containers and labels.

Regulatory Developments in the State of Ohio

HB 523, effective on September 8, 2016, legalized medical marijuana in Ohio. The Ohio Medical Marijuana Control Program ("OMMCP") allows people with certain medical conditions, upon the recommendation of an Ohio licensed physician certified by the State Medical Board, to purchase and use medical marijuana. Though Ohio was required to implement a fully operational OMMCP by September 8, 2018 with a controlled system for cultivation, laboratory testing, physician/patient registration and dispensing, the timeline was delayed until November 2018. The three (3) following state government agencies are responsible for the operation of OMMCP: (1) the Ohio Department of Commerce is responsible for overseeing medical marijuana cultivators, processors and testing laboratories; (2) the State of Ohio Board of Pharmacy ("Ohio Pharmacy Board") is responsible for overseeing medical marijuana retail dispensaries, the registration of medical marijuana patients and caregivers, the approval of new forms of medical marijuana and coordinating the Medical Marijuana Advisory Committee and, (3) the State Medical Board of Ohio is responsible for certifying physicians to recommend medical marijuana and may add to the list of qualifying conditions for which medical marijuana can be recommended. Several forms of medical marijuana are legal in Ohio, these include: inhalation of marijuana through a vaporizer (not direct smoking), oils, tinctures, plant material, edibles, patches and any other forms approved by the Ohio Pharmacy Board.

Ohio Storage Requirements

Ohio has selected METRC as the T&T system. Individual licensees, whether directly or through third-party APIs, are required to push data to the state to meet all reporting requirements. A holder of a processing or cultivation license must track and submit through the inventory tracking system any information the Ohio Department of Commerce determines necessary for maintaining and tracking medical cannabis extracts and products.

A holder of a cultivation license must conduct a weekly inventory of medical cannabis which includes (a) date of inventory; (b) amount of medical cannabis on hand; (c) total count of plants, whether in the flowering, vegetative, or clone phase of growth and organized by room in which the plants are being grown; (d) amount of medical cannabis sold since previous weekly inventory; (e) date, quantity, and method of disposal of medical cannabis; (f) summary of the inventory findings; and (g) name, signature, and title of the employees who conducted the inventory and oversaw the inventory. On an annual basis and as a condition for renewal of a cultivation license, a holder of a cultivation license must conduct a physical, manual inventory of the medical cannabis on hand at the cultivation facility and compare the findings to an annual inventory report generated using the inventory tracking system.

A holder of a processing license must conduct weekly inventory of medical cannabis which includes (a) the date of the inventory, (b) net weight of plant material and the net weight and volume of medical cannabis extract, (c) net weight and unit count of medical cannabis products prepared or packaged for sale to a dispensary, (d) the amount of medical cannabis and medical cannabis products sold since previous weekly inventory; (e) the date, quantity, and method of disposal of any plant material, medical cannabis extract, and medical cannabis products; (f) a summary of the inventory findings; and (g) name, signature and employees who conducted the inventory and oversaw the inventory. On an annual basis and as a condition for renewal of a processing license, a holder of a processing license shall conduct a physical, manual inventory of plant material, medical cannabis extract, and medical cannabis products on hand at the processor and compare the findings to an annual inventory report generated using the inventory tracking system. A holder of a processing license

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

must store plant material, medical cannabis extract, and medical cannabis product inventory on the premises in a designated, enclosed, locked area and accessible only by authorized individuals.

A holder of a dispensary license must use the METRC T&T system to push data to the Ohio Board of Pharmacy on a real-time basis. The following data must be transmitted (a) each transaction and each day's beginning inventory, acquisitions, sales, disposal and ending inventory, (b) acquisitions of medical cannabis from a licensed processor or cultivator holding a plant-only processor designation, (c) name and license number of the licensed dispensary employee receiving the medical cannabis and, (d) other information deemed appropriate by the Ohio State Board of Pharmacy. A dispensary's designated representative shall conduct the inventory at least once a week. Records of each day's beginning inventory, acquisitions, sales, disposal and ending inventory shall be kept for a period of three years.

The dispensary licensee must restrict access areas and keep stock of medical cannabis in secured area enclosed by a physical barrier with suitable locks and an alarm system capable of detecting entry at a time when licensed dispensary employees are not present. Medical cannabis must be stored at appropriate temperatures and under appropriate conditions to help ensure that its identity, strength, quality and purity are not adversely affected.

Ohio Security Requirements

All licensees must have a security system that remains operational at all times and that uses commercial grade equipment to prevent and detect diversion, theft or loss of medical cannabis, including (a) a perimeter alarm, (b) motion detectors, and (c) duress and panic alarms. All licensees must also employ a holdup alarm, which means a silent alarm signal generated by the manual activation of a device intended to signal a robbery in progress. Processing and cultivation facilities are also required to have secondary alarm systems installed and monitored by a vendor that differs from the primary alarm system.

Video cameras at a dispensary must be positioned at each point of egress and each point of sale. The cameras must capture the sale, the individuals and the computer monitors used for the sale, approved safes, approved vaults and any area where cannabis is stored, handled or destroyed. Video surveillance recording must operate 24 hours a day, seven days a week. Recording from all video cameras during hours of operation must be made available for immediate viewing by the Ohio State Board of Pharmacy upon request and must be retained for at least six months.

Video cameras at a processing or cultivation facility must be directed at all approved safes, approved vaults, and any other area where plant material, medical cannabis extract, or medical cannabis products are being processed, stored, handled or destroyed. Video surveillance must take place 24 hours a day, seven days a week. Recordings from all video cameras during hours of operation must be readily available for immediate viewing by the Ohio regulatory bodies upon request and must be retained for at least six months. Video recording must be maintained for at least a 45-day period. Video recording must be maintained beyond the 45-day period when the cultivator or processor becomes aware of a pending criminal, civil or administrative investigation or legal proceeding for which a recording may contain relevant information. The cultivator or processor must retain an unaltered copy of the recording until the investigation or proceeding is closed or the entity conducting the investigation or proceeding is closed or the entity conducting the investigation or proceeding notifies the cultivator or processor that it is no longer necessary to retain the recording.

Ohio Reporting Requirements

A holder of a processing license must maintain the following records: (a) samples sent for testing, (b) disposal of products, (c) tracking of inventory, (d) form and types of medical cannabis maintained at the processing facility on a daily basis, (e) production records, including extraction, refining, manufacturing, packaging and labeling, (f) financial records, (g) employee records and (h) purchase invoices, bills of lading, manifests, sales records, copies of bills of sale, and any supporting documents, including the items and/or services purchased, from whom the items were purchased, and the date of purchase. Records must be maintained for five years.

A holder of a cultivation license must maintain the following records: (a) forms and types of medical cannabis maintained at the cultivator on a daily basis; (b) soil amendment, fertilizers, pesticides, or other chemicals applied to the growing medium or plants or used in the process of growing medical cannabis; (c) production records, including planting, harvesting and curing, weighing, and packaging and labeling; (d) financial records; (e) employee records; and (f) purchase invoices, bills of lading, manifests, sales records, copies of bills of sale, and any supporting documents, including the items

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

and/or services purchased, from whom the items were purchased, and the date of purchase. Records will be maintained for five years.

A holder of a dispensary license must maintain the following records (a) confidential storage and retrieval of patient information or other medical cannabis records, (b) records of all medical cannabis received, dispensed, sold, destroyed, or used, (c) dispensary operating procedures, (d) a third-party vendor list, (e) monetary transactions, and (f) journals and ledgers. All records relating to the purchase or return, dispensing, distribution, destruction, and sale of medical cannabis must be maintained under appropriate supervision and control to restrict unauthorized access on the licensed premises for a five-year period.

Ohio Transportation Requirements

Medical cannabis entities must maintain a transportation log in METRC containing the names and addresses of the medical cannabis entities sending and receiving the shipment, names and registration numbers of the registered employees transporting the medical cannabis or the products containing medical cannabis, the license plate number and vehicle type that will transport the shipment, the time of departure and estimated time of arrival, the specific delivery route, which includes street names and distances; and the total weight of the shipment and a description of each individual package that is part of the shipment, and the total number of individual packages. Copies of the log described above must be transmitted to the recipient and to the Ohio Department of Commerce through METRC before 11:59 p.m. on the day prior to the trip.

Vehicles transporting medical cannabis or cannabis products must be insured as required by law, store the products in locked compartments, ensure that the products are not visible from outside the vehicle, be staffed with two employees registered with the department (with one remaining with the vehicle at all times) and have access to the 911 emergency system. Vehicles must not be marked with any marks or logos.

Trips must be direct, other than to refuel the vehicle. Drivers must have their employee identification cards on their person at all times and must ensure that delivery times and routes are randomized. A copy of the transportation log must be carried during the trip.

Ohio Inspections Requirements

The submission of an application that results in the issuance of a provisional license or certificate of operation for a cultivator irrevocably gives the Ohio Department of Commerce consent to conduct all inspections necessary to ensure compliance with the cultivator's application, state and local law and regulators. An inspector conducting an inspection pursuant to this rule shall be accompanied by a "type 1" key employee during the inspection. The inspector may review and make copies of records, enter any area of a facility, inspect vehicles, equipment, premises, and question employees, among other actions. Dispensaries are not permitted to deliver cannabis products to the homes of patients or their designated caregivers.

Dispensaries in Ohio are subject to random and unannounced dispensary inspections and medical cannabis testing by the Ohio Board of Pharmacy. The Ohio Board of Pharmacy and its representatives may enter facilities and vehicles where medical cannabis is held and conduct inspections in a reasonable manner each place and all pertinent equipment, containers and materials and data. The Ohio Board of Pharmacy may also obtain any medical cannabis or related products from such facility.

Regulatory Developments in the State of Arizona

In 2010, Arizona passed Ballot Proposition 203, which amended Title 36 to the Arizona Revised Statutes. This amendment added Chapter 28.1, titled the Arizona Medical Marijuana Act (the "AMMA"). The AMMA is codified in Arizona Revised Statutes § 36-2801 et. seq. The AMMA also appointed the Arizona Department of Health Services ("ADHS") as the regulator for the program and authorized ADHS to promulgate, adopt and enforce regulations for the AMMA. These ADHS regulations are embodied in the Arizona Administrative Code Title 9 Chapter 17 (the "Medical Rules"). ARS §36-2801(12) defines a "nonprofit medical marijuana dispensary" as a not-for-profit entity that acquires, possesses, cultivates, manufactures, delivers, transfers, transports, supplies, sells or dispenses marijuana or related supplies and educational materials to cardholders.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

The ADHS has established the medical marijuana program, which includes a vertically integrated license, meaning if allocated a Medical Marijuana Dispensary Registration Certificate (a "Certificate"), entities are authorized to dispense and cultivate medical cannabis. Each Certificate allows the holding entity to operate one on-site cultivation facility, and one off-site cultivation facility which can be located anywhere within the State of Arizona. An entity holding a Certificate is required to file an application to renew with the ADHS on an annual basis, which must also include audited annual financial statements. While a Certificate may not be sold, transferred or otherwise conveyed, Certificate holders typically contract with third parties to provide various services related to the ongoing operation, maintenance, and governance of its dispensary and/or cultivation facility so long as such contracts do not violate the requirements of the AMMA or the medical marijuana program.

The ADHS had until April 2012 to establish a registration application system for patients and nonprofit marijuana dispensaries, as well as a web-based verification platform for use by law officials and dispensaries to verify a patient's status as such. It also specified patients' rights, qualifying medical conditions, and allowed out-of-state medical marijuana patients to maintain their patient status (though not to purchase cannabis). On December 6, 2012, Arizona's first licensed medical marijuana dispensary opened in Glendale. Arizona recently enacted SB 1494, which, among other things will require testing of medical marijuana and require biannual renewal of agent licensure.

To qualify to use medical marijuana under the AMMA, a patient is required to have a debilitating medical condition. Valid medical conditions include HIV, cancer, glaucoma, immune deficiency syndrome, Hepatitis C, Crohn's disease, agitation of Alzheimer's disease, ALS, cachexia/wasting syndrome, muscle spasms, nausea, seizures, severe and chronic pain or another chronic or debilitating condition.

Arizona S.B. 1494 went into effect in August 2019. The bill authorized the ADHS to adopt rules for inspecting medical marijuana dispensaries and created an independent testing regime for marijuana cultivated by a medical marijuana dispensary. Beginning in November 2020, before marijuana is sold, it must be tested for unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents.

S.B. 1494 also authorized civil penalties of up to \$1,000 per violation (not to exceed \$5,000 in a 30-day period) on medical marijuana dispensaries. The bill makes patient ID cards and medical marijuana dispensary registration certificates expire every two years rather than every year. Regulations implementing S.B. 1494 went into effect on August 27, 2019. In February 2020, the Department began an additional round of rulemaking designed to improve the regulations regarding independent testing. In 2020, Arizona passed Ballot Proposition 207, which amended Title 36 to the Arizona Revised Statutes. This amendment added Chapter 28.2, titled the Smart and Safe Arizona Act (the "SSAA"). The SSAA is codified in Arizona Revised Statutes § 36-2850 et. seq. The SSAA appointed ADHS as the regulator for the program and required ADHS to promulgate, adopt, and enforce regulations for the SSAA. ADHS has published draft rules to administer the Adult-use Marijuana Program to be embodied in the Arizona Administrative Code Title 9 Chapter 18 (the "Adult-use Rules," together with the Medical Rules, the "Rules"). These Adult-use Rules became effective on January 15, 2021. ARS § 36-2850 defines "marijuana establishment" as an entity licensed by the department to operate all of the following: a single retail location at which the licensee may sell marijuana and marijuana products to consumers, cultivate marijuana and manufacture marijuana products; a single off-site cultivation location at which the licensee may cultivate marijuana, process marijuana and manufacture marijuana products, but from which marijuana and marijuana products may not be transferred or sold to consumers; and a single off-site cultivation location at which the licensee may cultivate marijuana, process marijuana and manufacture marijuana products, but from which marijuana and marijuana products may not be transferred or sold to consumers.

Arizona Medical Marijuana Licensing Requirements

In order for an applicant to receive a Certificate, it must: (i) fill out an application on the form prescribed by ADHS, (ii) submit the applicant's articles of incorporation and by-laws, (iii) submit fingerprints for each principal officer or board member of the applicant for a background check to exclude felonies, (iv) submit a business plan and policies and procedures for inventory control, security, patient education, and patient recordkeeping that are consistent with the AMMA and the Medical Rules to ensure that the dispensary will operate in compliance, and (v) designate an Arizona licensed physician as the Medical Director for the dispensary. Certificates are renewed annually so long as the dispensary is in good standing with ADHS, pays the renewal fee, and submits an independent third-party financial audit.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Once an applicant has been issued a Certificate, they are allowed to establish one physical retail dispensary location, one cultivation location which is co-located at the dispensary's retail site (if allowed by local zoning) and one additional off-site cultivation location. None of these sites can be operational, however, until the dispensary receives an approval to operate from ADHS for the applicable site. This approval to operate requires: (i) an application on the ADHS form, (ii) demonstration of compliance with local zoning regulations, (iii) a site plan and floor plan for the applicable property, and (iv) an in-person inspection by ADHS of the applicable location to ensure compliance with the Medical Rules and consistency with the dispensary's applicable policies and procedures.

Arizona Adult-use Marijuana Licensing Requirements

In order for an applicant to receive a marijuana facility agent license, it must submit to ADHS (i) the personal identification information prescribed by ADHS including a background check and fingerprints and (ii) the applicable fee as prescribed in the Adult-use Rules. The license must be renewed every two years. A licensee may seek renewal by submitting to ADHS, at least thirty calendar days before the license expiration, (a) information on the license, (b) updated personal information including a criminal records check, and (c) the applicable fee as prescribed in the Adult-use Rules.

ADHS may issue one marijuana establishment license for every 10 pharmacies registered under § 32-1929 and no more than two licenses per county that contains no registered medical marijuana dispensaries, or one license per county that contains one registered medical marijuana dispensary. In the event that more complete and compliant applications are received than ADHS may issue, ADHS will issue the licenses according to criteria prescribed in the Adult-use Rules. The initial round of license applications were due March 9, 2021.

In order for an application to be considered complete and compliant such that an applicant may be considered for a marijuana establishment license, the applicant must (i) pay the appropriate non-refundable fee prescribed by ADHS, (ii) submit the ADHS-prescribed application, (iii) documentation of: facility agent licenses for principal officers and board members, good standing with the Arizona Corporation Commission, zoning compliance, ownership of or permission to use the physical address, and sufficient funds.

Applicants that have a Certificate issued under the Medical Rules, the applicant may apply for a marijuana establishment license by submitting (i) an attestation from each principal officer and board member approving the application, (ii) the license number on the applicant's dispensary registration certificate, (iii) whether the applicant wants to transfer the cultivation site under the registration certificate to the marijuana license, and (iv) the applicable fee.

A holder of a marijuana establishment license may apply for approval to operate a marijuana establishment by submitting, within 18 months after the marijuana establishment license was issued, the following: (i) an application on the form prescribed by ADHS, (ii) documentation of local permission to use the property as a marijuana establishment (such as a certificate of occupancy, special use permit, or a conditional use permit), (iii) a list of activities the establishment is requesting, including cultivation, manufacturing, or preparation of edible products, (iv) a license of the location as a food establishment if preparing edible products, (v) a site plan, and (vi) a floor plan.

Marijuana establishments that received their license through the process for applicants with Certificates may begin operating without submitting the above if the entity holding the license (i) received approval to operate under the Medical Rules and (ii) is operating and available to dispense medical marijuana in accordance with the Medical Rules.

Marijuana establishment licenses must be renewed every two years.

Arizona Security Requirements for Dispensary Facilities

Any dispensary facility (both retail and cultivation) or marijuana establishment must abide by the following security requirements: (i) ensure that access to the facilities is limited to authorized agents of the dispensary who are in possession of a dispensary agent identification card, and (ii) equip the facility with: (a) intrusion alarms and surveillance equipment, (b) exterior and interior lighting to facilitate surveillance, (c) at least one 19-inch monitor for surveillance and a video capable of printing a high resolution still image, (d) high resolution video cameras at all points of sale, entrances, exits, and limited access areas, both in and around the building, (e) 30 days' video storage, (f) failure notifications and battery backups for the security system, and (g) panic buttons inside each building.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Arizona Dispensing Requirements

In order to dispense medical marijuana to a qualifying patient or designated caregiver, a licensed dispensary is required to (1) verify the qualifying patient's or designated caregiver's identity, (2) offer appropriate patient education or support materials, (3) make available testing results related to the product sought, if requested by the qualifying patient or designated caregiver, (4) enter the qualifying patient's or designated caregiver's registry identification number on the identification card presented into the medical marijuana electronic verification system, (5) verify the validity of the identification card presented, (6) verify that the amount of marijuana product to be dispensed would not cause the qualifying patient to exceed the regulatory limit, and (7) enter information into the medical marijuana electronic verification system regarding the amount of medical marijuana dispensed, whether it was dispensed directly to the qualifying patient or to a caregiver, the date and time of dispensing, the registry identification number of the dispensary agent, and the dispensary's registry identification number.

Arizona Storage Requirements

Any dispensary facility (both retail and cultivation) or marijuana establishment must abide by the following requirements for the storage of product: (i) product must be stored in an area that is separate from areas used to store toxic and flammable materials, (ii) product must be stored in a manner that is clean and sanitary, (iii) product must be protected from flies, dust, dirt, and any other contamination, and (iv) surfaces and objects used in the handling and storage of product must be cleaned daily.

Additionally, the Rules establish strict inventory protocols for tracking product from "seed to sale," which requires product to be traceable to the original plants used to grow the cannabis used in the product. These requirements include (1) daily updated inventory amounts of marijuana products, (2) acquisitions of medical marijuana from qualifying patients or designated caregivers, (3) acquisitions of medical marijuana from other dispensaries, (4) information related to batches of marijuana cultivated by the licensee, (5) information regarding provision of medical marijuana to other dispensaries, (6) information relating to required testing of marijuana products, and (7) the disposition of marijuana products determined not to be dispensed to a patient or to be included in manufacturing a marijuana product. Licensed dispensaries are additionally required to keep records regarding qualifying patients that: (1) include dated entries from registered dispensary agents regarding dispensing, (2) are safeguarded against unauthorized access and tampering, (3) include documentation of requests by qualifying patients and caregivers regarding marijuana products and educational materials.

Arizona Transportation Requirements

Dispensaries may transport medical cannabis and marijuana establishments may transport adult-use cannabis between their own sites or between their sites and another dispensary's site and must comply with the following Rules: (i) prior to transportation, the dispensary agent must complete a trip plan showing: (a) the name of the dispensary agent in charge of transporting the cannabis, (b) the date and start time of the trip, (c) a description of the cannabis, cannabis plants, or cannabis paraphernalia being transported; and (d) the anticipated route of transportation, including any anticipated stops during the trip; (ii) during transport the dispensary agent shall: (a) carry a copy of the trip plan at all times, (b) use a vehicle with no medical cannabis identification, (c) have a means of communicating with the dispensary, and (d) ensure that no cannabis is visible, and (iii) dispensaries must maintain trip plan records for at least two years.

Arizona Adult-use Operating Requirements

Marijuana establishments must (i) ensure that the retail location is operating and available at least 30 hours a week between the hours of 7:00 a.m. and 10:00 p.m. within 18 months after receiving the marijuana establishment license, (ii) develop, implement and regularly review and update, no less than once every 12 months, policies related to job descriptions and employment contracts, training of facility agents, and inventory control, (iii) ensure all principal officers, board members, employees, and volunteers maintain valid marijuana facility agent licenses and keep them in their possession when working with marijuana, (iv) inform ADHS within 10 days when a marijuana facility agent is no longer employed or volunteering with the marijuana establishment, (v) document loss or theft and (vi) post the marijuana establishment's approval to operate, the license, hours of operation, and the applicable ADHS-prescribed warning signs.

Marijuana products to be sold at a marijuana establishment's retail location must (i) comply with the packaging and labeling requirements in the SSAA, (ii) be labeled with the appropriate product information and warnings as prescribed by ADHS, and (iii) be placed in child-resistant packaging. Prior to selling or transferring any marijuana product to a

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

consumer, the marijuana facility agent must (i) verify the consumer's age, (ii) make available the results of testing of the marijuana if requested, and (iii) ensure that the amount to be sold or transferred does not exceed one ounce, with not more than 5 grams being in the form of a marijuana concentrate.

A marijuana establishment that prepares, sells, or transfers marijuana-infused edible food products shall (i) obtain a license or permit as a food establishment under 9 A.A.C. 8, Article 1, (ii) ensure that the products are prepared according to the applicable requirements in 9 A.A.C. 8, Article 1, whether prepared on-site or by another marijuana establishment, and (iii) ensure that any sold products (a) are sold in accordance with 9 A.A.C. 8, Article 1, (b) contain no more total THC than 10 mg per serving or 100 mg per package, and (c) if packaged as more than one serving, are scored or delineated into standard serving size and consistent in THC disbursement.

Arizona Inspections and Enforcement

ADHS may inspect a medical facility at any time upon five (5) days' notice to the dispensary. However, if someone has alleged that the dispensary is not in compliance with the AMMA or the Medical Rules, ADHS may conduct an unannounced inspection. ADHS will provide written notice to the dispensary of any violations found during any inspection and the dispensary then has 20 working days to take corrective action and notify ADHS.

ADHS must revoke a Certificate if a dispensary: (i) operates before obtaining approval to operate a dispensary from ADHS, (ii) dispenses, delivers, or otherwise transfers cannabis to an entity other than another licensed dispensary, a qualifying patient with a valid registry identification card, a designated caregiver with a valid registry identification card, or a laboratory with a valid laboratory registration certificate, (iii) acquires usable cannabis or mature cannabis plants from any entity other than another licensed dispensary, a qualifying patient with a valid registry identification card, or a designated caregiver with a valid registry identification card, or (iv) if a principal officer or board member has been convicted of an excluded felony offense.

ADHS may revoke a Certificate if a dispensary does not: (i) comply with the requirements of AMMA or the Medical Rules, (ii) implement the policies and procedures or comply with the statements provided to ADHS with the dispensary's application. ADHS may inspect an adult-use facility at any time during regular hours of operation. ADHS must make at least one unannounced visit annually to each licensed facility.

ADHS may suspend or revoke a marijuana establishment license if (i) the marijuana establishment (a) provides false or misleading information to ADHS, (b) operates before obtaining approval to operate from ADHS, (c) diverts marijuana to an individual or entity not allowed to possess marijuana, or (d) acquires marijuana from an individual or entity not allowed to possess marijuana; (ii) a principal officer or board member (a) has been convicted of an excluded felony offense, or (b) provides false or misleading information to ADHS; (iii) the marijuana establishment does not (a) comply with the requirements in the SSAA or the Adult-use Rules, or (b) implement the policies or procedures or comply with the statements provided to ADHS in the marijuana establishment's application.

Regulatory Developments in the State of New York

In July 2014, the New York Legislature and Governor enacted the Compassionate Care Act (the "CCA") to provide a comprehensive, safe and effective medical cannabis program. The CCA provides access to the program to certified patients who suffer from one of 14 qualifying serious conditions including, debilitating or life-threatening conditions including cancer, HIV/AIDS, ALS and chronic pain. Certified patients must also have one of the following associated or complicating conditions: cachexia or wasting syndrome, severe or chronic pain, severe nausea, seizures, or severe or persistent muscle spasms, post-traumatic stress disorder, or opioid use disorder (if enrolled in a treatment program pursuant to Article 32 of the Mental Hygiene Law).

Pursuant to the CCA, only a limited number of product offerings are allowed including metered liquid or oil preparations, solid and semi-solid preparations (e.g. capsules, chewable and effervescent tablets), metered ground plant preparations, and topical forms and transdermal patches. Smoking medical cannabis is not allowed. Medical cannabis may not be incorporated into the food products unless approved by the Commissioner of Health and smoking of cannabis flower is prohibited. According to the Cowen report, Charting Cannabis: A U.S. State Level Deep Dive, published February 19, 2020, there were 35 open dispensaries in New York as of the end of 2019.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

On March 31, 2021, New York became the 16th state to legalize the adult-use of cannabis with the enactment of Senate Bill S854A, also known as The Marihuana Regulation and Taxation Act (the "MRTA"). Under MRTA, the current medical cannabis program is set to undergo several changes. A new Office of Cannabis Management-an independent agency operating as part of the New York State Liquor Authority-will be responsible for regulating the adult-use cannabis market as well as the existing medical cannabis and hemp programs, and will be overseen by a new five-member Cannabis Control Board. The list of medical conditions covered under the CCA will be widened to include additional qualifying conditions, medical patients will no longer be restricted from smoking medical cannabis, and the current limit on cannabis supply for medical patients will be doubled. Medical cannabis license holders may also be allowed to double their existing number of dispensaries for up to a total of eight dispensaries, but no more than three of the dispensary locations will be permitted to serve as adult-use cannabis retail stores. The legislation takes effect immediately, though full implementation will not occur until the Cannabis Control Board develops regulations for the adult-use cannabis program. It is currently expected that full implementation could take between 18 months to two years. On January 24, 2022, the Office of Cannabis Management announced the launch of a new Medical Cannabis Program certification and registration system expanding the existing medical cannabis program. Moving forward, the program will allow the certification of a patient by a practitioner for any condition that the practitioner believes can be treated with medical cannabis.

On February 22, 2022 Governor Kathy Hochul signed into law S.8084-A/A.9283-A creating a new Adult-Use Conditional Cultivator license, authorizing eligible hemp growers to apply for a license to grow cannabis containing over 0.3% THC for the upcoming adult-use market. To be eligible to apply, the hemp grower must have been authorized to grow hemp under the Department of Agriculture and Markets Industrial Hemp Research Pilot Program and meet certain other requirements.

New York Licenses

The New York Department of Health ("NYDOH") approves entities to operate as "registered organizations" under the CCA. Each registered organization is vertically integrated and can operate one cultivation/processing facility and up to four dispensaries.

Licenses under New York's medical cannabis program are valid for two years from the date of issuance and registered organizations are required to submit a renewal application not more than six months nor less than four months prior to expiration. Registered organizations must ensure that no medical cannabis product is sold, delivered, transported or distributed by a producer from or to a location outside of New York.

New York Record-Keeping/Reporting

The NYDOH uses the BioTrack THC T&T system to track medical cannabis activity. Each month, each registered organization is required to file reports with the NYDOH which provides information showing all medical cannabis products dispensed during the month. All other data shall be pulled from the T&T system. The data must include (a) documentation, including lot numbers where applicable, of all materials used in the manufacturing of the approved medical cannabis product to allow tracking of the materials including but not limited to soil, soil amendment, nutrients, hydroponic materials, fertilizers, growth promoters, pesticides, fungicides, and herbicides, (b) cultivation, manufacturing, packaging and labeling production records, and (c) laboratory testing results. The records are required to be maintained for a period of five years.

New York Inventory/Storage Requirements

A record of all approved medical cannabis products that have been dispensed must be filed with the NYDOH electronically through BioTrack THC no later than 24 hours after the medical cannabis product was dispensed to the certified patient or designated caregiver. The information filed must include (a) a serial number for each approved medical cannabis product dispensed to the certified patient or designated caregiver, (b) an identification number for the registered organization's dispensing facility, (c) the patient's name, date of birth and sex, (d) the patient's address, including street, city, state and zip code, (e) the patient's registry identification card number, (f) if applicable, the designated caregiver's name and registry identification number, (g) the date the approved medical cannabis was filled by the dispensing facility, (h) the medical cannabis product drug code number, (i) the number of days of supply dispensed, (j) the registered practitioner's Drug Enforcement Administration number, (k) the date the written certification was issued by the registered practitioner, and (l) the payment method.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

All cannabis must be stored in a secure area or location within the registered organization accessible only to a minimum number of employees essential for efficient operation and in such a manner as approved by the NYDOH in advance, to prevent diversion, theft or loss and against physical, chemical and microbial contamination and deterioration. Cannabis must be returned to its secure location immediately after completion of manufacture, distribution, transfer or analysis.

New York Security Requirements

All facilities operated by a registered organization, including any manufacturing facility and dispensing facility, must have a security system to prevent and detect diversion, theft or loss of cannabis and/or medical cannabis products, utilizing commercial grade equipment which includes, at a minimum (a) a perimeter alarm, (b) motion detectors, (c) video cameras in all areas that may contain cannabis and at all points of entry and exit, (d) a duress alarm, (e) a panic alarm, (f) a holdup alarm, (g) an automatic voice dialer, (h) a failure notification system, and (i) the ability to remain operational during a power outage.

The manufacturing and dispensing facilities' cameras must have the ability to product a clear color still photo that is a minimum of 9600 dpi from any camera image and must be directed at all approved safes, approved vaults, dispensing areas, cannabis sales areas and any other area where cannabis is manufactured, stored, handled, dispensed or disposed of. The manufacturing and dispensing facilities must angle the cameras to allow for the capture of clear and certain identification of any person entering or exiting the facilities. The surveillance cameras must record 24 hours a day, seven days a week. Recordings from all video cameras must include a date and time stamp embedded on all recordings and must be readily available for immediate viewing by a state authorized representative upon request and must be retained for at least 90 days. A registered organization must test the security and surveillance equipment no less than semi-annually at each manufacturing and dispensing facility that is operated under the registered organization's registration. Records of security tests must be maintained for five years and be made available for inspection by the NYDOH.

New York Transportation Requirements

Prior to transporting any medical cannabis, a registered organization must complete a shipping manifest using a form determined by NYDOH. A copy of the shipping manifest must be transmitted to the destination that will receive the products and to NYDOH at least two business days prior to transport unless otherwise expressly approved NYDOH. The registered organization shall maintain all shipping manifests and make them available to the department for inspection upon request, for a period of 5 years.

Approved medical cannabis products must be transported in a locked storage compartment that is part of the vehicle transporting the cannabis and in a storage compartment that is not visible from outside the vehicle. An employee of a registered organization, when transporting approved medical cannabis products must (a) travel directly to his or her destination(s) and may not make any unnecessary stops in between, (b) ensure that all approved medical cannabis product delivery times are randomized, (c) appoint each transport vehicle with a minimum of two employees where at least one transport team member remains with the vehicle at all times that the vehicle contains cannabis, (d) have access to a secure form of communication with employees at the registered organization's manufacturing facility at all times that the vehicle contains cannabis, (e) possess a copy of the shipping manifest at all times when transporting or delivering approved medical cannabis products, and (f) keep the manifest in a safe compartment for a minimum of five years.

New York Inspections

Medical cannabis facilities in New York must make its books, records and manufacturing and dispensing facilities available to the NYDOH or its authorized representatives for monitoring, on-site inspection, and audit purposes, including but not limited to periodic inspections and/or evaluations of facilities, methods, procedures, materials, staff and equipment to assess compliance with requirements of the CCA and the regulations promulgated thereunder.

Regulatory Developments in the State of Massachusetts

The Massachusetts Medical Use of Marijuana Program (the "MA Program") was formed pursuant to the Act for the Humanitarian Medical Use of Marijuana (the "MA ACT"). The MA Program allows registered persons to purchase medical cannabis and applies to any patient, personal caregiver, Medical Marijuana Treatment Center (each, a "MTC"), and MTC agent that qualifies and registers under the MA Program. To qualify, patients must suffer from a debilitating condition as defined by the MA Program. Currently there are eight conditions that allow a patient to acquire cannabis in

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Massachusetts, including AIDS/HIV, ALS, cancer and Crohn's disease. The MA Program is administrated by the Cannabis Control Commission of Massachusetts (the "CCC").

In November 2016, Massachusetts voted affirmatively on a ballot petition to legalize and regulate cannabis for adult-use. The Massachusetts legislature amended the law on December 28, 2016, delaying the date adult-use cannabis sales would begin by six months. The delay allowed the legislature to clarify how municipal land-use regulations would treat the cultivation of cannabis and authorized a study of related issues. After further debate, the state House of Representatives and state Senate approved H.3818 which became Chapter 55 of the Acts of 2017, An Act to Ensure Safe Access to Marijuana, and established the CCC. The CCC consists of five commissioners and regulates both the Adult Use and Medical Use of Marijuana programs. Sales of adult-use cannabis in Massachusetts started in July 2018. Adult-use cannabis in Massachusetts is regulated under M.G.L. ch. 94G and 935 CMR 500 et seq.

Under the MA Program, MTCs are heavily regulated. Vertically integrated MTCs grow, process, and dispense their own cannabis. As such, each MTC is required to have a retail facility as well as cultivation and processing operations, although retail operations may be separate from grow and cultivation operations. An MTC's cultivation location may be in a different municipality or county than its retail facility.

The MA Program mandates a comprehensive application process for MTCs. Each Registered Marijuana Dispensary (each, a "RMD") applicant must submit a Certificate of Good Standing, comprehensive financial statements, a character competency assessment, and employment and education histories of the senior partners and individuals responsible for the day-to-day security and operation of the MTC. Municipalities may individually determine what local permits or licenses are required if an MTC wishes to establish an operation within its boundaries.

Massachusetts Licenses

Each Massachusetts dispensary, grower and processor license is valid for one year and must be renewed no later than 60 calendar days prior to expiration. As in other states where cannabis is legal, the CCC can deny licenses and renewals for multiple reasons, including (per 935 CMR 500.400) (1) failure to complete the application process within the required time period; (2) submission of deceptive, misleading, or fraudulent information, (3) an indication of an inability to maintain and operate a compliant cannabis establishment, (4) determination of unsuitability pursuant to, for example, certain criminal convictions, (5) failure to comply with cannabis license control limitations, (6) rejection of revocation of another cannabis license in Massachusetts or elsewhere; or (7) any other ground that serves the purposes of the law. Revocations can also be based on (per 935 CMR 500.450) (1) failure to submit or implement a plan of correction; (2) attempting to assign ownership to another entity or making other significant changes without proper permission, (3) lack of responsible operation of a cannabis establishment, (4) maintaining a substandard level of compliance with applicable statutory and regulatory requirements, (5) financial insolvency; (6) failure to cooperate with law enforcement, (7) violation of the safety, health, or welfare of the public; or (8) committing, permitting, aiding, or abetting of any illegal practices in the operation of the cannabis establishment. Additionally, license holders must ensure that no cannabis is sold, delivered, or distributed by a producer from or to a location outside of the state.

Regulation of the Adult-Use Cannabis Market in Massachusetts

Adult-use cannabis has been legal in Massachusetts since December 15, 2016, following a ballot initiative in November of that year. The CCC, a regulatory body created in 2018, licenses adult-use cultivation, processing and dispensary facilities (collectively, "Marijuana Establishments" or "MEs") pursuant to 935 CMR 500.000 et seq. The first adult-use cannabis facilities in Massachusetts began operating in November 2018.

Massachusetts Licensing Requirements (Adult-Use)

Applicants must submit proof of being an entity registered to do business in Massachusetts, as well as a list of all people and entities having direct or indirect control of the business, documentation of any such people or entities' other business interests, details of the amounts and sources of capital resources, and documentation of a bond or escrow account. Furthermore, the applicant must provide a specific address for the location of the establishment, proof of a property interest in that address, documentation that the applicant has a "host community agreement" with the municipality, and documentation that the applicant has held at least one community outreach meeting. The applicant must also provide a description of plans to ensure that the cannabis establishment will be compliant with all applicable laws and regulations, and also a specific plan to positively impact areas of disproportionate impact (geographical locations in the state which

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

have had historically high rates of arrest, conviction, and incarceration related to cannabis crimes). The application also requires payment of a fee.

All individuals identified as having direct or indirect control in the license must undergo an extensive background check that includes criminal, civil, and regulatory records; certain criminal convictions, civil actions, or regulatory infractions may trigger a finding of unsuitability

Each license applicant must submit detailed information about its business registration, certificates of good standing, and a plan to obtain liability insurance. The application must include a detailed business plan, a detailed summary of operating policies and procedures addressing issues like security, storage, prevention of diversion, transportation, inventory practices, recordkeeping, and a specific diversity plan demonstrating promotion of equity among people of color, women, veterans, persons with disabilities, and LGBTQ+ individuals. Such plans must have specific goals and measurable outcomes that will be monitored and updated through the entire existence of the cannabis establishment.

Pursuant to 935 CMR 500.050, no person or entity may own or have direct or indirect control over more than three licenses in each Marijuana Establishment category (i.e., cannabis retailer, cannabis cultivator, cannabis product manufacturer). Additionally, there is a 100,000 square foot cultivation canopy restriction for adult-use licenses.

Massachusetts Dispensary Requirements (Adult-Use)

Cannabis retailers may purchase, transport, sell, repack, or otherwise transfer cannabis and cannabis products to consumers. On-site consumption is prohibited. All permitted cannabis-related activities must take place solely at the licensed address.

All cannabis establishment employees must receive at least eight hours of training annually. A total of four hours of training shall be from Responsible Vendor Training Program courses established under 935 CMR 500.105(2)(b). The remaining four hours may be conducted in-house by the cannabis establishment as on-the-job training.

All cannabis establishments must have written operating procedures addressing security measures, employee security policies, descriptions of operating hours and after-hours contact information, storage and waste disposal, product descriptions, price list, recordkeeping, quality control, staffing, emergency procedures, alcohol/smoke/drug-free workplace policies, confidential information handling, plans for immediate dismissal of employees who divert cannabis, engage in unsafe practices or are convicted of certain crimes, board of directors and members list, cash handling, prevention of diversion, energy efficiency, and workplace safety. Retail establishments must also have plans to check the identification of each customer both upon entering the store and again at the point of sale. No one under 21 is permitted to purchase cannabis or to be on the premises. Retail stores must ensure that customers purchase no more than one ounce of cannabis (or its equivalent in other forms) per day. Retailers also have the right to refuse sales to customers, for example, those that appear to be impaired by the influence of substances.

The retail point of sale system must be approved by both the CCC and the state Department of Revenue. It must be integrated with Metrc, the state's seed-to-sale tracking system. The system must also be audited on a monthly basis to ensure that no additional software has been installed that could alter sales data. Cannabis retailers must have available extensive consumer education materials, including in languages other than English.

Massachusetts Security and Storage Requirements (Adult-Use)

Each Marijuana Establishment must implement sufficient safety measures to deter and prevent unauthorized entrance into areas containing cannabis and theft of cannabis at the establishment. Security measures taken by the establishments to protect the premises, employees, consumers and general public must include, but not be limited to, the following:

- positively identifying individuals seeking access to the premises of the Cannabis Establishment or to whom or cannabis products are being transported pursuant to 935 CMR 500.105(13) to limit access solely to individuals 21 years of age or older;
- adopting procedures to prevent loitering and ensure that only individuals engaging in activity expressly or by necessary implication permitted by the regulations and its enabling statute are allowed to remain on the premises;
- disposing of cannabis in accordance with 935 CMR 500.105(12) in excess of the quantity required for normal, efficient operation as established within 935 CMR 500.105;

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

- securing all entrances to the Marijuana Establishment to prevent unauthorized access;
- establishing limited access areas pursuant to 935 CMR 500.110(4), which shall be accessible only to specifically authorized personnel limited to include only the minimum number of employees essential for efficient operation;
- storing all finished cannabis products in a secure, locked safe or vault in such a manner as to prevent diversion, theft and loss;
- keeping all safes, vaults, and any other equipment or areas used for the production, cultivation, harvesting, processing or storage of cannabis products securely locked and protected from entry, except for the actual time required to remove or replace cannabis;
- keeping all locks and security equipment in good working order;
- prohibiting keys, if any, from being left in the locks or stored or placed in a location accessible to persons other than specifically authorized personnel;
- prohibiting accessibility of security measures, such as combination numbers, passwords or electronic or biometric security systems, to persons other than specifically authorized personnel;
- ensuring that the outside perimeter of the Marijuana Establishment is sufficiently lit to facilitate surveillance, where applicable;
- ensuring that all cannabis products are kept out of plain sight and are not visible from a public place without the use of binoculars, optical aids or aircraft;
- developing emergency policies and procedures for securing all product following any instance of diversion, theft or loss of cannabis, and conduct an assessment to determine whether additional safeguards are necessary;
- developing sufficient additional safeguards as required by the CCC for Marijuana Establishments that present special security concerns;
- establishing procedures for safe cash handling and cash transportation to financial institutions to prevent theft, loss and associated risks to the safety of employees, customers and the general public;
- sharing the establishment's floor layout with law enforcement and as required by the municipality to identify the use of any flammable or combustible solvents, chemicals, or other such materials in use; and
- sharing the Marijuana Establishment's security plan and procedures with law enforcement authorities and fire services and periodically updating law enforcement authorities and fire services if the plans or procedures are modified in a material way.

Cannabis must be stored in special limited access areas, and alarm systems must meet certain technical requirements, including a failure notification system, perimeter alarms on all entry and exit points, duress/panic alarms, and video surveillance in all areas where cannabis or cash is kept and at all points of entry and exit. The surveillance system must have the ability to record footage 24 hours a day and to retain such footage for at least 90 days. The systems must be angled so as to allow for the capture of clear identification of any person entering or existing the establishment and must be able to remain operational for a minimum of four hours in the event of a power outage. Regular audits are required every 30 days.

Massachusetts Transportation Requirements (Adult-Use)

Cannabis products may only be transported between licensed MEs by registered Marijuana Establishment agents. A licensed cannabis transporter may contract with a licensed Marijuana Establishment to transport that licensee's cannabis products to other licensed establishments. The originating and receiving licensed establishments shall ensure that all transported cannabis products are linked to METRC, Massachusetts' seed-to-sale tracking program. For the purposes of tracking, seeds and clones will be properly tracked and labeled in a form and manner determined by the CCC. Any cannabis product that is undeliverable or is refused by the destination Marijuana Establishment shall be transported back to the originating establishment. All vehicles transporting cannabis products shall be staffed with a minimum of two Marijuana Establishment agents. At least one agent shall remain with the vehicle at all times that the vehicle contains cannabis or cannabis products. Prior to the products leaving a Marijuana Establishment for the purpose of transporting cannabis products, the originating Marijuana Establishment must weigh, inventory, and account for, on video, all cannabis products to be transported. Within eight hours after arrival at the destination Marijuana Establishment, the destination establishment must re-weigh, re-inventory, and account for, on video, all cannabis products transported. When videotaping the weighing, inventorying, and accounting of cannabis products before transportation or after receipt, the video must show each product being weighed, the weight, and the manifest. Cannabis products must be packaged in

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

sealed, labeled, and tamper or child-resistant packaging prior to and during transportation. In the case of an emergency stop during the transportation of cannabis products, a log must be maintained describing the reason for the stop, the duration, the location, and any activities of personnel exiting the vehicle. A Marijuana Establishment or a cannabis transporter transporting cannabis products is required to ensure that all transportation times and routes are randomized. An establishment or transporter transporting cannabis products shall ensure that all transport routes remain within Massachusetts. All vehicles and transportation equipment used in the transportation of cannabis products or edibles requiring temperature control for safety must be designed, maintained, and equipped as necessary to provide adequate temperature control to prevent the cannabis products or edibles from becoming unsafe during transportation, consistent with applicable requirements pursuant to 21 CFR 1.908(c).

Vehicles used for transport must be owned or leased by the Marijuana Establishment or transporter, and they must be properly registered, inspected, and insured in Massachusetts. All vehicles must be equipped with a video system that includes at least one camera in the storage area and at least one camera in the driver area. All cameras must remain functional throughout the entire transportation process. All vehicles must also be equipped with an alarm system, and functioning heating and air conditioning. Cannabis may not be visible from outside the vehicle, and it must be transported in a secure, locked storage compartment. The vehicle may not have any external markings indicating that it is used to transport cannabis. Each vehicle must have a global positioning system, and any agent transporting cannabis must have access to a secure form of communication with the originating location. Firearms are forbidden inside the vehicle or on the person of an agent. Each transport must have a manifest filled out in triplicate.

Massachusetts CCC Inspections

The CCC or its agents may inspect a Marijuana Establishment and affiliated vehicles at any time without prior notice in order to determine compliance with all applicable laws and regulations. All areas of a Marijuana Establishment, all Marijuana Establishment agents and activities, and all records are subject to such inspection. Marijuana establishments must immediately upon request make available to the CCC all information that may be relevant to a CCC inspection, or an investigation of any incident or complaint. A Marijuana Establishment must make all reasonable efforts to facilitate the CCC's inspection, or investigation of any incident or complaint, including the taking of samples, photographs, video or other recordings by the CCC or its agents, and to facilitate the CCC's interviews of Marijuana Establishment agents. During an inspection, the CCC may direct a Marijuana Establishment to test cannabis for contaminants as specified by the CCC, including but not limited to mold, mildew, heavy metals, plant-growth regulators, and the presence of pesticides not approved for use on cannabis by the Massachusetts Department of Agricultural Resources.

Moreover, the CCC is authorized to conduct a secret shopper program in retail establishments to ensure compliance with all applicable laws and regulations.

Regulatory Developments in the State of Washington

Washington has authorized the cultivation, possession, processing, wholesaling, and retail sale of marijuana by certain licensed Washington businesses. The Washington State Liquor and Cannabis Board ("WSLCB") regulates Washington's marijuana regulatory program. Every individual with an ownership or equity interest, with a right to receive a percentage of gross or net profits, or who exercises control over a licensed marijuana operator must apply for licensing with the WSLCB and be approved. Each applicant must be over 21 years of age and a Washington resident for a minimum of 6 months prior to the application for licensure.

An applicant must provide the WSLCB with the applicant's organizational and operational documents, including the entity's operating agreement and a detailed operating plan, in order to verify that the proposed business meets the minimum requirements for licensing. Any change in the initial ownership of a cannabis entity must receive prior approval through the WSLCB and undergoes a review of the same rigor and breadth as an initial application.

Regulatory Developments in the State of Maryland

The Maryland Medical Cannabis Commission (the "Maryland MCC") grants medical cannabis grower, processor, dispensary and transportation licenses. A licensee may hold a license in each category to obtain vertical integration. The applicant must first seek pre-approval from the Maryland MCC to be granted a license. As part of the pre-approval application, the applicant must submit information related to its operations; safety and security; medical cannabis professionalism; retail management factors; business and economic factors; and other additional factors that may apply.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Dispensary licenses in Maryland are renewed every six years. Before expiry, licensees are required to submit a renewal application. While renewals are granted every six years, there is no ultimate expiry after which no renewals are permitted. Additionally, in respect of the renewal process, provided that the requisite renewal fees are paid, the renewal application is submitted in a timely manner, and there are no material violations noted against the applicable license.

Maryland Licensing Requirements

To become a licensed medical cannabis dispensary, each applicant must submit an application detailing the location of the proposed dispensary, the personal details of each principal officer or director, and operating procedures the dispensary will use. Owners, members, shareholders, officers, and directors of dispensary holding a 5% or greater interest in the company must undergo a criminal and financial background checks. Employees, volunteers and personnel who will be working in the dispensary with access to the non-public areas are required to undergo background checks and register as a dispensary agent with the Maryland MCC.

Maryland Reporting Requirements

Once licensed, the medical cannabis dispensary is required to submit to the Maryland MCC quarterly reports including the following information: (i) the number of patients served; (ii) the county of residence of each patient served; (iii) the medical condition for which medical cannabis was recommended; (iv) the type and amount of medical cannabis dispensed; and (v) if available, a summary of clinical outcomes, including adverse events and any cases of suspected diversion. The medical cannabis dispensary must not include any patient personal information in the quarterly report.

Maryland Inspections

Licensees must be inspected by the Maryland MCC prior to receiving approval from the Maryland MCC to be authorized to begin cultivation, processing, and dispensing. Licensees are eligible to apply to renew their license every two years during which time a full inspection of the facility is performed. Spot-inspections may be performed at the dispensary at any time and without advance notice.

Maryland Safety and Security Requirements

As part of the medical cannabis dispensary application, the applicant must provide information about the dispensary's operating procedures consistent with the oversight regulations established by the Maryland MCC, including the following: (i) storage of cannabis and products containing cannabis only in enclosed and locked facilities; (ii) security features and procedures; (iii) how the dispensary will prevent diversion; and (iv) safety procedures. As part of the safety and security requirements, the applicant must detail how the premises will be constructed to prevent unauthorized entry, including a designation of a secured room meeting high-security requirements. The applicant must describe how it would train all registered dispensary agents on safety procedures, including responding to: (i) a medical emergency; (ii) a fire; (iii) a chemical spill; and (iv) a threatening event including: (a) an armed robbery, (b) an invasion, (c) a burglary, or (d) any other criminal incident.

The applicant must describe its security and surveillance plan with information including the following: (i) an alarm system that covers perimeter entry points, windows, and portals at the premises that: (a) will be continuously monitored; (b) detects smoke and fire capabilities; (c) detects power loss capabilities; (d) includes panic alarm devices mounted at convenient, readily-accessible locations through the licensed premises; (e) inclusion of a second, independent alarm system to protect where records are stored on- and off-site and where any secure room holds medical cannabis; (f) equipped with auxiliary power to continue operation for at least 48 hours; (ii) a video surveillance system that: (a) records continuously for 24 hours per day for 365 days a year without interruption, (b) has cameras in fixed places that allow for the clear facial identification and of activities in the controlled areas of the premises, including where medical cannabis is packaged, tested, processed, stored, or dispensed, (c) has the capability of recording clear images and displays the time and date of the recording, and (d) demonstrates a plan for retention of recordings for at least 30 days.

Following issuance of a license, no major renovation or modification may be undertaken without notification to the Maryland MCC. Other than while the dispensary is open for business and one hour before and one hour after, the medical cannabis inventory must be stored in the secure room.

Medical cannabis products are subject to testing for contaminants by an independent testing laboratory. In November 2019, the Maryland MCC mandated enhanced testing requirements for vape cartridges and disposable vape pens. Such

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

products must be screened for vitamin E acetate, and any product found to contain vitamin E acetate is prohibited from being sold to patients.

Maryland Operating Requirements

As part of the dispensary application, the applicant must provide information about the dispensary's operations, including the following: (i) communication systems; (ii) facility odor mitigation; and (iii) back-up systems for cultivation and processing systems. The applicant must establish a standard operating procedure of the receipt, storage, packaging, labelling, handling, tracking, and dispensing of products containing medical cannabis and medical cannabis waste.

In addition, the applicant must provide information about the dispensary's medical cannabis professionalism, including the following information: (i) experience, knowledge, and training in training dispensary agents in the science and use of medical cannabis; and (ii) use of a clinical director (optional). The applicant must also provide information about the dispensary's retail management operations, including the following: (i) a detailed plan to preserve the quality of the medical cannabis; (ii) a plan to minimize any negative impact on the surrounding community and businesses; (iii) a detailed inventory control plan; and (iv) a detailed medical cannabis waste disposal plan.

The business and economic factors of the dispensary business must also be detailed, including the following information: (i) a business plan demonstrating a likelihood of success, demonstrating sufficient business ability and experience on the part of the applicant, and providing for appropriate employee working conditions, benefits, and training; (ii) demonstration of adequate capitalization; and (iii) a detailed plan evidencing how the dispensary will enforce the alcohol and drug free workplace policy.

Additional information the applicant must also provide includes the following: (i) demonstration of Maryland residency among the owners and investors; (ii) evidence that the applicant is not in arrears regarding any tax obligation in Maryland or other jurisdictions; and (iii) the medical cannabis extracts and medical cannabis-infused products proposed to be dispensed with proposed cannabinoid profiles, including varieties with high CBD content, and the varieties of routes of administration.

Maryland Record Keeping and Inventory Tracking

Maryland requires use of a seed-to-sale tracking system software operated by Metrc LLC ("METRC"). Licensees must create and use a perpetual inventory control system that identifies and tracks the stock of medical cannabis from the time it is delivered or produced to the time it is delivered to a patient or qualified caregiver. The applicant must describe how it will assure the integrity of the electronic manifest and inventory control system and that a cannabis transportation agent will continue the chain of custody to a dispensary agent. In May 2020, Maryland amended the medical marijuana statutes to authorize a parent or legal guardian of a medical cannabis patient under 18 to designate up to two additional adults to be caregiver and authorizing the patient to obtain medical cannabis from certain school personnel.

The applicant must retain attendance records and ensure dispensary agents are trained on the record retention and standard operating procedure. Maryland MCC regulators have the authority to audit the records of licensees to ensure they comport with the reporting in METRC.

Maryland Dispensing

In order to dispense medical cannabis, a licensed dispensary is required to comply with various dispensing requirements: (1) require presentment of a written certification from a qualifying patient or caregiver, (2) query the MMCC's date network to verify that the patient is currently registered and has a certification from a provider, as well as the amount of medical cannabis that has already been dispensed pursuant to the written certification (3) dispense no more than a 30 day supply, (4) refuse to dispense medical cannabis if the patient or caregiver appears to be under the influence of drugs or alcohol. Registered patients and caregivers are required to provide attestations relating to their knowledge of the status of medical cannabis under Maryland and Federal law, as well as limitations on use of medical cannabis, such as keeping away from children and refraining from transfer to any other person.

Maryland Transportation

Only licensed medical cannabis growers, processors, or authorized secure transportation companies may transport business-to-business packages containing medical cannabis. Dispensaries are not authorized to pick up medical cannabis

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

products from licensed growers or processors. Owners and employees of secure transportation companies must register as transportation agents with the Maryland MCC by undergoing criminal and financial background checks, and they must carry identification cards evidencing they hold current registration at all times while in possession of medical cannabis. Transportation agents must possess a current, valid driver's license and may not wear any clothing or symbols that indicate ownership or possession of medical cannabis while on duty. Medical cannabis transport vehicles must be approved by the Maryland MCC and shall display current registration from the state, be insured, and may not display any sign or illustration related to medical cannabis or a licensee.

Electronic manifests must accompany shipments to record the chain of custody and includes (i) the name and address of the shipping licensee; (ii) the shipping licensee's shipment identification number; (iii) the weight and description of each individual package that is part of the shipment, and the total number of individual packages; (iv) the name of the licensee agent that prepared the shipment; (v) the name and address of the receiving licensee; (vi) any special handling or storage instructions; (vii) the date and time the shipment was prepared; (viii) the date and time the package was placed in the secure transport vehicle; and (ix) a listing of any other people who had custody or control over the shipment, and the person's identity, circumstances, duration and disposition.

Dispensary licensees in Maryland are authorized to perform home delivery directly to patients. To do so, the dispensary must (i) independently verify the patient's identification and registration status, (ii) enter the transaction in METRC prior to delivery; (iii) perform the delivery through a registered dispensary agent; and (iv) confirm the transaction otherwise complies with other requirements regarding sale of medical cannabis under applicable regulations. All home deliveries must be performed using a properly registered and insured secure medical cannabis transport vehicle. The vehicle may not bear any markings related to medical cannabis.

Regulatory Developments in the State of Texas

Regulatory Framework Texas initially limited the scope of authorization of cannabis for medical purposes to the cultivation, processing, and dispensing of low-THC cannabis prescribed to epilepsy patients. In May 2019, the Texas legislature passed a bill that significantly expanded the Texas Compassionate Use Act. It was subsequently signed into law by the Governor. The May 2019 law increased legal access to medical cannabis products containing up to 0.5 percent THC for patients coping with a broader list of chronic medical conditions and diseases including epilepsy, a seizure disorder, multiple sclerosis, spasticity, amyotrophic lateral sclerosis, autism and terminal cancer. Compassionate Use Act. The Texas Legislature enacted the Texas Compassionate Use Act, found in Chapter 169 of the Texas Occupations Code and Chapter 487 of the Texas Health and Safety Code, in 2015. The Texas Compassionate Use Act directs the Texas Department of Public Safety ("DPS") to create a secure registry of Texas-licensed physicians who are authorized to treat qualifying conditions by prescribing low-THC cannabis to qualified, registered patients who have been diagnosed with epilepsy, a seizure disorder, multiple sclerosis, spasticity, amyotrophic lateral sclerosis (ALS), autism, terminal cancer, or an incurable neurodegenerative disease. In addition, the bill required DPS to license at least three dispensing organizations by September 1, 2017, should they meet the requirements. The license authorizes the organizations to cultivate, process and dispense low-THC cannabis to prescribed patients.

Regulatory Developments in the State of Colorado

Colorado's medical cannabis program was introduced in November 2000, when 54% of voters approved "Amendment 20". Colorado became the first state in the nation to legalize adult-use cannabis when 55% of voters approved "Amendment 64" in November 2012. The first adult-use dispensaries opened in January 2014. As of January 1, 2020, medical and adult use marijuana are regulated together under a single statute – the Colorado Marijuana Code.

Under the Colorado Marijuana Code, the Colorado Department of Revenue Marijuana Enforcement Division is empowered to grant licenses to both adult use and medical marijuana businesses, including cultivation facilities, products manufacturers, testing facilities, transporters, researchers and developers, and (in the adult use context) accelerator cultivators, accelerator stores, and hospitality businesses. Cannabis businesses must also comply with local licensing requirements. Colorado localities are allowed to limit or prohibit the operation of marijuana businesses.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Colorado Security Requirements

All marijuana businesses in Colorado are required to (1) create and enforce limited access areas for the protection of marijuana and marijuana products, (2) maintain security alarm systems installed and maintained by a licensed alarm installation company, as well as approved locks and surveillance equipment, (3) follow all applicable laws regarding waste disposal (including cannabis-containing wastes), (4) implement an inventory tracking system used for inventory tracking and recordkeeping, (5) comply with both state and local requirements as to hours of operation, (6) comply with sanitary requirements applicable to employees and production spaces, including sanitation audits, (7) comply with recordkeeping requirements, and (8) maintain and provide procedures for dealing with product recalls.

Cultivation facilities are additionally required to (1) provide and maintain copies of standard operating procedures for cultivation, harvesting, drying, curing, trimming, packaging, storing, and sampling, (2) comply with requirements related to pesticides, and (3) comply with additional sanitary and product safety requirements. Marijuana products manufacturers are required to (1) comply with labeling and dosing requirements related to standardized doses of marijuana, (2) comply with specific prohibitions regarding the shapes, colors, and similar characteristics of edible products, refrain from use of prohibited additives and ingredients, (3) maintain and provide standard operating procedures related to manufacturing of each category of products. Marijuana dispensaries are subject to additional requirements regarding (1) methods of accepting orders, (2) payments by customers, and (3) identification of customers.

Colorado Inspection Requirements

The Marijuana Enforcement Division and local licensing authorities may conduct announced or unannounced inspections of licensees to determine compliance with applicable laws and regulations. Licensees may also be subject to inspection of the licensed premises by the local fire department, building inspector, or code enforcement officer to confirm that no health or safety concerns are present.

Colorado Reporting Requirements

Colorado uses METRC as the Marijuana Enforcement Division's marijuana inventory tracking system for all medical and adult use licensees. Marijuana is required to be tracked and reported with specific data points from seed to sale through METRC for compliance purposes under Colorado marijuana laws and regulations. This tracking is conducted by using electronic tags on plants and shipments between licensees and facilities.

Regulatory Developments in the State of Nevada

Nevada's medical cannabis program was introduced in June 2013 when the legislature passed SB374, legalizing the medicinal use of cannabis for certified patients. The first dispensaries opened to patients in August 2015. In November 2016, Nevada voters approved Question 2 with 55% of the vote, legalizing adult-use cannabis in the state. Adult-use sales launched on July 1, 2018. The market is divided into five classes of licenses: dispensaries, cultivators, distribution, product manufacturing, and testing. Licenses are tied to the locality in which they were awarded. As of March 31, 2021, there were approximately 81 operational dispensaries, 152 operational cultivators, and 108 operational processors. Extracted oils, edibles, and flower products are permitted. Wholesaling is permitted.

Regulatory Developments in the State of Delaware

Medical marijuana was legalized in 2011 with the passage of the Medical Marijuana Act (SB 17). Medical patients may possess up to six ounces of marijuana obtained from licensed dispensaries. Maximum THC concentration is not specified in the legislation. Qualifying conditions are physician-diagnosed ailments that can be treated by medical cannabis. Patients may apply for a Delaware Medical Marijuana ID Card.

Delaware's medical marijuana program is governed by the Delaware Medical Marijuana Act, 16 Del. C. § 4901A et seq., and the Department of Health and Social Services' (the "Department") implementing regulations, CDR 16-4000-4470. The program authorizes registered qualified patients with a debilitating medical condition to use marijuana. "Debilitating medical condition" includes: (a) terminal illness, cancer, HIV, AIDS, decompensated cirrhosis, amyotrophic lateral sclerosis, agitation of Alzheimer's disease, PTSD, intractable epilepsy, seizure disorder, glaucoma, chronic debilitating migraines; (b) a chronic or debilitating disease or medical condition or its treatment that produces cachexia or wasting syndrome; severe, debilitating pain that has not responded to previously prescribed medication or surgical measures for

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

more than 3 months or for which other treatment options produced serious side effects; intractable nausea; seizures; severe and persistent muscle spasms, including those characteristic of multiple sclerosis; and (c) other medical conditions or treatments that may be added by the Department. Citizens may petition the Department to add conditions or treatments to the list of debilitating medical conditions.

The medical marijuana program creates a licensing regime for medical marijuana compassion centers ("Compassion Centers"). Compassion Centers must be operated on a not-for-profit basis. Once registered, a Compassion Center may acquire, possess, cultivate, manufacture, deliver, transfer, transport, supply, or dispense marijuana strictly for the purpose of assisting registered patients or their designated caregivers with the medical use of marijuana.

Compassion Centers' registrations expire every two years. A renewal application must be submitted between 90 and 30 days prior to the expiration of the current registration certificate.

Delaware Security, Storage, and Transportation Requirements

Compassion Centers must store marijuana in a locked area with adequate security. The adequacy of security is to be determined based on the quantity of usable marijuana on hand, the Compassion Center's inventory system, the number of people with access to the marijuana, the location of the Compassion Center, the scope and sustainability of the alarm system, and the root cause analysis of any prior breaches. Compassion Centers are also subject to detailed security and inventory-management requirements. A Compassion Center must implement appropriate security and safety measures to deter and prevent the unauthorized entrance into areas containing marijuana and the theft of marijuana. This includes access and entry limitations; maintaining a fully operational alarm system with immediate automatic notification to alert local authorities of a security breach; maintaining a log of security inspections and tests, alarm activations, and security breaches; and instituting a 24/7 video surveillance system covering areas in which marijuana is handled. The Department has also instituted a number of inventory controls. Compassion Centers must utilize a bar-coding inventory control system to track sales and inventory data; store marijuana in a locked area with adequate security; and conduct and document monthly inventory reviews and bi-annual comprehensive inventory reviews.

A registered Compassion Center agent must have documentation when transporting marijuana on behalf of the registered Compassion Center that specifies the amount of marijuana being transported, the date the marijuana is being transported, the registry ID certificate number of the registered Compassion Center or registered safety compliance facility, and a contact number to verify that the marijuana is being transported on behalf of the registered Compassion Center or registered safety compliance facility.

Delaware Inspections

Compassion Centers are also subject to inspections by the Department's Office of Medical Marijuana. These inspections may include: a review of the Compassion Center's financial and dispensing records; a review of the physical facility; an inspection for pesticides, fungus, or mold; and random sampling of marijuana plants. Moreover, the Department or an independent auditor with which it contracts shall at all times have access to all books and records kept by any Compassion Center.

Regulatory Developments in Washington, D.C.

Washington, D.C.'s medical marijuana program is governed by D.C. Code § 7-1671.01 et seq. and the Department of Health's implementing regulations, CDCR 22-C100 et seq. The program authorizes patients with a qualifying medical or dental condition to use marijuana via inhalation, ingestion, or other means. Qualifying medical conditions include chemotherapy, the use of azidothymidine or protease inhibitors, radiotherapy, or any other treatment, as determined by rulemaking, whose side effects require treatment through the administration of medical marijuana in the same manner as a qualifying medical or dental condition. The program also authorizes patients from other states to purchase medical marijuana in Washington, D.C. An emergency rulemaking action from the Mayor's Office expanded the number of states whose medical cards the program will accept to include any state or U.S. territory that has an active medical marijuana program and issues either a card or state-issued document evidencing the patient's participation in the program. An emergency rulemaking action by the Council of the District of Columbia on November 2, 2021, provided for the issuance

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

of two-year registrations cards to qualifying patients and caregiver for the purpose of attracting and keeping qualified patients and their caregivers in the legal medical cannabis market.

The medical marijuana program creates licensing regimes for dispensaries and cultivation centers. A dispensary registered to operate in the District of Columbia may (a) possess and sell medical marijuana to registered qualified patients and caregivers; and (b) manufacture, purchase, possess, and distribute paraphernalia and cigarette rolling papers to registered qualified patients and caregivers. A cultivation center registered to operate in the District of Columbia may: (a) possess, manufacture, grow, cultivate, and distribute medical marijuana for sale to registered dispensaries; and (b) manufacture, purchase, possess, and distribute paraphernalia and cigarette rolling papers to registered dispensaries. The number of dispensaries in the District of Columbia is capped at 7, with discretion for the mayor to increase the number to 8, while the number of cultivation centers is capped at 10. Currently, there are seven dispensaries and eight cultivation centers. There are also pending application processes for an additional dispensary license, two additional cultivation centers, and two testing laboratories. Columbia Care submitted a letter of intent to apply the additional dispensary license and was approved. The application period ran from Monday, November 29, 2021, through Monday, March 28, 2022.

Before issuing or renewing a registration or permit for either a business applicant or an individual applicant, the Director of the Alcoholic Beverage Regulation Administration ("ABRA") shall determine that the applicant meets all of the following criteria: the applicant is of good character and generally fit for the responsibilities of registration; the applicant is at least twenty-one (21) years of age; the applicant has not been convicted of any felony before filing the application; the applicant has not been convicted of a misdemeanor for a drug-related offense before filing the application; the applicant has paid the annual fee; the applicant is not a licensed physician making patient recommendations; the applicant is not a person whose authority to be a caregiver or qualified patient has been revoked by the ABRA; and the applicant has complied with the relevant laws and regulations. The application process is extensive and requires dispensaries to submit information about the proposed facility; a security plan; an inventory plan; a product safety and labeling plan; a business and marketing plan; comments from a neighborhood commission; and an educational materials plan. Cultivation centers must similarly submit information about the proposed facility; a security plan; a cultivation plan; a product safety and labeling plan; a business plan; comments from a neighborhood commission; and an environmental plan.

Applicants' leadership team and personnel are also subject to scrutiny during the application process. Applicants must identify all of its directors, officers, members, or incorporators on its application. Those individuals and other agents of the applicant must submit to a registration process which includes (a) written statements or evidence establishing to the satisfaction of the ABRA that the applicant meets all of the registration qualifications; (b) a copy of the applicant's medical marijuana training and education certificate, and (c) a criminal background check. An applicant's managers and employees are subject to a similar registration process that involves a criminal background check.

Washington, D.C. Security, Storage, and Transportation Requirements

Dispensaries and cultivation centers must comply with a number of security measures. Medical marijuana located on the premises must be stored in a separate storage area which is securely closed and locked when the establishment is prohibited from operating or is closed. The storage area shall have a volumetric intrusion detection device(s) installed and connected to the facility intrusion detection system. A cultivation center or dispensary must also install and use a highly secured safe for overnight storage of any processed marijuana, transaction records, and cash on the registered premises. A dispensary or cultivation center must operate and maintain in good working order a 24/7 closed-circuit television surveillance system on the premises that complies with several minimum standards, including: (1) the system must visually record and monitor the entire facility including entrances and exits, parking lots, limited access areas, and areas where medical marijuana is cultivated, stored, dispensed, or destroyed; (2) cameras must be adequate for the lighting, produce digital, time stamped video, and capable of producing a DVD; (3) the system must be in good working order, and malfunctions must be reported; (4) footage must be stored for 30 days. Upon request, recordings must be turned over to police or the Department. A dispensary or cultivation center must also install, maintain, and use a professionally monitored robbery and burglary alarm system meeting certain requirements.

Unused surplus marijuana must be weighed, documented, and submitted to the police for destruction. Stolen or lost marijuana must be reported to the police within 24 hours of becoming aware of the theft or loss.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

In order to transport marijuana within the district, a cultivation center must obtain a transport permit from the ABRA. Each vehicle used for the transportation of marijuana must have its own original permit. Only cultivation center employees, directors, officers, members, incorporators, agents, or contracted agents may transport marijuana.

Washington D.C. Operational Requirements

Applicants for a cultivation center or dispensary must submit a proposed staffing plan; a proposed security plan meeting a number of criteria specified in CDCR 22-C5406.2 or C5405.2, respectively; a cultivation plan that covers where medical marijuana will be cultivated and stored (for cultivators); a product safety and labeling plan that satisfies several criteria specified in CDCR 22-C 5607; a written statement regarding the suitability of the proposed facility for the medical marijuana operation; and a notarized written statement from the applicant that they have read the District of Columbia's medical marijuana law and have knowledge of the District of Columbia and federal laws relating to marijuana. Two or more cultivation centers may operate in the same building, provided that they maintain separate books and records and their own secure premises. And, a cultivation center and a dispensary may operate in the same building so long as they have the same ownership, maintain separate books and records, maintain separate secure space, and provided that patients and caregivers are prohibited from entering the cultivation area.

Washington D.C. Inspections

The ABRA may conduct announced and unannounced investigations and inspections of cultivation centers and dispensaries. During such inspections and investigations, the ABRA may review the cultivation center's confidential records, and failure by a dispensary or cultivation center to provide the ABRA with immediate access to requested information may result in a civil fine and further sanctions.

Regulatory Developments in the State of Florida

Although recreational use of cannabis is criminalized at the state level, medical cannabis is now legal under the Florida Constitution. The process of legalization began in 2014. On June 16, 2014, the Florida state governor signed Senate Bill 1030, also known as the Compassionate Medical Cannabis Act of 2014 (the "CMCA"), which was the first legal medical cannabis program in the State's history. The CMCA legalized low THC for medical patients suffering from cancer or "a physical medical condition that chronically produces symptoms of seizures", such as epilepsy, "or severe and persistent muscle spasms". The CMCA required physician approval and determination that no other satisfactory alternative treatment options exist for that patient. The CMCA also authorized medical centers to conduct research on low THC cannabis. On November 8, 2016, Florida voters approved the Florida Medical Marijuana Legalization Initiative, Amendment 2 ("Amendment 2"), ballot measure with 71% of the vote. Amendment 2 protects qualifying patients, caregivers, physicians, and medical cannabis dispensaries and their staff from criminal prosecution or civil sanctions under Florida law. Pursuant to Amendment 2, qualified patients who have been diagnosed with debilitating medical conditions and have been evaluated by a qualified physician may be prescribed medical cannabis. Amendment 2 also expanded the definition of debilitating diseases to include 12 conditions including HIV/AIDS, Crohn's disease, post-traumatic stress disorder and any medical condition that the physician believes will benefit from the use of medical cannabis. Amendment 2 became effective on January 3, 2017. Amendment 2 provides a regulatory framework that requires licensed producers, which are defined as Medical Marijuana Treatment Centers ("MMTCs"), to cultivate, process and dispense medical cannabis in a vertically integrated marketplace. On June 9, 2017, the Florida House of Representatives and Florida Senate passed respective legislation to implement the expanded program by replacing large portions of the existing Compassionate Use Act, which officially became law on June 23, 2017. The Florida Department of Health, Office of Medical Marijuana Use (the "OMMU"), is the organization responsible for the regulation of Florida's medical cannabis program. Specifically, the OMMU writes and implements the Department's rules for medical cannabis, oversees the statewide medical cannabis patient database, and licenses Florida businesses to cultivate, process and dispense medical cannabis to qualified patients.

The Company is a publicly traded company with access to both Canadian and US capital markets. The Company's business requires compliance with many laws and regulations. As a public company, the Company has obtained legal advice from both Canadian & US lawyers regarding compliance with applicable state regulatory frameworks and potential exposure and implications arising from the U.S. federal law. As of November 30, 2022, 26% of the Company's investment portfolio is represented by companies with either direct, indirect or ancillary involvement with the US cannabis industry.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Issuer Licenses in Florida

Cresco Labs, Inc., operating under the Sunnyside brand, is the holder of a vertically-integrated MMTC license issued by the Florida Department of Health, Office of Medical Marijuana Use, pursuant to Florida Statutes section 381.986. Cresco's MMTC license grants it the right to cultivate, process and dispense medical cannabis and medical cannabis products throughout the state of Florida, to operate licensed dispensaries in the State of Florida and to effectuate state wide delivery of medical cannabis and medical cannabis products and related approved activities. On April 14, 2022, Cresco acquired One Plant Florida's MMTC license and associated assets, including cultivation facilities in Ruskin and Indiantown and 8 dispensing facilities. As of November 26, 2022, Cresco operated 12 dispensing facility in Florida.

Florida Licenses and Regulations

Cannabis is illegal in Florida for recreational use. However, medical use of cannabis in Florida was legalized in 2016 by way of a constitutional amendment appearing on the ballot as Amendment 2, which was approved with 71% of the vote. The State of Florida Statutes 381.986 provides a regulatory framework that requires licensed producers, statutorily defined as MMTCs, to cultivate, process and dispense medical cannabis in a vertically integrated marketplace. Only licensed MMTCs can sell and dispense medical cannabis; medical cannabis may not be purchased from any vendor other than a MMTC. MMTC licenses are issued by the OMMU. Applicants for licenses are required to provide comprehensive business plans with demonstrated knowledge and experience on execution, detailed facility plans, forecasted performance and robust financial resources. The applicant's technical ability on plant and medical cannabis cultivation, infrastructure, processing, dispensing and safety are also assessed. Each MMTC must receive authorization at three stages, (i) cultivation authorization, (ii) processing authorization and (iii) dispensing authorization, prior to dispensing medical cannabis.

License holders are only permitted to hold one MMTC license pursuant to the State of Florida Statutes. However, each license allows for the cultivation, processing and dispensing of medical cannabis products. Originally, each MMTC was permitted to open up to 25 dispensaries statewide. With each additional 100,000 qualified patients that registered for the program, the dispensary cap for each MMTC increased by five dispensaries. On April 1, 2021, the cap on the number of dispensaries that could be opened and operated by a license holder expired. As of November 26, 2022, there were 644,173 qualified patients with an approved medical ID card, 22 approved MMTCs and 384 approved retail dispensing locations.

Each licensee is required to cultivate, process and dispense medical cannabis. The license permits the sale of derivative products produced from extracted cannabis plant oil as medical cannabis to qualified patients to treat certain medical conditions in the State of Florida, which conditions are delineated in Florida Statutes section 381.986.

On March 18, 2019, Florida Governor Ron DeSantis signed Florida Senate Bill 182 (2019) ("SB 182") into law, repealing the previous ban on smoking medical cannabis. SB 182 also allows patients to receive up to 2.5 ounces of whole flower cannabis every 35 days as recommended by their doctor and requires patients under the age of 18 to have a terminal condition and to get a second opinion from a pediatrician before smoking medical cannabis. On April 1, 2019, the State legalized the dispensing of whole flower cannabis products and pre-rolled cannabis joints.

Under its license, Cresco Labs, Inc. is permitted to sell cannabis to those patients who are entered into Florida's electronic medical cannabis use registry by a qualified physician and possess a state-issued medical cannabis identification card. The physician determines patient eligibility as well as the routes of administration (e.g. topical, oral, inhalation) and number of milligrams per day a patient is able to obtain under the program. An MMTC may not dispense more than a 70-day supply of cannabis within a 70-day period to a qualified patient or caregiver, except an MMTC may

not dispense more than a 35-day supply of cannabis in a form for smoking within a 35-day period. The MMTC employee who dispenses the cannabis must enter into the registry his or her name or unique employee identifier. The MMTC must verify that: (i) the qualified patient and the caregiver, if applicable, each has an active registration in the registry and active and valid medical cannabis use registry identification card, (ii) the amount and type of cannabis dispensed matches the physician certification in the registry for the qualified patient, and (iii) the physician certification has not already been filled. An MMTC may not dispense to a qualified patient younger than 18 years of age, only to such patient's caregiver. An MMTC may not dispense or sell any other type of cannabis, alcohol, or illicit drug-related product, except a cannabis delivery device as specified in the physician certification. An MMTC must, upon dispensing, record in the registry: (i) the date, time, quantity and form of cannabis dispensed, (ii) the type of cannabis delivery device dispensed,

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

and (iii) the name and registry identification number of the qualified patient or caregiver to whom the cannabis delivery device was dispensed. An MMTC must ensure that patient records are not visible to anyone other than the patient, caregiver, and MMTC employees.

Licenses issued by the OMMU may be renewed biennially so long as the licensee meets requirements of Florida Statute 381.986 and pays a renewal fee. One Plant Florida (the prior MMTC license holder) timely submitted its biennial renewal on February 28, 2021, and the OMMU approved the renewal on June 2, 2021. Applicants must demonstrate (and licensed MMTCs must maintain) that: (i) they have been registered to do business in the State of Florida for the previous five years, (ii) they possess a valid certificate of registration issued by the Florida Department of Agriculture & Consumer Services, (iii) they have the technical and technological ability to cultivate and produce cannabis, including, but not limited to, low-THC cannabis, (iv) they have the ability to secure the premises, resources, and personnel necessary to operate as an MMTC, (v) they have the ability to maintain accountability of all raw materials, finished products, and any by-products to prevent diversion or unlawful access to or possession of these substances, (vi) they have an infrastructure reasonably located to dispense cannabis to registered qualified patients statewide or regionally as determined by the OMMU, (vii) they have the financial ability to maintain operations for the duration of the two-year approval cycle, including the provision of certified financial statements to the Department, (viii) all owners, officers, board members and managers have passed a Level II background screening, inclusive of fingerprinting, and ensure that a medical director is employed to supervise the activities of the MMTC, and (ix) they have a diversity plan and veterans plan accompanied by a contractual process for establishing business relationships with veterans and minority contractors and/or employees. Upon approval of the application by the OMMU, the applicant must post a performance bond of up to US\$5 million, which may be reduced to US\$2 million by meeting certain criteria such as a minimum patient count of 1,000 patients.

Several of Cresco Labs, Inc and its subsidiaries' licenses are subject to renewal on an annual or periodic basis; however, they are generally renewed, as a matter of course, if the license holder continues to operate in compliance with applicable legislation and regulations and without any material change to its operations. While the Cresco Labs, Inc (and its subsidiaries') compliance controls have been developed to mitigate the risk of any material violations of any license it holds arising, there is no assurance that the Cresco Labs, Inc (or its subsidiaries') licenses will be renewed by each applicable regulatory authority in the future in a timely manner.

Florida Reporting Requirements

The OMMU requires that any licensee establish, maintain, and control a computer software tracking system that traces cannabis from seed to sale and allows real-time, 24-hour access by the OMMU to data. The tracking system must allow for integration of other seed-to-sale systems and, at a minimum, include notification of certain events, including when cannabis seeds are planted, when cannabis plants are harvested and destroyed, and when cannabis is transported, sold, stolen, diverted, or lost. Each MMTC shall use the seed-to-sale tracking system established by the OMMU or integrate its own seed-to-sale tracking system with the seed-to-sale tracking system established by the OMMU. The OMMU also maintains a patient and physician registry and the licensee must comply with all requirements and regulations relative to providing required data or proof of key events to said system. The State of Florida requires all MMTCs to abide by representations made in their original application to the State of Florida. Any changes or expansions must be requested pursuant to and in accordance with a variance process.

Florida Security and Transportation

With respect to security requirements for cultivation, processing and dispensing facilities, a MMTC must maintain a fully operational security alarm system that secures all entry points and perimeter windows, and is equipped with motion detectors, pressure switches, duress, panic and hold-up alarms. The MMTC must also have a 24-hour video surveillance system with the following features: (a) cameras positioned for the clear identification of persons and activities in controlled areas including growing, processing, storage, disposal and point-of-sale rooms, (b) cameras fixed on entrances and exits to the premises, which shall record from both indoor and outdoor, or ingress and egress, vantage points, and (c) ability to record images clearly and accurately together with the time and date. MMTCs must retain video surveillance recordings for at least 45 days, or longer upon the request of law enforcement. Facilities may not display products or dispense cannabis or cannabis delivery devices in the waiting area and may not dispense cannabis from its premises between the hours of 9:00 p.m. and 7:00 a.m. However, it may perform all other operations and deliver cannabis to qualified patients 24 hours a day.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Cannabis must be stored in a secured, locked room or a vault. A MMTC must have at least two employees, or two employees of a security agency, on the premises at all times where cultivation, processing, or storing of cannabis occurs. MMTC employees must wear a photographic identification badge and visitors must wear a visitor pass at all times on the premises.

A cannabis transportation manifest must be maintained in any vehicle transporting cannabis or a cannabis delivery device. The manifest must be generated from the MMTC's seed-to-sale tracking system. The manifest must include the following information: (i) departure date and time; (ii) name, address and license number of the originating MMTC; (iii) name and address of the receiving entity; (iv) the quantity, form and delivery device of the cannabis; (v) arrival date and time; (vi) the make, model and license plate of the delivery vehicle; and (vii) the name and signatures of the MMTC delivery employees. Further, a copy of the transportation manifest must be provided to the recipient of the delivery. Each MMTC must retain copies of all cannabis transportation manifests for at least three years. Cannabis and cannabis delivery devices must be locked in a separate compartment or container within the vehicle and employees transporting cannabis or cannabis delivery devices must always have their employee identification on their person. Lastly, at least two people must be in a vehicle transporting cannabis, and at least one person must remain in the vehicle while the cannabis is physically delivered.

The business premises of Cresco's operating locations are targets for theft. While the company has implemented security measures at each location and continues to monitor and improve its security measures, its cultivation, processing and dispensary facilities could be subject to break-ins, robberies and other breaches in security. If there was a breach in security and the CannCure fell victim to a robbery or theft, the loss of cannabis plants, cannabis oils, cannabis flowers or cultivation and processing equipment could have a material adverse impact on the business, financial condition and results of operation of the CannCure.

As the CannCure's business involves the movement and transfer of cash which is collected from dispensaries or patients/customers and deposited into its bank, there is a risk of theft or robbery during the transport of cash. The company has engaged a security firm to provide security in the transport and movement of large amounts of cash. Employees sometimes transport cash and/or products and each employee has a panic button in their vehicle and, if requested, may be escorted by armed guards. While the CannCure has taken robust steps to prevent theft or robbery of cash during transport, there can be no assurance that there will not be a security breach during the transport and the movement of cash involving the theft of product or cash.

Florida Inspections

The OMMU may conduct announced or unannounced inspections of MMTCs to assess compliance with applicable laws and regulations. The OMMU is required to inspect a MMTC upon receiving a complaint or notice that the MMTC has dispensed cannabis containing mold, bacteria, or other contaminants that have caused or which may cause an adverse effect to humans or the environment. The OMMU is required to conduct at least a biennial inspection of each MMTC to evaluate the MMTC's records, personnel, equipment, security, sanitation practices, and quality assurance practices.

To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action in Florida.

Regulatory Developments in the State of California

Cannabis is legal in California for both medical and adult (recreational) use. Medical cannabis first became legal in 1996 when voters passed the Compassionate Use Act. Cannabis became legal for adult use (over 21 years of age) in 2016 when voters passed the Adult Use of Marijuana Act. Cannabis was previously regulated at the state level by three different agencies: the Department of Food and Agriculture regulated cultivation; the Department of Public Health regulated manufacturing; and the Bureau of Cannabis Control, within the Department of Consumer Affairs, regulated distribution, testing, and the retail sale of cannabis. As of July 12, 2022, all regulatory powers and duties relating to cannabis were transferred from the aforementioned agencies to the newly created Department of Cannabis Control (DCC). DCC has combined the regulations from the three agencies into a single consolidate set of regulations.

SOL Global Investments Corp

Management’s discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Cities and counties are authorized to pass ordinances that regulate the time, place, and manner in which a cannabis business may operate within the city or county. The ordinances may be more specific than, but may not contradict, state law. In addition, nine local jurisdictions have adopted “equity ordinances” that help certain qualified applicants in various ways, such as faster application processes, help operating the business, and direct financial support. An applicant must have obtained local approval prior to applying for a license from DCC.

The Medical and Adult Use Cannabis Regulation and Safety Act (MAUCRSA) is the state-level regulatory framework that governs all aspects of cannabis business operations. The MAUCRSA governs the issuance of licenses; the tracking and tracing of cannabis; the cultivation, manufacturing, distribution, transportation, testing, delivery, and retail sale of cannabis; packaging and labeling of products; and advertising, among other things. The MAUCRSA, also includes enforcement provisions and creates the Cannabis Control Appeals Panel to allow any person aggrieved by a DCC decision to seek review of the decision.

DCC is authorized to issue over 20 different types of cannabis licenses that address cultivation, manufacturing, testing, distributing, retailing, and the operation of a cannabis microbusinesses. Licenses are designated as either adult use or medical licenses. The MAUCRSA allows adults over 21 to cultivate up to six plants for personal use, subject to local approval.

During the 2022 legislative session, the MAUCRSA was modified to include additional criteria to renew provisional licenses (formerly called temporary licenses) and to phase out provisional licenses. Under the new law, no provisional licenses will be in effect after January 1, 2026.

California License Types

Once an operator obtains local approval, the operator must obtain state licenses before conducting any commercial marijuana activity. There are 12 different license types that cover all commercial activity. License types 1-3 authorize the cultivation of medical and/or adult-use marijuana plants. Type 4 licenses are for nurseries that cultivate and sell clones and “teens” (immature marijuana plants that have established roots but require further vegetation prior to being sent into the flowering period). Type 6 and 7 licenses authorize manufacturers to process marijuana biomass into certain value-added products such as shatter or marijuana distillate oil with the use of volatile or non-volatile solvents, depending on the license type. Type 8 licenses are held by testing facilities who test samples of marijuana products and generate “certificates of analysis,” which include important information regarding the potency of products and whether products have passed or failed certain threshold tests for pesticide and microbiological contamination. Type 9 licenses are issued to “non-storefront” retailers, commonly called delivery services, who bring marijuana products directly to customers and patients at their residences or other chosen delivery location. Type 10 licenses are issued to storefront retailers, or dispensaries, which are open to the public and sell marijuana products onsite. Type 11 licenses are known as “Transport-Only” distribution licenses, and they allow the distributor to transport marijuana and marijuana products between licensees, but not to retailers. Type 12 licenses are issued to distributors who move marijuana and marijuana products to all license types, including retailers.

In September 2018, the Governor of California approved the Senate Bill 1459 (“SB-1459”). SB-1459 created a new scheme of provisional licenses for cannabis operators. This provisional licensing scheme was essentially intended to replace the temporary licensing scheme. SB-1459 was necessary because the three main state cannabis licensing agencies - the Bureau of Cannabis Control (“BCC”), California Department of Public Health, and California Department of Food and Agriculture - and localities which issue permits to cannabis operators, were all backlogged with numerous applications and couldn’t process all of the applications in time for applicants to get operational in 2018. The steps, per SB-1459 to obtain a provisional license are as follows: (1) an applicant must hold or previously have held a temporary license for the same commercial cannabis activity for which it seeks a provisional, and (2) the applicant must submit a completed annual license application and proof that California Environmental Quality Act compliance is underway. Provisional licenses last for 12 months and can be issued through the end of 2019.

Retail Compliance in California

California requires that certain warnings, images, and content information be printed on all marijuana packaging. BCC regulations also include certain requirements about tamper-evident and child-resistant packaging. Distributors and retailers are responsible for confirming that products are properly labeled and packaged before they are sold to a

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

customer. Consumers aged 21 and up may purchase marijuana in California from a dispensary with an "adult-use" license. Some localities still only allow medicinal dispensaries.

Consumers aged 18 and up with a valid physician's recommendation may purchase marijuana from a medicinal-only dispensary or an adult-use dispensary. Consumers without valid physician's recommendations may not purchase marijuana from a medicinal-only dispensary. All marijuana businesses are prohibited from hiring employees under the age of 21.

California Record-keeping/Reporting

Licensees are required to maintain records for at least seven years from the date a record is created. These records include: (a) a cultivation plan, (b) all supporting documentation for data or information input into the T&T system, (c) all unique identifiers ("UID") assigned to product in inventory and all unassigned UIDs, (d) financial records related to the licensed commercial cannabis activity, including bank statements, tax records, sales invoices and receipts, and records of transport and transfer to other licensed facilities, (e) records related to employee training for the T&T system, and (f) permits, licenses, and other local authorizations to conduct the licensee's commercial cannabis activity.

California Inventory/Storage

Each licensee is required to assign an account manager to oversee the T&T system. The account manager is fully trained on the system and is accountable to record all commercial cannabis activities accurately and completely. The licensee is expected to correct any data that is entered into the T&T system in error within three business days of discovery of the error.

The licensee is required to report information in the T&T system for each transfer of cannabis or non-manufactured cannabis products to, or cannabis or non-manufactured cannabis products received from, other licensed operators. Licensees must use the T&T system for all inventory tracking activities at a licensed premise, including, but not limited to, reconciling all on-premise and in-transit cannabis or non-manufactured cannabis product inventories at least once every 14 business days. The licensee must store cannabis and cannabis products in a secure place with locked doors.

California Security

A licensee is required to maintain an alarm system capable of detecting and signaling the presence of a threat requiring urgent attention and to which law enforcement are expected to respond. A licensee must also ensure a professionally qualified alarm company operator or one of its registered alarm agents installs, maintains, monitors, and responds to the alarm system.

The manufacturing and cultivation of cannabis must use a digital video surveillance system which runs 24 hours a day, seven days a week and effectively and clearly records images of the area under surveillance. Each camera must be placed in a location that clearly records activity occurring within 20 feet of all points of entry and exit on the licensed premises. The areas that will be recorded on the video surveillance system should include the following: (a) areas where cannabis goods are weighed, packed, stored, loaded, and unloaded for transportation, prepared, or moved within the premises, (b) limited-access areas, (c) security rooms, and (d) areas storing a surveillance-system storage device with at least one camera recording the access points to the secured surveillance recording area. Surveillance recordings must be kept for a minimum of 90 days.

California Transportation

Transporting cannabis goods between licensees and a licensed facility may only be performed by persons holding a distributor license. The vehicle or trailer used must not contain any markings or features on the exterior which may indicate or identify the contents or purpose. All cannabis products must be locked in a box, container, or cage that is secured to the inside of the vehicle or trailer. When left unattended, vehicles must be locked and secured. At a minimum, the vehicle must be equipped with an alarm system, motion detectors, pressure switches, duress, panic, and hold-up alarm.

California Inspections

All licensees are subject to annual and random inspections of their premises. Cultivators may be inspected by the California Department of Fish and Wildlife, the California Regional Water Quality Control Boards, and the California

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Department of Food and Agriculture. Manufacturers are subject to inspection by the California Department of Public Health, and Retailers, Distributors, Testing Laboratories, and Delivery services are subject to inspection by the Bureau of Cannabis Control. Inspections can result in notices to correct, or notices of violation, fines, or other disciplinary action by the inspecting agency.

Marijuana Taxes in California

Several types of taxes are imposed in California for adult use sale. As of January 1, 2021, the California Department of Tax and Fee Administration raised the tax rate on wholesale cannabis from 60% to 80%. Cultivators have the choice of being taxed at \$9.65, per dry-weight ounce of cannabis flowers or \$1.35 per ounce of wet-weight plants. Further, cultivators are required to pay \$2.87 per ounce for cannabis leaves. California also imposes an excise tax of 15%. Cities and counties apply their sales tax along with the state's excise and many cities and counties have also authorized the imposition of special cannabis business taxes which can range from 2% to 10% of gross receipts of the business.

To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action in California.

Regulatory Developments in the State of Illinois

Cannabis is legal in Illinois for both medical and recreational use. Medical cannabis first became legal on January 1, 2014, following the passage of Compassionate Use of Medical Cannabis Pilot Program Act. Cannabis became legal for recreational use (21 years of age and older) on January 1, 2021, following the passage of the Cannabis Regulation and Tax Act. Multiple state agencies have regulatory oversight of the state's cannabis program. The Department of Agriculture regulates cultivation centers, craft growers, infusers, and transporting organizations. The Department of Financial and Professional Regulation regulates dispensing organizations. The Department of Public Health administers the registry of patients. The Department of Revenue is responsible for enforcing and collecting taxes associated with the sale of cannabis.

No local government unit may enact ordinances conflict with state cannabis laws; except that local government units may enact ordinances governing the time, place, manner, and number of cannabis business establishment operations, including prohibiting, or significantly limiting a cannabis business establishment location.

Illinois' comprehensive regulatory framework includes a licensing process for recreational use and medical cannabis businesses, operational requirements and standards for licensees, packaging and labeling requirements, advertising restrictions, and enforcement provisions. Illinois law authorizes the following classes of licenses: cannabis cultivation centers, craft growers, infusers, transporters, and dispensing organizations. Cannabis testing facilities are issued registrations. There is a cap on the number of licenses (other than transporters) that the state may issue. A person or entity may have an interest in up to three cultivation licenses, three craft grower licenses, three infuser licenses, and ten dispensing licenses. Registered qualifying patients may cultivate cannabis for personal use subject to certain restrictions, including limitations on the number and size of plants.

Regulatory Developments in the State of Michigan

Cannabis is legal in Michigan for both medical and adult (recreational) use. Medical cannabis was initially legalized in 2008 following the passage of the Michigan Compassionate Care Initiative. After an extensive legal battle, the Michigan Supreme Court determined in 2013 that the Michigan Compassionate Care Initiative did not allow for the operation of medical cannabis dispensaries. In 2016, the legislature passed a series of laws that legalized medical cannabis dispensaries and regulated growing and processing facilities. In 2018, voters passed the Michigan Regulation and Taxation of Marijuana Act ("MRTMA"). The MRTMA abolished the Bureau of Marijuana Regulation, which previously regulated cannabis in Michigan, and transferred all regulatory authority to the newly created Marijuana Regulatory Agency ("MRA").

The MRA regulates both medical and adult use of cannabis. The Medical Marijuana Facilities Licensing Act ("MMFLA") governs the medical use of cannabis in Michigan. The MRTMA governs the adult use of cannabis in Michigan. The Marijuana Tracking Act establishes a statewide seed-to-sale monitoring system. The MMFLA authorizes Class A, B, and C grower licenses, processor licenses, provisioning center licenses, secure transporter licenses, and safety compliance

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

facility licenses. The MRTMA authorizes retailer licenses, safety compliance facility licenses, secure transporter licenses, processor licenses, microbusiness licenses, and Class A, B, and C grower licenses. The MRMTA allows individuals 21 years or older to possess up to 12 cannabis plants for personal use.

No cannabis license will be issued to an applicant unless the city, township, or village in which the proposed facility will be operated has adopted an ordinance authorizing that type of facility. Cities, townships, and villages may adopt ordinances that limit the number of facilities and adopt other ordinances relating to cannabis, except that no ordinance may regulate the purity or pricing of cannabis.

RISK FACTORS

There are a number of risk factors that could cause future results to differ materially from those described in this MD&A. The risks and uncertainties described herein are not the only ones the Company faces but are those the Company currently believes to be material. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business.

The following are certain risk factors relating to the business of the Company which may cause future results to differ materially from those currently anticipated by management of the Company. If any of the following risks actually occur: (i) shareholders of SOL Global could lose all or part of their investment; (ii) the business, financial condition, liquidity, results of operations and prospects of SOL Global could be materially adversely affected; and (iii) the ability of SOL Global to implement its future plans could be adversely affected.

- The Company will require additional financing from time to time in order to pursue its business objectives and fund its ongoing and future operations and the failure to raise such capital on satisfactory terms or at all could result in the delay or postponement of current business objectives or the going out of business.
- Funding may be difficult to obtain given the fact that part of the Company's business is materially investing into cannabis companies in the United States of America, where federally cannabis is illegal by virtue of the fact that it is categorized as a Schedule I controlled substance under the U.S. Controlled Substances Act.
- Servicing the Company's debt will require a significant amount of cash, and the Company may not have significant cash flow from the Company's business to pay the Company's debt.
- The outbreak of the novel strain of coronavirus, "COVID-19", has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown, as is the efficacy of the government and central bank interventions. The severity and impact on the financial results and condition of the Company and its operations in future periods cannot be estimated. COVID-19 may affect the ability to raise capital.
- If additional funds are raised by the Company through issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution.
- Laws, regulations and the policies with respect to the enforcement of such laws and regulations affecting the U.S. cannabis industry are constantly changing, which could detrimentally affect the Company's current or proposed business operations.
- There are risks inherent in investing in the United States cannabis industry.
- Inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry may affect the reputation of the Company.
- The market price of securities of companies involved in the cannabis industry (such as the Company) have historically been very volatile and subject to wide fluctuations in response to various factors, many of which are beyond the Company's control. Such volatility, whether resulting from external market forces or as a result of the Company's failure to meet expectations, downward revision in analysts' estimates or other adverse changes, could negatively affect the market price of the Company's securities or impair the liquidity of the Company's securities.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

- The U.S. federal government's approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined.
- The states in which the Company's investee companies operate may change their approach to either enforcement of cannabis laws or adversely change their laws altogether. This may have the effect of eroding the value of their businesses.
- The business of the Company, while believed to be compliant with applicable U.S. state and local laws, currently are illegal under U.S. federal law, and existing state or federal regulatory bodies could impose additional regulatory restrictions which may make it difficult for the Company or its investee companies to continue doing business as presently conducted.
- The Company may have difficulty accessing the service of banks or other essential services or third party service providers, which may make it difficult to operate and counterparties with whom the Company or its investee companies currently does business may suspend or withdraw services.
- U.S. border officers could deny entry into the United States to non-U.S. citizens who are employees of or investors in companies with cannabis operations in the United States or Canada.
- Certain events or developments in the cannabis business generally may affect the Company's business, its reputation or the market price of the Company's securities.
- Adverse publicity resulting from litigation may impact the reputation of the Company.
- Potentially significant costs resulting from litigation may affect the financial position of the Company.
- The Company may become party to litigation or regulatory proceedings which could negatively affect the Company's business, financial condition and results of operations, or harm the Company's reputation. Such risks could arise regardless of the ultimate outcome of the litigation or regulatory proceedings.
- The Company has and may continue to invest in securities of private companies which may limit the Company's ability to sell or otherwise transfer those securities and realize value.
- The Company may hold minority interests in such companies, which may limit the Company's ability to sell or otherwise transfer those securities and/or direct management decisions of such companies.
- There is no assurance that an investment in the Company's securities will earn any positive return.
- Parties with whom the Company does business may perceive themselves as being exposed to reputational risk because of their relationship with the Company and may refuse to do business with the Company.
- Conflicts of interest may arise between the Company and the Company's directors and officers.
- The Company's investments in the United States may be subject to heightened scrutiny by regulators, stock exchanges and other authorities in Canada and the United States.
- Up until the fiscal year ended March 31, 2019, the Company had incurred significant operating losses since inception. The Company may not be able to achieve or maintain profitability and may incur significant losses in the future.
- The Company must be able to service its outstanding debt.
- The requirements of being a public company may strain the Company's resources, result in more litigation and divert the attention of the Company's management.
- Any failure by the Company to maintain effective internal controls over financial reporting could have an adverse effect on the Company.
- The Company's success depends on the ability, expertise, judgment, discretion, reliance on and good faith of its senior management, and the loss of services of such individuals, or an inability of the Company to attract, retain and motivate sufficient numbers of qualified senior management or skilled personnel could adversely affect the Company's business, financial condition and results of operations.
- Prior to obtaining regulatory approval for the sale of product candidates, the Company or companies that the Company has invested in must conduct pre-clinical testing and clinical trials, the results of which are uncertain and may not be favourable and are subject to delay, suspension or termination by the Company, the companies that the Company has invested in or other regulatory authorities for a variety of reasons.
- Investee's ability to compete and grow will depend on having access at a reasonable cost and in a timely manner to skilled labour, equipment, parts and components and no assurance can be provided that such resources will be available on favourable terms or at all.
- The Company or companies that the Company has invested in may face intense competition from other companies, some of which may have longer operating histories, more financial resources and manufacturing and marketing experience.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

- A decision to declare dividends in the future will be made at the discretion of the board of directors, and will depend on financial results, cash requirements, contractual restrictions and other factors that they may deem relevant. The Company currently has no dividends on record and may not pay any dividends in the foreseeable future. In addition, any dividends paid could be subject to tax and, potentially, withholdings.
- The Company or companies that the Company has invested in may be subject to growth related risks including capacity constraints and pressure on its internal systems and controls and the inability to manage growth could adversely affect its business, financial condition and results of operations.
- The success of the companies in which the Company has invested in depends in part on their ability to protect their ideas and technology, and no assurance can be given that they will be able to adequately protect their intellectual property in all relevant jurisdictions or that they will be successful in defending their intellectual property against claims by third parties that such intellectual property is invalid or infringes upon the intellectual property of others.
- The Company's investments in the United States are subject to applicable anti-money laundering laws and regulations in the United States and Canada.
- The Company relies on the operators of the companies to which it invests to execute their respective business plans and operations. There is no assurance that these companies will be able to execute their business and strategic plans as contemplated or at all
- Cannabis cultivation operations of certain companies to which the Company has invested are subject to risks inherent in an agricultural business, are vulnerable to rising energy costs and dependent upon key inputs.
- The cannabis industry is highly regulated and the Company or the companies in which it invests, as applicable, may not always succeed in complying fully with all applicable regulatory requirements in all jurisdictions where the Company or the companies in which it invests carries on business.
- Cannabis pricing and supply regulation may adversely affect the Company's business or that of the companies in which it invests.
- The sale of cannabis products is subject to stringent regulatory limitations on advertising and marketing activities.

CRITICAL ACCOUNTING ESTIMATES

Use of Judgement, Estimates and Assumptions

The preparation of the Company's financial statements in accordance with IFRS requires the Company to make judgments in applying its accounting policies and estimates and assumptions about the future. Judgments, estimates and assumptions affect the Company's reported amounts of assets, liabilities, and items in net income or loss, and related disclosure. Estimates are based on various assumptions that the Company believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying value of assets and liabilities and the reported amounts of items in net earnings or loss that are not apparent from other sources. The Company evaluates its estimates on an ongoing basis. Actual results may differ from the Company's estimates. Certain areas of significant judgement include: the valuation of private company investments, the assessment of impairment of the Company's investments, the estimation of income taxes payable and deferred income tax payable, the values of warrants and options and judgement with respect to legal claims.

Comparative Figures

Certain comparative figures have been reclassified to conform to the current period's presentation.

FINANCIAL RISK MANAGEMENT

The Company is exposed to certain financial risks. The impact on these Financial Statements are summarized below:

Market Risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates, and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavorable market conditions could result in dispositions of investments at less than favourable prices. The market risks to which the Company is exposed are equity price risk and interest rate risk.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

- Equity price risk - Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices or general movements in the level of the stock market or the cannabis sub-market. The Company's investments are subject to fluctuations in fair value arising from changes in the equity market. As at February 28, 2023, a 30% change in closing trade price of the Company's equity investment portfolio would impact net gain by \$39,888,014. (November 30, 2022: \$43,507,111).
- Interest rate risk - Interest rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate due to changes in market interest rates. The Company's exposure to interest rate risk relates to its ability to earn interest income on cash and cash equivalents, promissory notes and convertible debts held. The change in fair value of the Company's cash and cash equivalents, promissory notes and convertible debts held, due to changes of interest rates, is considered low.

Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company does not hedge its currency risk. The Company holds financial instruments that are denominated in a currency other than the Canadian dollar. A significant portion of the Company's cash outflows are in United States Dollars. In addition, numerous of the Company's investments are denominated in foreign currencies. During the three-month period ended February 28, 2023, a 10% change in foreign currencies held would have resulted in a change in income/(loss) by \$6,031 (November 30, 2022: \$5,880). During the three-month period ended February 28, 2023, the Company recognized a foreign currency exchange loss of \$15,027 (November 30, 2022: gain of \$605,018).

Liquidity Risk

Liquidity risk refers to the risk that the Company will not be able to meet its obligations as they become due. A company's ability to continue as a going concern is dependent on receiving continued financial support from its stakeholders and, ultimately, on the ability to generate continued and sustainable profitable operations. The Company generates cash flow from the disposal of investments, financing activities, fees and dividend and interest income. The Company primarily invests in equity and debt instruments of various public and private companies. Due to a lack of an active market, the return on the disposal of investments in non-publicly traded companies may differ significantly from the carrying value of these investments. As of February 28, 2023, the Company's contractual cash flows, which were payable under financial liabilities consists of accounts payables and accrued liabilities as well as income tax payable with payments due in less than one year. The Company's financial assets are classified as being convertible into cash in less than one year. Management is of the opinion that sufficient working capital is available from its financings, its operations and its divestitures to meet the Company's liabilities and commitments as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Given the relatively small size of the Company's staff, senior management and the Board are actively involved in the review, planning and approval of significant expenditures and commitments. The Company's financial liabilities are due within the next 12 months. A payment schedule of the Company's lease obligations is disclosed in note 16.

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

Concentration risk

Concentration risk is the risk that any single investment or group of investments will have the potential to materially affect the Company's operating results. As at February 28, 2023, the Company has invested in common shares, convertible debentures, and warrants of public and private companies in the cannabis and non-cannabis sectors. The allocation between public and private companies is as follows:

	Cost \$	Fair value \$	Fair Value Percentage %
Public company common shares	48,669,869	24,221,707	18%
Private company common shares	146,566,788	86,745,631	65%
Warrants held in public and private companies	4,350,485	1,028,926	1%
Commercial Asset	13,803,091	20,963,781	16%
	213,390,233	132,960,045	100%

As at February 28, 2023, 57% (November 30, 2022: 55%) of the total fair value of the Company's investments were United States based companies while 41% (November 30, 2022: 43%) and 2% (November 30, 2022: 1%) of the total fair value of the Company's investments were in Canada and UK, respectively.

The primary goals of the Company's risk management programs are to ensure that the outcomes of activities involving elements of risk are consistent with the Company's objectives and risk tolerance. The Company's investment strategy requires a level of risk in exchange for an above average return on investment. The Company plans to maintain an appropriate risk and reward balance while protecting the Company's financial operations from events that have the potential to materially impair its financial strength. Balancing risk and reward is achieved through aligning risk tolerance with the Company's business strategy, diversifying risk, pricing appropriately for risk, mitigating risk through preventative controls and transferring risk to third parties. The Company considers its shareholders' equity as its capital. The Company has no externally imposed capital requirements.

Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company has two types of financial assets that are subject to the expected credit loss model: (a) other receivables from government agency and third parties; and (b) promissory notes. While cash and cash equivalents are subject to the impairment requirements of IFRS 9, the identified credit risk and impairment loss is immaterial, as these funds are held with reputable financial institutions. The Company applies the simplified approach to providing for ECL prescribed by IFRS 9, which permits the use of the lifetime expected loss provision for all promissory notes and other receivables while ECL calculation based on stage assessment has been performed for promissory notes. Below is a summary of credit ratings of debt instruments including convertible debentures and promissory notes held by the Company as part of its investment portfolio.

Credit Ratings	Percentage of Total Convertible Debentures and Promissory Notes (%)	Percentage of Total Investments (%)
Unrated (Private Convertible Debt/Promissory Notes)	100.0%	1.58%
	100.0%	1.58%

SOL Global Investments Corp

Management's discussion and analysis for the three-month period ended February 28, 2023, and the three-month period ended February 28, 2022 (Expressed in Canadian Dollars)

CHANGES TO MANAGEMENT AND THE BOARD OF DIRECTORS

The following changes to management and Board have occurred since November 30, 2021:

- On February 8, 2022, Alex Spiro resigned from the Board.
- On April 25, 2022, Andrew DeFrancesco was terminated as CEO/Chairman.
- On April 25, 2022, Kevin Taylor was appointed as CEO/Chairman.
- On February 27, 2023, Kevin Taylor resigned as CEO and Director.
- On February 27, 2023, Paul Kania was appointed as Interim CEO, replacing Kevin Taylor.
- On February 27, 2023, Olivier Centner resigned as Director.
- On February 27, 2023, Deena Siblock and Mehdi Azodi were appointed to the Board to replace Olivier Centner and Kevin Taylor.

LISTING OF KEY COMPANY PERSONNEL AS OF THE DATE OF THIS MD&A

- **Board of Directors:** Mehdi Azodi (independent), Arena J. Prado-Acosta (independent) and Deena Siblock (Vice President and Corporate Secretary)
- **Senior Officers:** Paul Kania (Interim Chief Executive Officer and Chief Financial Officer).